Deep Learning for Large-Scale and Complex-Structured Biomedical Data

by

Yuming Sun

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
(Biostatistics)
in the University of Michigan
2023

Doctoral Committee:

Professor Yi Li, Co-Chair
Professor Jian Kang, Co-Chair
Professor Veera Baladandayuthapani
Professor Chad Brummett

Yuming Sun

yumsun@umich.edu

ORCID iD: 0000-0001-5705-5553

Dedication

To My Parents and My Grandmother

Acknowledgments

First and foremost, I would like to thank my advisors, Drs. Yi Li and Jian Kang, for their outstanding mentorship throughout my Ph.D. study. They have been extremely supportive, passionate, and knowledgeable. Dr. Yi Li is an expert in survival analysis, and I have benefited so much from his insights into survival analysis and rigorous statistical thinking. He has kindly offered me opportunities to work with many great collaborators. Dr. Jian Kang has taught me much about deep learning, imaging analysis, and statistical computing. In addition, his optimism helped me to overcome challenges in my research. They have set great exemplars as biostatisticians, and I will keep looking up to and learning from them in my future career.

I would also like to thank Drs. Chad Brummett and Veera Baladandayuthapani for serving as members of my dissertation committee and providing me with valuable comments on my dissertation. I am deeply grateful to Dr. Chad Brummett for sharing the Analgesic Outcomes Study data and his expertise in opioid research. The data applications in the dissertation would not be possible without his help. I also want to thank Dr. Veera Baladandayuthapani for his insightful suggestions on the imaging analysis of chest CT. The interpretation of radiomic features from a clinical perspective is constructive for my dissertation.

My sincere appreciation also goes to Drs. David Christiani and Chi-Fu Jeffrey Yang. I want to thank Dr. David Christiani and his lab members at Harvard for giving me their valuable suggestions on lung cancer and the Boston Lung Cancer Study. I benefit a lot from meeting with them weekly for my research. I want to thank Dr. Chi-Fu Jeffrey Yang for sharing the National Lung Cancer Screen Trial data and helping with the pre-processing of the CT images.

I would like to thank the Department of Biostatistics at the University of Michigan for providing a supportive research and study environment. Thank the knowledgeable faculty and friendly staff in the department. Especially it has been an enjoyable and meaningful experience working with Dr. Lu Wang as a graduate student instructor. I am deeply grateful for her great advice on career development. I also thank Dr. Li's and Dr. Kang's lab members for their helpful feedback in the weekly group meetings.

Finally, I would like to thank Luying Yang for her support and encouragement during my Ph.D. study. I want to thank my parents and my grandmother for their unconditional love. I could not have done any of this without the help of my family.

TABLE OF CONTENTS

Chapter

LIST OF FIGURES

FIGURE

LIST OF TABLES

TABLE

LIST OF APPENDICES

ABSTRACT

In this dissertation, we propose novel Deep Neural Network (DNN) based statistical learning models that can provide accurate predictions and clear interpretations simultaneously. Chapter 1 presents an introduction to the DNN as a nonparametric approximator to complex, non-linear functions.

Chapter 2 introduces the Interpretable Neural Network Regression (INNER), a logistic regression model with nonparametric covariate-dependent coefficients constructed by DNNs. Applied to the individualized risk assessment of preoperative opioid use, the proposed INNER model can predict preoperative opioid use based on the preoperative characteristics and estimate the individual-level odds of opioid use induced by overall body pain, leading to straightforward interpretations of the tendency to use opioids. Applying INNER to Analgesic Outcomes Study (AOS), we identify patient characteristics strongly associated with opioid use.

Chapter 3 develops the Penalized Deep Partially Linear Cox Model (Penalized DPLC) that incorporates the SCAD penalty to select significant features and employs the DNN to estimate the nonparametric component of the partially linear Cox model. An efficient alternating optimization algorithm is used for model estimation. We also prove the convergence and asymptotic properties of the estimator. The merits of this method are shown through intensive simulations. Finally, the Penalized DPLC is applied to the National Lung Screening Trial (NLST) to uncover the effects of critical clinical and imaging risk factors on patients' survival.

Chapter 4 presents the Deep Survival Learner (DSL) for estimating the Conditional Average Treatment Effects (CATEs) in survival settings. DSL adapts the Doubly-Robust Learner to right-censored data by Inverse Probability of Censoring Weights (IPCW). DNNs are used as base learners to account for the complex relationships between baseline characteristics and survival outcomes. Large-scale simulation experiments are conducted to assess the performance of the proposed model under various scenarios. We then use DSL to study the treatment heterogeneity of perioperative chemotherapy for patients from the Boston Lung Cancer Study (BLCS).

CHAPTER 1

Introduction

1.1 Review of Deep Neural Network

The explosion of large-scale datasets with complex structures in biomedical research creates challenges unmet by existing statistical and computational methods [33, 127, 81]. For example, the strict parametric assumptions of traditional regression models are often invalid for these complex structured data, resulting in a lack of representational power and prediction performance [137, 25]. On the other hand, Deep Neural Network (DNNs), a machine learning algorithm inspired by the connectivity of neurons and structures within the human brain, have achieved much success in nonparametric approximation with high dimensional predictors [10, 138]. A DNN has multiple layers, with neurons being the basic processing units [93]. For example, in the commonly used feedforward neural network [142], starting from the first layer (input layer), neurons in one layer are connected to and may "activate" those in the adjacent and higher layers. Specifically, the inputs of each neuron are multiplied by some weights, added with respective bias terms, and summed up [142, 51]. The sums are passed onto some transformation functions, called "activation" functions, such as linear, Sigmoid, hyperbolic tangent, or rectified linear unit (ReLU) activation functions [82, 99]. The outputs returned by these activation functions are fed to neurons in the next layer as inputs. Passing all of the layers, the outputs of the final layer (output layer) will be used for prediction. It has been shown that a shallow neural network can approximate any continuous function to any degree of accuracy, given enough training samples and computation resources [38]. Furthermore, DNNs with multiple layers can achieve similar accuracy with fewer parameters [108]. Following these remarkable, significant results in nonparametric approximation, DNNs have achieved great success in computational phenotyping [26, 101], medical imaging analysis [86, 157] and predictive modeling [30]. However, the black-box nature of DNNs prevents us from interpreting and explaining the results as regression models [2, 124, 18]. Motivated by these challenges, this dissertation proposes three novel statistical learning models that combine traditional regression models with DNNs to provide accurate predictions and clear interpretations simultaneously.

1.2 An Example of Nonparametric Approximation using DNN

To illustrate the promise of DNN for nonparametric approximation, we consider a simple simulation experiment where we use DNN to approximate a polynomial function. Consider the following data generating process, where the data is simulated from a polynomial function of degree five adding the noise ϵ.

$$f(x) = 9.45x^5 - 10.5x^3 - 2x^2 + 4.25x + \epsilon \tag{1.1}$$

x is generated from 200 grid points from -1 to 1, and the noise ϵ follows a Gaussian distribution with a mean of 0 and a standard deviation of 0.15. The true generating function and the simulated noisy data are shown in Figure 1.1. In this experiment, DNNs with different numbers of hidden layers and different numbers of neurons in each hidden layer are used to recover the true function from the noisy data. First, we use DNN with one hidden layer to approximate the polynomial function. We vary the number of neurons in the hidden layer to be 4, 16, or 64 so that the number of parameters in the DNN is 13, 49, or 193. Additionally, DNNs with two hidden layers are used to recover the true function. The number of neurons in the two hidden layers is (2,2), (8,2), or (14,10), indicating that the number of parameters in the DNN is 13, 37, or 189. The results of the simulation study are shown in Figure 1.2, where Mean Squared error (MSE) is reported to evaluate the approximation error. The upper three panels are the estimated functions using DNNs with one hidden layer, and the lower three panels are the estimated functions from DNNs with two hidden layers. The approximation error decreases as the number of parameters in the DNN increases. For



Figure 1.1: **Simulated Data from Polynomial Function of Degree Five**

example, the MSE of DNNs with one hidden layer decreases from 0.333 to 0.126 as the number of parameters increases from 13 to 193. What's more, DNNs with two hidden layers can achieve similar or better approximation accuracy with fewer parameters. In this experiment, DNNs with two hidden layers with achieves the MSE of 0.184 to 0.116.



Figure 1.2: **DNN Approximation to Polynomial Function.** The upper three panels are estimated functions by DNNs with one hidden layer varying the number of neurons. The lower three panels are estimated functions by DNNs with two hidden layers varying the number of neurons in each hidden layer.

1.3 Overview of the Work

In this chapter, we give the literature review of DNNs and provide an example of applying DNNs with various structures to approximate a polynomial function. Most of the papers we cite here focus on the prediction performance of DNNs. There has been little work in explaining and interpreting the results of DNNs. In the following chapters, we are going to propose novel statistical learning methods that address these challenges by combining DNN with traditional statistical models.

In Chapter 2, we develop a novel Interpretable Neural Network Regression (INNER). The proposed INNER model is a logistic regression model with nonparametric covariate-dependent coefficients constructed by DNNs. We use the proposed INNER to conduct an individualized risk assessment of preoperative opioid use. Intensive simulations and an analysis of patients expecting surgery in the Analgesic Outcomes Study (AOS) show that the proposed INNER not only can accurately predict preoperative opioid use by preoperative characteristics as DNN but also can estimate the patient-specific odds of opioid use induced by overall body pain, leading to more straightforward interpretations of the tendency to use opioids than DNN. Furthermore, our results identify the patient characteristics strongly associated with opioid use. They are consistent with the previous findings, showing that INNER is a valuable tool for individualized risk assessment of preoperative opioid use.

In Chapter 3, we propose a Penalized Deep Partially Linear Cox Model (Penalized DPLC), which incorporates the SCAD penalty to select significant features and employs the DNN to estimate the nonparametric component of the partially linear Cox model accurately. An efficient alternating optimization algorithm for numerical implementation is provided. We also prove the convergence and asymptotic properties of the estimator and compare it to other methods through extensive simulation studies, evaluating its performance in risk prediction and feature selection. Finally, the proposed method is applied to the texture analysis of Chest CT scans from National Lung Screening Trial (NLST) to uncover the effects of critical clinical and imaging risk factors on patients' survival. Our findings provide valuable insights into the relationship between these factors and survival outcomes.

In Chapter 4, we develop a Deep Survival Learner (DSL) for estimating the heterogeneous treatment effects in survival settings. DSL is an adaption of Doubly Robust Learner to right-censored data by Inverse Probability of Censoring Weights (IPCW). DNNs are used as base learners to account for the complex relationships between baseline characteristics and survival outcomes. DSL estimates the conditional average treatment effects (CATEs) as a function of pre-treatment characteristics and given time of interest. We apply the fusion penalty to promote similarity between contiguous time points in the estimates. In the simulation studies, we assess the numerical performance of DSL under various scenarios, comparing it to other metalearners. We then apply DSL to the Boston Lung Cancer Study (BLCS) to investigate the treatment heterogeneity of perioperative chemotherapy for patients with Non-Small Cell Lung Cancer (NSCLC). Our findings contribute to a deeper understanding of the heterogeneous treatment effects of perioperative chemotherapy across individuals and contexts.

CHAPTER 2

Individualized Risk Assessment of Preoperative Opioid Use by Interpretable Neural Network Regression

2.1 Introduction

The drastic increase in the use of opioids has led to an epidemic in the U.S., with more than 46,000 estimated overdose deaths in 2018 [19]. As an effort to combat this crisis, researchers have begun to study preoperative opioid use because it is a major factor associated with opioid misuse [132], higher postoperative opioid demand [3, 139], worse postoperative outcomes [94, 144, 114, 78], and increased postoperative healthcare utilization and expenditures [35, 160, 78]. Understanding preoperative opioid use among patients expecting surgical services can help surgeons establish effective pain management for patients [67], including postoperative opioid management [129].

What has often been overlooked is that a sizeable portion of patients consumed opioids preoperatively even with no reported pains [129], which might hint at possible opioid misuse. As part of the Analgesic Outcomes Study (AOS) [20], a large observational cohort study investigating associations between preoperative pain and opioid use, individualized risk of preoperative opioid use is assessed to identify patients who tend to use preoperative opioids even when there is little pain as well as those who tend to take preoperative opoids even when the pain increases only slightly [21]. With opioid use (yes or no) as the outcome and pain level as the covariate, a logistic regression model with an intercept and a slope that depend on patients' other characteristics may help delineate the subgroups of patients who are at high risks of opioids misuse; see model (2.1). However, because of the curse of dimensionality, traditional nonparametric methods of fitting varying coefficient logistic models may not fare well [119, 63, 24], even when the number of patient characteristics is only moderately large.

On the other hand, deep neural network (DNN), a machine learning algorithm inspired by the structure of brains, has achieved much success in nonparametric approximation with high dimensional predictors [10, 138]. It has found applications in computational phenotyping [26, 101], medical imaging analysis [86, 157] and predictive modeling [30], among many others. It is challenging to explain the decision rules of DNN with the input variables, due to the black-box nature; directly applying DNN to the aforementioned AOS data cannot pinpoint the subgroup of patients who may be at high risks of opioid misuse.

For example, [42] use the Gini importance index from the random forest model to rank features, while [103] use the boosting decision tree. However, neither of these methods can give the direction of the association between features and opioid dependence. On the other hand, [27] use a weight matrix of each layer in the DNN model to generate "importance scores" to detect important features. The scores not only rank different features in terms of opioid overdose prediction but also inform the direction of the association. However, the method may not directly decipher the relationship between opioid use and pain, or, in particular, identify subpopulations who are likely to be sensitive to pain or be opioid dependent even without reported pains.

Bridging the gap between the statistical and machine learning fields, we propose an interpretable neural network regression (INNER) that combines the strengths of logistic regression and DNN models. We propose a logistic regression model with individualized coefficients, wherein the regression coefficients are functions of individual characteristics. We utilize DNN to estimate these individualized coefficients and construct two metrics, Baseline Opioid Tendency (BOT) and Pain-induced Opioid Tendency (POT), which are useful for the individualized assessment of opioid use for each patient. In particular, BOT refers to the odds of using preoperative opioids when the patient does not report pain and POT is the odds ratio of using preoperative opioids for a unit increase in the reported overall body pain. These two metrics can be used to identify subgroups of patients, whose characteristics are associated with preoperative opioid use: patients with high POT are more likely to get preoperative opioids when pain increases, and patients with high BOT have a high risk of preoperative opioid use even with no reported pain. To demonstrate the utility of our proposal, we conduct simulations and apply the INNER model to analyze the AOS study. Our analysis identifies patient characteristics that are associated with opioid tendency, as quantified by BOT and POT, and is largely consistent with the literature, evidencing the usefulness of INNER for individualized risk assessment of preoperative opioid use.

2.2 Interpretable Neural Network Regression

Our proposed INNER model is a logistic regression model with covariate-dependent coefficient functions constructed by DNN. The general formulation is similar to that of a DNN. Specifically, let $\mathbb{R}^d$ be a d-dimensional Euclidean vector space. To construct a prediction based on input $\mathbf{x} \in \mathbb{R}^{k_l}$ via a neural network with L layers, where the lth ($l = 1, \dots, L$) layer consists of k_l neurons, we adopt an L-fold composite function $F_L : \mathbb{R}^{k_1} \to \mathbb{R}^{k_{L+1}}$ with the parameter $\boldsymbol{\theta}$, i.e.,

$$F_L(\cdot; \boldsymbol{\theta}) = f_L \circ f_{L-1} \circ \cdots \circ f_1(\cdot),$$

where $f_l(\mathbf{x}) = \sigma_l(\mathbf{W}_l\mathbf{x} + \mathbf{b}_l) \in \mathbb{R}^{k_{l+1}}$ and "$\circ$" indicates the composition of two functions. The function $\sigma_l : \mathbb{R}^{k_{l+1}} \to \mathbb{R}^{k_{l+1}}$ is a (non)linear activation function for the lth layer. The parameter $\boldsymbol{\theta} = \{\mathbf{W}_l, \mathbf{b}_l\}_{l=1}^{L}$, where $\mathbf{W}_l$ is the weight matrix of dimension $k_{l+1} \times k_l$ and $\mathbf{b}_l \in \mathbb{R}^{k_{l+1}}$ is the bias vector. Typical choices of $\sigma_l(\mathbf{x})$ include a linear function of $\mathbf{x}$, a ReLU function, i.e., $\max(0, \mathbf{x})$, and a softmax function, i.e., $\exp(\mathbf{x})/\| \exp(\mathbf{x})\|_1$, where max and $\exp$ operate componentwise.

Let $\mathcal{D} = \{(X_i, \mathbf{Z}_i, Y_i), i = 1, \ldots, N\}$ be a dataset consisting of N independent patients. For patient $i \in \{1, \ldots, N\}$, let $Y_i \in \{0, 1\}$ be a binary variable indicating whether the patient uses opioids preoperatively. Let $X_i \in [0, 10]$ represent the overall body pain score and $\mathbf{Z}_i \in \mathbb{R}^p$ represent a vector of p preoperative characteristics. We model the conditional probability of preoperative opioid use given the preoperative characteristics and the overall body pain score via

$$\operatorname{logit}\{\mathrm{P}(Y_i = 1 \mid X_i, \mathbf{Z}_i)\} = F_L(\mathbf{Z}_i; \boldsymbol{\alpha}) + F_L(\mathbf{Z}_i; \boldsymbol{\beta}) \cdot X_i, \tag{2.1}$$

where $\operatorname{logit}(p) = \log\{p/(1 - p)\}$, with $p \in (0, 1)$, is the logit link function. The two covariate-dependent coefficient functions are constructed by two neural networks with the same network architecture but different parameters: $\boldsymbol{\alpha}$ and $\boldsymbol{\beta}$. Model (2.1) is termed an INNER model, wherein the number of neurons in the input layer is $k_1 = p$ and the output layer has only one neuron, i.e., $K_{L+1} = 1$. Figure 2.1 shows an example of three layers ($L = 3$), where the first two layers have 250 and 125 hidden neurons, respectively, with a ReLU activation function, and the third layer has one hidden neuron with a linear activation function. During training, we may randomly select a certain number of neurons in a layer and ignore them in order to overcome overfitting [145]. The proportion of such ignored neurons in a layer is called the dropout rate with that layer. During testing, dropout is set to be inactive with no neurons ignored.

We use the Sigmoid activation function, i.e., $\operatorname{Sigmoid}(x) = \{1 + \exp(-x)\}^{-1}$, for the output layer of the INNER model. Here, x comes from the affine combination of the two sub-networks whose final layers have a linear activation function, and the Sigmoid function returns a value between 0 and 1, ensuring numerical stability. The number of hidden layers, along with the number of hidden neurons and the dropout rate in each layer, are hyperparameters to be selected based on the prediction performance.

Our proposed INNER is interpretable within the traditional logistic regression framework, and can assess the individualized risk of preoperative opioid use via two derived metrics: Baseline Opioid Tendency (BOT), the odds of taking opioid with no reported pain, and Pain-induced Opioid Tendency (POT), the odds ratio of taking opioid for a unit increase in overall body pain. In particular, BOT and POT can be represented by the output of the two neural networks with the input



Figure 2.1: **Example of INNER. Input:** overall pain score (X) and other characteristics (**Z**). **Two neural networks for $F_L(\mathbf{Z};\boldsymbol{\alpha})$ and $F_L(\mathbf{Z};\boldsymbol{\beta})$:** the same network architecture with different parameters, $\boldsymbol{\alpha}$ and $\boldsymbol{\beta}$; three hidden layers in each network, with the first layer having 250 neurons with a ReLu activation function, the second layer having 125 neurons with a ReLu activation function, and the last layer having one neuron with a linear activation function. **Ouput:** estimated probability of preoperative opioid use.

$\boldsymbol{Z}$ respectively:

$$\text{Baseline Opioid Tendency (BOT)} := \exp\{F_L(\mathbf{Z};\boldsymbol{\alpha})\},$$
$$\text{Pain-induced Opioid Tendency (POT)} := \exp\{F_L(\mathbf{Z};\boldsymbol{\beta})\}.$$

Therefore, a high Baseline Opioid Tendency (BOT) or a high Pain-induced Opioid Tendency (POT) indicates a potential high risk of taking preoperative opioids.

The estimates of parameters, denoted by $\hat{\boldsymbol{\alpha}}$ and $\hat{\boldsymbol{\beta}}$, are obtained by minimizing the negative log likelihood or the cross entropy loss function

$$\mathcal{L}(\boldsymbol{\alpha},\boldsymbol{\beta};\mathcal{D}) = -\sum_{i=1}^{N} Y_i \log\{\mathrm{P}(Y_i = 1 \mid X_i, \mathbf{Z}_i)\} + (1 - Y_i)\log\{1 - \mathrm{P}(Y_i = 1 \mid X_i, \mathbf{Z}_i)\}, \quad (2.2)$$

where $\mathrm{P}(Y_i = 1 \mid X_i, \mathbf{Z}_i)$ is as defined in (2.1). We use stochastic gradient descent (SGD) [15] for optimization. In our later data analysis and out of a total of 34,186 patients, we randomly assign 23,931 (70%) patients to be training samples ($\mathcal{T}$) and the rest 10,256 (30%) patients to be validation samples ($\mathcal{V}$) when computing the training and validation loss.

In general, classical stochastic gradient descent is sensitive to the choice of learning rates; a large learning rate gives fast convergence but may induce numerical instability [102, 39], while a small learning rate may ensure stability, though at the price of more iterative steps. In our implementation,

```
Algorithm 1: Stochastic Gradient Descent
  Input: learning rate ($\eta$), maximum difference ($\Delta$), batch size ($M$)
  Output: $\hat{\boldsymbol{\alpha}}$, $\hat{\boldsymbol{\beta}}$
  Data: Partition full data $\mathcal{D}$ to training ($\mathcal{T}$) and validation ($\mathcal{V}$) samples
  Initialization $\boldsymbol{\alpha}^0$, $\boldsymbol{\beta}^0$, training loss = validation loss
  while validation loss - training loss $\leq \Delta$ do
      for mini-batch $m \leftarrow 1$ to $M$ do
          Draw random samples without replacement $(X_i, \mathbf{Z}_i, Y_i) \in \mathcal{T}$
      end
      Compute gradients $\nabla_{\boldsymbol{\alpha}}\mathcal{L}$ and $\nabla_{\boldsymbol{\beta}}\mathcal{L}$ of mini-batch
      Update parameters $\boldsymbol{\alpha} = \boldsymbol{\alpha} - \eta\nabla_{\boldsymbol{\alpha}}\mathcal{L}$ and $\boldsymbol{\beta} = \boldsymbol{\beta} - \eta\nabla_{\boldsymbol{\beta}}\mathcal{L}$
      Compute training loss: $\mathcal{L}(\boldsymbol{\alpha}, \boldsymbol{\beta}; \mathcal{T})$
      Compute validation loss: $\mathcal{L}(\boldsymbol{\alpha}, \boldsymbol{\beta}; \mathcal{V})$
  end
```

we use grid search to tune the learning rates. For the real data analysis, we tune the learning rate over the range between 0.005 to 0.1 with 20 equally spaced grid points, and set the batch size to be 64 and the maximum difference between the training and validation loss to be 10^{-2}. We obtain the estimates, $\hat{\boldsymbol{\alpha}}$ and $\hat{\boldsymbol{\beta}}$, after 200 iterations. We also conduct sensitivity analysis to assess the robustness of SGD towards the choices of these hyperparameters, and find the model's predictiveness performance is fairly robust to them; see Appendix B.

With $\hat{\boldsymbol{\alpha}}$ and $\hat{\boldsymbol{\beta}}$, BOT and POT can be estimated by plugging in these estimates: for a patient with $\mathbf{Z}_i$, the estimated BOT and POT are $\exp\{F_L(\mathbf{Z}_i; \hat{\boldsymbol{\alpha}})\}$ and $\exp\{F_L(\mathbf{Z}_i; \hat{\boldsymbol{\beta}})\}$, respectively.

2.3 Simulation Study

We compare the prediction power and robustness of the proposed INNER with the existing methods, including decision trees, random forests, Bayesian additive regression trees regression (BART), support vector machine (SVM), logistic regression and DNN. Under various scenarios examined, we find that INNER outperform these competing methods. The prediction power of INNER is similar to or even better than DNN when the model assumptions of INNER hold, whereas INNER achieves a performance comparable to DNN even when the model assumptions are violated. Codes for the simulation study are provided in the Supplementary Material.

2.3.1 Prediction Power

We simulate data from a logistic regression model with non-linear varying-coefficient functions:

$$\mathrm{logit}\{\mathrm{P}(Y = 1 \mid X, \mathbf{Z})\} = \sin(\mathbf{Z}^\top\boldsymbol{\alpha}) + \cos(\mathbf{Z}^\top\boldsymbol{\beta}) \cdot X.$$

The simulation study is designed with varying signal strengths, noise variances, number of covariates and sample sizes. The signal strength is measured by a signal-to-noise ratio, i.e.,

$$\frac{\mathrm{Var}\{\mathrm{P}(Y=1 \mid X, \mathbf{Z})\}}{\mathrm{Var}(Y)-\mathrm{Var}\{\mathrm{P}(Y=1 \mid X, \mathbf{Z})\}}.$$

We assess the prediction power of INNER by varying the signal-to-noise ratio to be 0.2, 0.8 or 3.2, and setting the sample size and the number of signal covariates to be 40,000 and 16, respectively.

We next increase the noise variance by adding various numbers of noise covariates (8, 12 and 16) into the data, while fixing the signal-to-noise ratio, the number of samples and the number of covariates at 3.2, 40,000 and 16 respectively. We finally consider several combinations of the numbers of covariates (9, 16, 32) and samples (5,000; 10,000; 20,000), with a signal-to-noise ratio of 3.2 and in the absence of noise covariates.

For each simulation configuration, we conduct a total of 500 experiments. In each experiment, we randomly allocate 80% of the samples to the training data and the rest to the testing data, and compare seven methods: the INNER model [equation (2.1), DNN, decision trees, random forests, BART and SVM models with combined $\mathbf{Z}$ and X as the input, and the logistic regression model with a two-way interaction between $\mathbf{Z}$ and X. For the logistic regression, we present it as a special case of INNER with only one layer and a linear activation function, that is,

$$\mathrm{logit}\{\mathrm{P}(Y=1 \mid X, \mathbf{Z})\} = \mathbf{Z}^{\top}\mathbf{W}_{\alpha} + b_{\alpha} + (\mathbf{Z}^{\top}\mathbf{W}_{\beta} + b_{\beta}) \cdot X, \tag{2.3}$$

where $\mathbf{W}_{\alpha}$ and $\mathbf{W}_{\beta}$ are the weight parameters, and b_{α} and b_{β} are the bias terms.

For INNER, the number of hidden layers in the neural network for $F_L(\mathbf{Z}_i; \boldsymbol{\alpha})$ is set to be 3. The first two layers have 200 and 10 hidden neurons with a dropout rate of 0.5 and 0.3, respectively. These two layers are equipped with a ReLu activation function. The final layer has only one neuron with a linear activation function. The neural network for $F_L(\mathbf{Z}_i; \boldsymbol{\beta})$ is similar and has 3 layers, each with 100, 90 and 1 hidden neurons but with no dropouts. The learning rate for both networks is 0.0014. For DNN, we use a network architecture with 4 layers: the first 3 layers have 160, 120 and 160 hidden neurons, respectively, and ReLu activation functions; the first and the third layers are with a dropout rate of 0.1 and 0.3, respectively; the last layer has one hidden neuron and a Sigmoid activation function. The loss function and the optimizer are the same as in the INNER model, but with a learning rate of 0.0007. These network hyperparameters are chosen to yield good prediction performances under the specified simulation configurations.

For decision trees, the maximum depth of a tree is 10 and the minimum number of samples required to split an internal node is 2. The minimum number of samples required to be at a leaf node for the decision is 4. For random forests, the number of features considered for the best split is the square root of the number of features, the minimum number of samples required to be at a leaf node is 2, the minimum number of samples required to split an internal node is 2 and the number of trees in a forest is 1,000. For SVM, we use a radial basis function kernel and set the regularization parameter to be 10. For BART, the number of trees to be grown in a sum-of-trees model is 80.

Summarizing the results of 500 simulations for each setting, Table 2.1 shows that most of the models achieve better model performances as the signal-to-noise ratio increases. For example, the C-statistics of decision trees and BART increase from 0.5 to more than 0.6 when the signal-to-noise ratio increases from 0.2 to 3.2, while the C-statistic increases to more than 0.8 for random forests and SVM. The performance of INNER and DNN is comparable across different signal strengths and is better than that of the other models. The C-statistics of DNN and INNER are 0.96 when the signal-to-noise ratio is 3.2.

Moreover, the performances of all the models deteriorate with more noise covariates added (Table 2.1). For instance, the C-statistic of BART decreases to around 0.6 with 16 added noise covariates, while the C-statistics for random forests and SVM, though slightly better, decrease to around 0.7 when we add 16 noise covariates. In contrast, the performances of INNER and DNN are consistently better than those of the other models. Moreover, INNER slightly outperforms DNN with noise covariates added; with 16 added noise covariates, INNER achieves a C-statistic of 0.95, slightly better than 0.93 achieved by DNN.

With various combinations of the number of covariates and sample size, the performance of each model improves when we use more samples to train the model or decrease the number of covariates (Table 2.1). DNN, INNER, random forests, BART and SVM achieve a C-statistic of more than 0.9 when the number of covariates is 8. Moreover, the C-statistics of DNN and INNER are 0.97 with 20,000 samples. However, when the number of covariates is 18, only random forests, SVM, DNN and INNER can achieve a C-statistic of more than 0.6 with 20,000 samples. Also, INNER performs much better than DNN with smaller sample sizes and larger numbers of covariates. The C-statistic of INNER is 0.92, larger than 0.84 for DNN when the number of covariates is 18 and the sample size is 20,000.

Table 2.1: Average (SE) C-statistics for different methods under the correctly specified model

Model / Specifications	Decision Trees	Random Forests	BART	SVM	Logistic Regression	DNN	INNER
Signal-to-noise Ratio[a]							
0.2	0.51 (0.0003)	0.52 (0.0003)	0.51 (0.0003)	0.61 (0.0002)	0.50 (0.0003)	0.62 (0.0020)	0.64 (0.0003)
0.8	0.62 (0.0003)	0.73 (0.0002)	0.61 (0.0004)	0.75 (0.0002)	0.50 (0.0009)	0.84 (0.0002)	0.85 (0.0002)
3.2	0.65 (0.0003)	0.81 (0.0002)	0.69 (0.0003)	0.85 (0.0002)	0.50 (0.0002)	0.96 (0.0013)	0.96 (0.0002)
Noise Covariates[b]							
8	0.64 (0.0003)	0.76 (0.0003)	0.68 (0.0003)	0.73 (0.0002)	0.50 (0.0002)	0.93 (0.0040)	0.96 (0.0003)
12	0.64 (0.0003)	0.74 (0.0003)	0.67 (0.0003)	0.73 (0.0002)	0.50 (0.0002)	0.93 (0.0036)	0.96 (0.0003)
16	0.64 (0.0003)	0.73 (0.0003)	0.66 (0.0003)	0.70 (0.0002)	0.50 (0.0002)	0.93 (0.0032)	0.95 (0.0019)
Number of Covariates[c]							
8							
Number of Samples							
5,000	0.60 (0.0008)	0.93 (0.0003)	0.90 (0.0004)	0.91 (0.0003)	0.67 (0.0054)	0.96 (0.0002)	0.96 (0.0003)
10,000	0.62 (0.0006)	0.94 (0.0002)	0.92 (0.0003)	0.93 (0.0002)	0.67 (0.0052)	0.97 (0.0002)	0.97 (0.0002)
20,000	0.63 (0.0004)	0.95 (0.0001)	0.94 (0.0002)	0.95 (0.0001)	0.68 (0.0052)	0.97 (0.0001)	0.97 (0.0001)
16							
Number of Samples							
5,000	0.60 (0.0008)	0.68 (0.0008)	0.59 (0.0007)	0.74 (0.0006)	0.50 (0.0005)	0.89 (0.0005)	0.88 (0.0010)
10,000	0.62 (0.0006)	0.72 (0.0005)	0.62 (0.0005)	0.78 (0.0004)	0.50 (0.0004)	0.92 (0.0004)	0.93 (0.0005)
20,000	0.63 (0.0004)	0.77 (0.0004)	0.66 (0.0004)	0.82 (0.0003)	0.50 (0.0003)	0.95 (0.0009)	0.96 (0.0003)
18							
Number of Samples							
5,000	0.60 (0.0008)	0.51 (0.0007)	0.50 (0.0007)	0.60 (0.0007)	0.50 (0.0005)	0.63 (0.0036)	0.70 (0.0048)
10,000	0.62 (0.0006)	0.54 (0.0008)	0.51 (0.0006)	0.62 (0.0004)	0.50 (0.0003)	0.78 (0.0046)	0.86 (0.0036)
20,000	0.63 (0.0004)	0.60 (0.0008)	0.51 (0.0006)	0.66 (0.0003)	0.50 (0.0002)	0.84 (0.0057)	0.92 (0.0049)

[a] the numbers of samples and covariates are fixed at 40,000 and 16, with varying signal-to-noise ratios and no noise covariates

[b] the signal-to-noise ratio, the numbers of samples and covariates are fixed at 3.2, 40,000 and 16, with varying numbers of noise covariates

[c] the signal-to-noise ratio is fixed at 3.2, with varying numbers of covariates and samples and no noise variables

2.3.2 Robustness

We assess the robustness of INNER when the INNER model (2.1) deviates from the true data-generating model, which is

$$\text{logit}\{\mathrm{P}(Y = 1 \mid X, \mathbf{Z})\} = -X \cdot \sin(\mathbf{Z}^\top \boldsymbol{\alpha}) + \sqrt{|\cos(\mathbf{Z}^\top \boldsymbol{\beta}) \cdot X|}.$$

The model structures of DNN and INNER used here differ from those in the prediction power study. DNN has four layers: the first two layers each have 100 hidden neurons with a ReLu activation function; the third layer has 160 neurons with a ReLu activation function and a dropout rate of 0.3; the last layer has one neuron with a Sigmoid function and a learning rate of 0.00046. For INNER, there are 3 hidden layers in the neural networks of $F_L(\mathbf{Z}_i; \boldsymbol{\alpha})$ and $F_L(\mathbf{Z}_i; \boldsymbol{\beta})$. There are 200, 10 and 1 neurons in each layer of $F_L(\mathbf{Z}_i; \boldsymbol{\alpha})$, and 180, 90 and 1 neurons in each layer of $F_L(\mathbf{Z}_i; \boldsymbol{\beta})$. The learning rate is set to be 0.004. Decision trees used here have a similar structure as those in the prediction power study, except that the minimum number of samples required to split an internal node is 10. For random forests, the maximum depth of a tree is 50, the minimum number of samples required to split an internal node is 2 and the number of trees in a forest is 2,500. For SVM, we use a radial basis function kernel and set the kernel coefficient to be 0.1. For BART, the number of trees to be grown in a sum-of-trees model is 90.

Based on 500 simulations for each setting, Table 2.2 reveals that, even under a misspecified model, INNER is able to achieve a performance as good as DNN and continues to outperform the other models. For example, when the signal-to-noise ratio is 3.2, both DNN and INNER achieve a C-statistic of 0.97, while the C-statistics of all the other models are less than 0.9. With 16 noise covariates added, DNN and INNER still achieve a C-statistic of 0.96, but the C-statistics for the other models are less than 0.8. When we increase the number covariates and decrease the number of samples, the C-statistics of DNN and INNER are still comparable and are higher than those of the other models.

Table 2.2: Average (SE) C-statistics for different methods under the misspecified model

Model Specifications	Decision Trees	Random Forests	BART	SVM	Logistic Regression	DNN	INNER
Signal-to-noise Ratio[a]							
0.2	0.55 (0.0003)	0.60 (0.0003)	0.55 (0.0003)	0.61 (0.0002)	0.50 (0.0004)	0.70 (0.0003)	0.71 (0.0020)
0.8	0.58 (0.0004)	0.69 (0.0003)	0.57 (0.0004)	0.76 (0.0002)	0.51 (0.0007)	0.86 (0.0002)	0.87 (0.0003)
3.2	0.62 (0.0003)	0.78 (0.0003)	0.62 (0.0005)	0.82 (0.0002)	0.51 (0.0006)	0.97 (0.0002)	0.97 (0.0003)
Noise Covariates[b]							
8	0.61 (0.0003)	0.76 (0.0003)	0.61 (0.0005)	0.71 (0.0002)	0.51 (0.0005)	0.96 (0.0002)	0.96 (0.0003)
12	0.61 (0.0003)	0.74 (0.0003)	0.60 (0.0005)	0.71 (0.0002)	0.51 (0.0005)	0.96 (0.0002)	0.96 (0.0003)
16	0.61 (0.0003)	0.73 (0.0003)	0.59 (0.0005)	0.68 (0.0002)	0.51 (0.0005)	0.96 (0.0002)	0.96 (0.0010)
Number of Covariates[c]							
8							
Number of Samples							
5,000	0.55 (0.0009)	0.93 (0.0003)	0.91 (0.0004)	0.91 (0.0004)	0.57 (0.0054)	0.94 (0.0004)	0.94 (0.0006)
10,000	0.58 (0.0007)	0.94 (0.0002)	0.93 (0.0003)	0.93 (0.0002)	0.57 (0.0056)	0.96 (0.0002)	0.96 (0.0004)
20,000	0.61 (0.0005)	0.95 (0.0001)	0.94 (0.0002)	0.94 (0.0001)	0.57 (0.0062)	0.97 (0.0002)	0.97 (0.0003)
16							
Number of Samples							
5,000	0.55 (0.0009)	0.61 (0.0007)	0.53 (0.0008)	0.69 (0.0007)	0.51 (0.0008)	0.90 (0.0005)	0.92 (0.0007)
10,000	0.58 (0.0007)	0.68 (0.0005)	0.56 (0.0007)	0.75 (0.0004)	0.51 (0.0007)	0.94 (0.0003)	0.95 (0.0004)
20,000	0.61 (0.0005)	0.74 (0.0003)	0.59 (0.0005)	0.79 (0.0003)	0.51 (0.0006)	0.96 (0.0002)	0.96 (0.0004)
18							
Number of Samples							
5,000	0.55 (0.0009)	0.54 (0.0007)	0.54 (0.0007)	0.65 (0.0006)	0.51 (0.0007)	0.86 (0.0021)	0.90 (0.0012)
10,000	0.58 (0.0007)	0.53 (0.0005)	0.54 (0.0005)	0.68 (0.0004)	0.51 (0.0005)	0.92 (0.0005)	0.94 (0.0014)
20,000	0.61 (0.0005)	0.53 (0.0004)	0.54 (0.0003)	0.73 (0.0003)	0.51 (0.0004)	0.95 (0.0002)	0.95 (0.0013)

[a] the numbers of samples and covariates are fixed at 40,000 and 16, with varying signal-to-noise ratios and no noise covariates

[b] the signal-to-noise ratio, the numbers of samples and covariates are fixed at 3.2, 40,000 and 16, with varying numbers of noise covariates

[c] the signal-to-noise ratio is 3.2, with varying numbers of covariates and samples and no noise variables

2.4 Analgesic Outcomes Study

We use the proposed INNER model to study the associations between patient characteristics and preoperative opioid use.

2.4.1 Data Preparation and Descriptive Analysis

The data are collected from the Analgesic Outcomes Study, an observational cohort study of acute and chronic pain [22, 20, 79, 21, 79, 58], with patients recruited from the preoperative assessment clinic before the surgery or in the preoperative waiting area on the surgery day during daytime hours (approximately 5:30 AM to 5 PM). Patients are excluded if they do not speak English, are unable to provide written informed consent, or are incarcerated. The institutional review board of the University of Michigan, Ann Arbor, approved this study, and all participants provided written informed consent. A total of 34,186 patients have been recruited and included in this analysis, and 7,894 (23.09%) of them are identified to have used opioids at least once. Preoperative opioid use is dichotomized and used as the response variable in this study. Preoperative characteristics are collected using self-report measures of pain, function and mood. A total of 6,819 (19.95%) patients have missing values of preoperative characteristics, and we impute the missing data with the mean (for continuous variables) or the mode (for categorical variables).

Sixteen preoperative characteristics are used to predict preoperative opioid use. Pain severity is measured with the Brief Pain Inventory [149], which assesses overall, average and worst body pain (11-point Likert-type scale, with higher scores indicating greater pain severity). Briefly, among all the patients in the analysis, 54.2% of them are female, most of them are white (89.06%), the mean age is 53.2 with a standard deviation (SD) of 16.2, and 7,984 (23.09%) of these patients have taken opioids preoperatively (Table 2.3).

It appears that some preoperative characteristics are associated with preoperative opioid use. Patients with more severe overall body pain (mean: 5.39, SD: 2.64) are more likely to use preoperative opioids. Smokers (4,341 [55.13%]) are more likely to use preoperative opioids than non-smokers (10,142 [39.02%]) ($P < 0.0001$). Patients with illicit drug use history (614 [7.80%]) and no alcohol consumption (4,677 [59.42%]) are at higher risks of preoperative opioid use ($P < 0.0001$). Patients with anxiety (3,324 [47.98%]), depression (2,409 [34.79%]) or less satisfied with life (mean: 6.02, SD: 2.63) tend to use preoperative opioids ($P < 0.0001$ for all). Patients who have poor physical conditions, e.g., those with American Society of Anaesthesiologists (ASA) score of 3 or 4 (3,755 [47.57%]) or high Fibromyalgia Survey Score (mean: 8.34, SD: 5.25), are more likely to use preoperative opioids ($P < 0.001$ for all). Preoperative opioid use is also associated with high BMI (mean: 30.74, SD: 7.74), sleep apnea (2,250 [29.15%]), race (Asian: 39[0.49%]) and surgical type ($P < 0.0001$ for all).

Table 2.3: Comparisons of Baseline Characteristics

	Overall	**Opioid Use**	**No Opioid Use**	**P Value**
	(N=34,186)	**(N=7,894)**	**(N=26,292)**	
BMI	29.90 (7.18)	30.74 (7.74)	29.64 (6.98)	<0.0001
Age	53.19 (16.15)	53.37 (14.97)	53.14 (16.49)	0.2441
Fibromyalgia Survey Score	5.47 (4.63)	8.34 (5.25)	4.61 (4.05)	<0.0001
Satisfaction with Life	7.03 (2.57)	6.02 (2.63)	7.33 (2.47)	<0.0001
Charlson Comorbidity Index	1.68 (3.30)	1.65 (3.32)	1.69 (3.29)	0.3037
Overall BPI Score	3.21 (2.86)	5.39 (2.64)	2.55 (2.58)	<0.0001
Gender				0.2605
Female	18,530 (54.20)	4,323 (54.76)	14,207 (54.04)	
Male	15,656 (45.80)	3,571 (45.24)	12,085 (45.96)	
Race				<0.0001
White	30,445 (89.06)	6,979 (88.41)	23,466 (89.25)	
African American	1,780 (5.21)	529 (6.70)	1,251 (4.76)	
Asian	467 (1.37)	39 (0.49)	428 (1.63)	
Other	1,494 (4.37)	347 (4.40)	1,147 (4.36)	
Tobacco use				<0.0001
No	19,384 (57.24)	3,533 (44.87)	15,851 (60.98)	
Yes	14,483 (42.76)	4,341 (55.13)	10,142 (39.02)	
Alcohol consumption				<0.0001
No	18,755 (55.39)	4,677 (59.42)	14,078 (54.17)	
Yes	15,105 (44.61)	3,194 (40.58)	11,911 (45.83)	
Illicit drug use				<0.0001
No	32,382 (95.61)	7,260 (92.20)	25,122 (96.65)	
Yes	1,486 (4.39)	614 (7.80)	872 (3.35)	
Sleep apnea				<0.0001
No	25,210 (75.96)	5,468 (70.85)	19,742 (77.51)	
Yes	7,977 (24.04)	2,250 (29.15)	5,727 (22.49)	
Depression				<0.0001
No	24,278 (80.40)	4,515 (65.21)	19,763 (84.91)	
Yes	5,920 (19.60)	2,409 (34.79)	3,511 (15.09)	
Anxiety				<0.0001
No	19,368 (64.15)	3,604 (52.02)	15,764 (67.77)	
Yes	10,822 (35.85)	3,324 (47.98)	7,498 (32.23)	
ASA Score				<0.0001
1-2	21,898 (64.06)	4,139 (52.43)	17,759 (67.55)	
3-4	12,288 (35.94)	3,755 (47.57)	8,533 (32.45)	
Body Group				<0.0001
Head	3,714 (11.06)	745 (9.52)	2,969 (11.53)	
Neck	4,150 (12.36)	806 (10.30)	3,344 (12.99)	
Thorax	2,167 (6.45)	363 (4.64)	1,804 (7.01)	
Intrathoracic	15,53 (4.62)	244 (3.12)	1,309 (5.08)	
Shoulder/Axilla	1854 (5.52)	321 (4.10)	1,533 (5.95)	
Upper Arm & Elbow	245 (0.73)	88 (1.12)	157 (0.61)	
Forearm, Wrist, Hand	1359 (4.05)	348 (4.45)	1,011 (3.93)	
Upper Abdomen	3,298 (9.82)	765 (9.77)	2,533 (9.84)	
Lower Abdomen	4,963 (14.78)	962 (12.29)	4,001 (15.54)	
Spine/Spinal Cord	1,472 (4.38)	841 (10.74)	631 (2.45)	
Perineum	3497 (10.41)	728 (9.30)	2,769 (10.75)	
Pelvis (Except Hip)	125 (0.37)	53 (0.68)	72 (0.28)	
Upper Leg (Except Knee)	1,582 (4.71)	567 (7.24)	1,015 (3.94)	
Knee/Popliteal	1,933 (5.76)	401 (5.12)	1,532 (5.95)	
Lower Leg	772 (2.30)	309 (3.95)	463 (1.80)	
Other	896 (2.67)	287 (3.67)	609 (2.36)	

[a] mean (SD) for each continuous characteristic is reported

[b] frequency (percentage) for each categorical characteristic is reported

[c] χ^2 test or unpaired 2-tailed t test is used to assess the univariate differences between non-users and opioid users as appropriate

2.4.2 Prediction Performance Evaluation

We compare the prediction performance of INNER with that of DNN and the logistic regression. We randomly split the data into the training and testing parts. Data imputation is then performed for the training and testing data separately. After training the INNER model using the training data, we test the prediction performance on the testing data. We conduct 100 independent trials by repeating the same procedure. We compare INNER with DNN and the logistic regression in accuracy, C-statistic, sensitivity, specificity and balance accuracy (the average of sensitivity and specificity).

Since the outcome data are unbalanced, we further propose a balanced subsampling strategy to avoid overfitting. That is, we split each training dataset into the opioid user and non-user groups. Among the non-user group, we randomly select the same number of patients as in the user group, append them to the user group and form a "balanced" dataset. We repeat the same procedure five times, generating five datasets and training five models on them. We then apply these five models to the testing data and compute the probability of taking opioids by averaging the probabilities estimated by these models. We also use different thresholds to predict whether a patient takes opioids. For example, the threshold can be 50.00% or 23.09%, the prevalence of taking opioids in the original data; patients with estimated probabilities of taking opioids higher than the threshold are predicted as using opioids.

The architecture of INNER is the same as the example shown in Figure 2.1. There are multiple hidden layers in each of the neural network, $F_L(\mathbf{Z}_i; \boldsymbol{\alpha})$ and $F_L(\mathbf{Z}_i; \boldsymbol{\beta})$. The last hidden layer has a linear activation function while the other layers have a ReLu activation function. We tune the number of layers and the number of hidden neurons in each layer based on the metrics we mentioned above. The best architecture has three hidden layers, each with 250, 125 and 1 hidden neuron, respectively.

When tuning the architecture of INNER, we vary the number of hidden layers and the number of neurons in each layer for $F_L(\mathbf{Z}_i; \boldsymbol{\alpha})$ and $F_L(\mathbf{Z}_i; \boldsymbol{\beta})$ and compare the different architectures based on accuracy, C-statistic, sensitivity, specificity and balance accuracy. We vary the number of hidden layers from 2 to 5, and the number of neurons in the first layer to be 125, 250 or 500. We set the number of neurons in the last layer to be 1. Each of the rest hidden layers has half of the previous layer's neurons. In Section B of the Supplementary Material, we show the performance of the best architecture and two other more complicated architectures.

For DNN, we define multiple inputs based on the nature of preoperative characteristics. We classify the characteristics into three categories, un-modifiable such as gender and race, modifiable such as BMI, alcohol and smoking status, and directly pain-related such as pain severity and Fibromyalgia Survey Score. As shown in Appendix A, each input is passed to the same structure of hidden layers by a ReLu activation function with different parameters, and is concatenated and passed to the output layer. We tune the number of hidden layers and the number of neurons in each layer before concatenation. The best architecture before concatenation has two layers and the number of hidden neurons in each of the corresponding layers is 500 and 250. After concatenation, there is one hidden layer with 15 neurons. The loss function and optimizer of DNN is the same as that of INNER. In Section B of the Supplementary Material, we shows the performance of the best architecture and two other more complicated architectures.

The INNER model achieves similar prediction power as DNN and is better than the logistic regression. We assess the performance of the three models with the best architectures using different sampling strategies and different; see Section B of the Supplementary Material. All the three models achieve the best balance accuracy with balance sampling and 0.5 as the threshold. Table 2.4 report the best performance of three models. The INNER and DNN achieve better performance in all four metrics (accuracy, sensitivity, specificity and balance accuracy) compared to the logistic regression. Moreover, there is no significant difference between the performance of INNER (accuracy: 0.72, SE: 0.0029; sensitivity: 0.69, SE: 0.0052; specificity: 0.73, SE: 0.0052; and balance accuracy: 0.71, SE: 0.0008) and DNN (accuracy: 0.72, SE: 0.0017; sensitivity: 0.694, SE: 0.0043; specificity: 0.73, SE: 0.0034; and balance accuracy: 0.71, SE: 0.0007).

Table 2.4: Comparisons of Model Goodness-of-fit with the AOS data

	Deep Neural Network	**Logistic Regression**	**INNER**
C-statistic	0.78 (0.0006)	0.76 (0.0027)	0.78 (0.0006)
Accuracy	0.76 (0.0017)	0.63 (0.0129)	0.72 (0.0029)
Sensitivity	0.69 (0.0043)	0.67 (0.0261)	0.69 (0.0052)
Specificity	0.73 (0.0034)	0.62 (0.0238)	0.73 (0.0052)
Balance Accuracy	0.71 (0.0007)	0.64 (0.0049)	0.71 (0.0008)

[a.] the results are obtained under the best architecture (for DNN and INNER) with the balanced subsampling strategy and a threshold of 0.5. For the performance of different sampling strategies, thresholds or structures, refer to Appendix B

[b.] based on 100 random splits.

2.4.3 Subgroup Analysis

We identify different subgroups based on the local false discovery rates [45, 47, 46] by looking at the distributions of the estimated POT and BOT. We then perform descriptive analysis on each of the subgroups and report the means (standard deviations) for continuous preoperative characteristics, and the frequencies (percentages) for categorical preoperative characteristics. We also estimate the probability of taking preoperative opioids for each patient with different pain scores and plot the average probability of taking preoperative opioids for each subgroup.

Our results lead to six subgroups (Fig 2.2) by controlling the local false discovery rate at 0.2. These subgroups include normal BOT & low POT (4,889 patients), normal BOT & normal POT (25,581 patients), normal BOT & high POT (3,579 patients), high BOT & low POT (67 patients), high BOT & normal POT (47 patients) and high BOT & high POT (6 patients). We estimate the probability of taking preoperative opioids with different pain scores stratified by subgroups in Fig 2.2. For the high BOT & high POT subgroup and the high BOT & normal POT subgroup, the probability of taking opioids exceeds 0.5 when the pain score is relatively low (high BOT & high POT: 0.2; high BOT & normal POT: 1.1), indicating these two subgroups have a high risk of taking preoperative opioids. The probability of taking opioids only exceeds 0.5 at the pain score of 6.0 for the high BOT & low POT subgroup and 6.3 for the normal BOT & high POT subgroup, and these two subgroups are considered as a moderate risk group. Finally, the normal BOT & normal POT subgroup has probability of taking opioids higher than 0.5 only when the pain score is larger than 8.6, and the probability for normal BOT & low POT is lower than 0.5 even when the pain score is 10. Thus, the normal BOT & normal POT subgroup and normal BOT & low POT subgroup are considered as a low risk group.



Figure 2.2: **Estimated Probability of Taking Preoperative Opioids Against Pain Score Stratified by Risk Groups**

Tables 2.5 and 2.6 show the characteristics for each subgroup. Patients in the high risk group (high BOT & normal and high BOT & high POT) and the moderate risk group (normal BOT & high POT and high BOT & low POT) tend to be more obese, younger, and have higher Fibromyalgia

Survey Scores and higher Charlson Comorbidity Indices than those in the low risk group. African Americans constitute about 17% of patients in the high risk group, while there are only 5% African Americans in the low risk group. Most of patients (100% for high BOT & normal POT group and 83% for high BOT & high POT group) in the high risk group have tobacco consumption. Patients are more likely to have illicit drug use history and sleep apnea in the high and moderate risk groups than in the low risk group. A large portion of patients in the high risk group (high BOT & normal POT: 97.83%, high BOT & high POT: 66.67%) have an ASA score of 3 or above, indicating a very poor overall physical condition.

We also perform an ANCOVA-type analysis to understand the importance of each covariate's contributions to the developed risk scores (Table 2.5, Table 2.6). Specifically, we use the log-transformed POT and BOT as response variables to fit separate linear models and calculate R^2 for each preoperative characteristic. Based on the R^2, Fibromyalgia Survey Score and ASA Score explain the most variations of BOT, while Fibromyalgia Survey Score, age and Charlson Comorbidity Index explain the most variations of POT.

Table 2.5: Subgroup Analysis

	Normal BOT **Low POT** **(N=4,889)**	**Normal BOT** **Normal POT** **(N=25,581)**	**Normal BOT** **High POT** **(N=3,597)**	**High BOT** **Low POT** **(N=67)**	**High BOT** **Normal POT** **(N=46)**	**High BOT** **High POT** **(N=6)**	$\mathbf{R^2}$ **(BOT,%)**	$\mathbf{R^2}$ **(POT,%)**
POT	1.13 (0.07)	1.31 (0.05)	1.54 (0.12)	1.05 (0.13)	1.27 (0.06)	1.79 (0.49)		
BOT	0.14 (0.10)	0.12 (0.08)	0.09 (0.07)	0.77 (0.14)	0.78 (0.13)	0.94 (0.38)		
BMI	29.63 (7.28)	29.62 (6.41)	32.18 (10.31)	33.99 (9.27)	28.95 (8.80)	36.44 (23.02)	0.91	1.29
Age	52.27 (19.17)	55.02 (14.74)	41.68 (16.48)	47.58 (10.61)	50.2 (12.97)	28.5 (6.98)	1.86	2.87
Fibromyalgia Survey Score	1.16 (3.20)	5.45 (4.62)	5.38 (4.43)	2.1 (7.47)	4.2 (9.55)	8.83 (13.72)	9.47	8.22
Satisfaction with Life	9.27 (1.45)	6.99 (2.58)	7.29 (2.75)	9.6 (1.59)	8.7 (2.84)	8.5 (2.51)	2.89	1.18
Charlson Comorbidity Index	1.13 (3.07)	1.63 (3.07)	2.77 (4.55)	3 (4.86)	2 (4.08)	6.67 (5.39)	0.06	2.75
Gender							0.60	0.08
Female	2,557 (52.30)	13,854 (54.16)	2,056 (57.16)	38 (56.72)	21 (45.65)	4 (66.67)		
Male	23,32 (47.70)	11,727 (45.84)	1,541 (42.84)	29 (43.28)	25 (54.35)	2 (33.33)		
Race							0.22	0.03
White	4,266 (87.26)	22,915 (89.58)	3,171 (88.16)	52 (77.61)	36 (78.26)	5 (83.33)		
African American	288 (5.89)	1,263 (4.94)	208 (5.78)	12 (17.91)	8 (17.39)	1 (16.67)		
Asian	95 (1.94)	327 (1.28)	44 (1.22)	1 (1.49)	0 (0.00)	0 (0.00)		
Other	240 (4.91)	1,076 (4.21)	174 (4.84)	2 (2.99)	2 (4.35)	0 (0.00)		
Tobacco use							16.96	0.69
No	3,217 (65.80)	14,417 (56.36)	2,064 (57.38)	4 (5.97)	0 (0.00)	1 (16.67)		
Yes	1,672 (34.20)	11,164 (43.64)	1,533 (42.62)	63 (94.03)	46 (100)	5 (83.33)		
Alcohol consumption							1.36	¡ 0.01
No	2,807 (57.41)	14,026 (54.83)	2,150 (59.77)	56 (83.58)	38 (82.61)	4 (66.67)		
Yes	2,082 (42.59)	11,555 (45.17)	1,447 (40.23)	11 (16.42)	8 (17.39)	2 (33.33)		
Illicit drug use							0.97	¡ 0.01
No	4,718 (96.50)	24,506 (95.80)	3,380 (93.97)	60 (89.55)	32 (69.57)	4 (66.67)		
Yes	171 (3.50)	1,075 (4.20)	217 (6.03)	7 (10.45)	14 (30.43)	2 (33.33)		
Sleep apnea							1.48	0.02
No	3,948 (80.75)	19,352 (75.65)	2,843 (79.04)	36 (53.73)	25 (54.35)	5 (83.33)		
Yes	941 (19.25)	6,229 (24.35)	754 (20.96)	31 (46.27)	21 (45.65)	1 (16.67)		

mean (SD) for each continuous characteristic and frequency (percentage) for each categorical characteristic are reported.

Table 2.6: Subgroup Analysis (Continued)

	Normal BOT Low POT (N=4,889)	**Normal BOT Normal POT (N=25,581)**	**Normal BOT High POT (N=3,597)**	**High BOT Low POT (N=67)**	**High BOT Normal POT (N=46)**	**High BOT High POT (N=6)**	**R^2 (BOT,%)**	**R^2 (POT,%)**
Depression							1.50	0.29
No	4,692 (95.97)	20,444 (79.92)	3,022 (84.01)	63 (94.03)	40 (86.96)	5 (83.33)		
Yes	197 (4.03)	5,137 (20.08)	575 (15.99)	4 (5.97)	6 (13.04)	1 (16.67)		
Anxiety							0.79	0.20
No	4,383 (89.65)	16,567 (64.76)	2,308 (64.16)	62 (92.54)	40 (86.96)	4 (66.67)		
Yes	506 (10.35)	9,014 (35.24)	1,289 (35.84)	5 (7.46)	6 (13.04)	2 (33.33)		
ASA score							8.26	¡ 0.01
0-2	3,389 (69.32)	16,102 (62.95)	2402 (66.78)	2 (2.99)	1 (2.17)	2 (33.33)		
3-4	1,500 (30.68)	9,479 (37.05)	1,195 (33.22)	65 (97.01)	45 (97.83)	4 (66.67)		
Body area							2.05	2.29
Head	835 (17.08)	2,507 (9.80)	361 (10.04)	9 (13.43)	1 (2.17)	1 (16.67)		
Neck	480 (9.82)	3,198 (12.5)	460 (12.79)	5 (7.46)	6 (13.04)	1 (16.67)		
Thorax	286 (5.85)	1,660 (6.49)	214 (5.95)	4 (5.97)	3 (6.52)	0 (0.00)		
Intrathoracic	332 (6.79)	1,095 (4.28)	120 (3.34)	5 (7.46)	1 (2.17)	0 (0.00)		
Shoulder/Axilla	279 (5.71)	1,399 (5.47)	170 (4.73)	5 (7.46)	1 (2.17)	0 (0.00)		
Upper Arm & Elbow	18 (0.37)	189 (0.74)	36 (1.00)	0 (0.00)	2 (4.35)	0 (0.00)		
Forearm, Wrist, Hand	414 (8.47)	848 (3.31)	94 (2.61)	3 (4.48)	0 (0.00)	0 (0.00)		
Upper Abdomen	325 (6.65)	2,443 (9.55)	506 (14.07)	16 (23.88)	8 (17.39)	0 (0.00)		
Lower Abdomen	716 (14.65)	4,176 (16.32)	666 (18.52)	6 (8.96)	3 (6.52)	2 (33.33)		
Spine/Spinal Cord	66 (1.35)	1,296 (5.07)	102 (2.84)	4 (5.97)	4 (8.70)	0 (0.00)		
Perineum	416 (8.51)	2,707 (10.58)	359 (9.98)	7 (10.45)	8 (17.39)	0 (0.00)		
Pelvis (Except Hip)	12 (0.25)	92 (0.36)	20 (0.56)	0 (0.00)	1 (2.17)	0 (0.00)		
Upper Leg (Except Knee)	107 (2.19)	1352 (5.29)	120 (3.34)	0 (0.00)	2 (4.35)	1 (16.67)		
Knee/Popliteal	424 (8.67)	1,384 (5.41)	124 (3.45)	0 (0.00)	1 (2.17)	0 (0.00)		
Lower Leg	89 (1.82)	540 (2.11)	140 (3.89)	1 (1.49)	1 (2.17)	1 (16.67)		
Other	90 (1.84)	695 (2.72)	105 (2.92)	2 (2.99)	4 (8.7)	0 (0.00)		

mean (SD) for each continuous characteristic and frequency (percentage) for each categorical characteristic are reported.

2.5 Discussion

The proposed INNER model achieves predictability comparable to DNN, but with more interpretability. The model leads to two metrics, BOT and POT, that may decipher the patterns of preoperative opioid use and explain the association between preoperative characteristics and preoperative opioid use. Patients with higher BMI and worse physical conditions (higher Charlson Comorbidity Indices, higher Fibromyalgia Survey Scores and higher ASA Scores) are more likely to consume preoperative opioids, and African American patients are more likely to be in the high and moderate risk groups. Patients with illicit drug use history and tobacco consumption are more likely to take preoperative opioids, while patients with alcohol consumption are less likely to have preoperative opioids. Patients with sleep apnea have a higher risk of taking preoperative opioids, as do patients expecting upper abdomen surgery. Detailed discussions of these subgroups can be found in the Appendix C.

Our results are largely consistent with the literature, which shows, for example, that patients with worse physical conditions are more likely to use preoperative opioids [146, 164, 57, 107]. [126] find that high BMI and Black race are preoperative risk factors for opioid use. Younger patients are reported to have a higher risk of preoperative opioid use controlling for sociodemographics and clinical variables [147]. Similarly, [103] find that age is the among the most important features for opioid overdose prediction. [61] report that patients with poor sleep quality are more likely to have preoperative opioid use. Tobacco use is reported to be a risk factor of preoperative opioid use by many studies [164, 107]. As for substance abuse, many studies find that subjects with drug use have higher risks of opioid use [147, 146]. Both [42] and [27] find that substance abuse history is among the most important features for opioid dependence prediction. [147] find that there is no significant association between problem alcohol use and opioid prescription (OR: 0.63; 95% CI: 0.35-1.15). The direction of OR in their study is consistent with our results. [146] report a non-significant association between alcohol use and opioid prescription, though the direction is opposite from our study (OR: 1.32, P = 0.479). More studies are warranted to identify the association between alcohol consumption and preoperative opioid use.

Finally, our proposed model can be extended to accommodate generalized linear models (GLMs) as discussed in [156]. Specifically, let $g(\cdot)$ be a link function to link the conditional mean $\mathbb{E}(y \mid x) = g^{-1}\{\eta(x)\}$ to covariates of interest (e.g., treatment or exposure), say, x, where $\eta(x) = \beta_0 + \boldsymbol{\beta}^\top x$. In order to model the nonlinear effects of additional features z (e.g., demographics, biomarkers) on η and achieve model flexibility, we can extend deep neural network to model the individualized intercepts and coefficients, namely, $\beta_0(z)$ and $\boldsymbol{\beta}(z)$. As such, the predictor can be written as $\eta(x, z) = \beta_0(z) + \boldsymbol{\beta}(z)^\top x$, which is to be linked to the conditional mean $\mathbb{E}(y \mid x, z)$ via $\mathbb{E}(y \mid x, z) = g^{-1}\{\eta(x, z)\} = g^{-1}\{\beta_0(z) + \boldsymbol{\beta}(z)^\top x\}$.

2.6 Conclusion

. Beyond preoperative outcomes, we could use this approach to better predict and understand important postoperative outcomes such as opioid refill [140], new chronic opioid use [22], hospital readmission, and opioid overdose. However, the best way to quantify the uncertainty of the estimates is still unknown. We will pursue this later.

CHAPTER 3

Penalized Deep Partially Linear Cox Models with Application to CT Scans of Lung Cancer Patients

3.1 Introduction

Lung cancer, as the leading cause of cancer mortality globally, yielded 2.09 million new cases and 1.76 million deaths worldwide in 2018 [16]. In the United States, lung cancer is the second most common cancer after prostate cancer [41], and there were about 229,000 new lung cancer cases in the country in 2020 [152]. Even with the advent of modern medicine, lung cancer mortality remains high, with a 5-year survival rate lower than 20% among advanced patients [6]. Identifying risk factors relevant to death among lung cancer patients is essential for establishing patient-centered therapy, which can improve patient survival [111].

The National Lung Cancer Screen Trial (NLST), 5. More than 53,000 participants were enrolled from August 2002 through April 2004 in the NLST, and around 26,000 subjects were randomly assigned to receive low-dose CT [151]. In addition, clinical information, such as age, gender, smoking history, and cancer stage, was collected for each patient. The study found a 20% decrease in lung cancer mortality for patients screened by low-dose CT [151]. It is of substantial interest to examine whether low-dose CT confers valuable features to help predict lung cancer survival and design efficient disease management strategies.

Due to the complexity of the features obtained by CT, it remains difficult to extract information from CT scans [128] and use such information to predict mortality among NLST patients. Several studies developed quantitative measurements of texture patterns on the CT scans related to patients' physiopathology characteristics [123]. CT texture analysis (CTTA) provides objective assessments of the texture patterns of the tumor by evaluating the distribution and relationship of voxel intensities [104], achieving promising prediction performances [53]. NLST utilized CTTA to analyze the diverse chest CT scans of patients, as CTTA can extract texture features of the same dimension for each patient, enabling comparison of these features across different patients [29]. Identifying reproducible and robust texture features in the presence of other clinical factors affecting patients' outcomes remains a challenge due to the sensitivity of radiomic features to factors such as scanner type, segmentation, and organ motion [92]. Thus, addressing this challenge is still a task that needs to be tackled [53].

Partially linear Cox models have gained popularity as a useful extension of the classic Cox models [34] for survival analysis. This model offers more flexibility in the risk function by separating the hazard function into parametric relative risks for certain covariates and nonparametric relative risks for the remaining covariates [71, 170]. In the NLST analysis, we have chosen to adopt this model by assigning the parametric risks to the texture features and the nonparametric risks to the clinical features such as age, gender, and race. This setup provides a clear interpretation of texture features like in regular Cox models, facilitates the selection of crucial radiomic features, and allows for extra flexibility in modeling the effects and potential interactions of the well-known clinical features.

To estimate the nonparametric risk function, researchers have proposed various methods, including spline-based approximation [135] and polynomial splines [71]. Recently, [170] made a breakthrough by using deep neural networks (DNN) to estimate the nonparametric risk function in partially linear Cox models and established an optimal minimax rate of convergence for the DNN-based estimator, and showed that DNN approximates a wide range of nonparametric functions with faster convergence. However, the performance of this method remains unknown when dealing with a large number of texture features, which is the case in the NLST study.

In many applications, the neural network has proven to be a powerful tool for approximating complex functions by providing accurate approximations of continuous functions [38, 97]. Under some smoothness and structural assumptions, [138] showed that DNN estimators may circumvent the curse of dimensionality and achieve the optimal minimax rate of convergence. With limited samples, however, a complex DNN can still lead to overfitting [12]. Various methods such as early stopping during training [98], adding dropout layers [145], and imposing penalties [141] have been proposed to address overfitting, but these methods have not been widely studied in the survival context.

To fill this gap, we introduce the Penalized Deep Partially Linear Cox Model (Penalized DPLC), a framework that identifies valuable radiomic features and models the complex relationships between survival outcomes and established clinical features such as age, body mass index (BMI), and pack years of smoking. Our work offers several benefits. Firstly, it employs the Smoothed Clipped Absolute Deviation (SCAD) penalty to select texture features that influence survival outcomes while avoiding overfitting, combining feature selection and deep learning in one solution. Secondly, we demonstrate the asymptotic properties of the estimator, determine its convergence rate, and provide theoretical guarantees. Additionally, we perform comprehensive simulations to validate the proposed model's theoretical properties and compare it with other methods in risk prediction and feature selection.

The structure of the paper is as follows. In Section 2, we introduce the Penalized DPLC model and the penalized log partial likelihood. Section 3 presents an efficient alternating optimization algorithm for minimizing the loss function. Theoretical guarantees for our estimator are provided in Section 4, where we prove its convergence rate to the true parameters. In Section 5, we conduct simulations to evaluate the performance of the Penalized DPLC and compare it with other state-of-the-art models. We apply the Penalized DPLC to a dataset from the NLST study in Section 6 to identify important texture features related to patient survival and find that the selected features are clinically interpretable and align with previous research findings.

3.2 SCAD-penalized Deep Partially Linear Cox Models

A partially linear Cox model assumes a hazard function:

$$\lambda(t|\mathbf{x},\mathbf{z}) = \lambda_0(t)\exp(\boldsymbol{\beta}_0^\top \mathbf{x} + g_0(\mathbf{z})), \tag{3.1}$$

where $\mathbf{x} \in \mathbb{R}^p$ and $\mathbf{z} \in \mathbb{R}^r$ are two covariate vectors, and $\lambda_0(t)$ is the baseline hazard. This class of models contains the Cox proportional hazards model as a special case if $g_0(\mathbf{z})$ is a linear function of $\mathbf{z}$. In the context of NLST, $\mathbf{x}$ represents texture features, while $\mathbf{z}$ represents known clinical features such as age, BMI, gender, race and cancer stage. The coefficients measuring the impact of texture features are represented by $\boldsymbol{\beta}_0$, while the non-parametric risk function of clinical features is represented by g_0 and is to be approximated by a function in a deep neural network (DNN). We consider a high dimensional setting for where p, the dimension of $\mathbf{x}$ can be larger than the sample size, while r, the dimension of known clinical features, is moderate. We assume that $\boldsymbol{\beta}_0$ is a s_β-sparse vector, i.e., $\|\boldsymbol{\beta}_0\|_0 = s_\beta < p$.

For an integer $L \geq 1$, we consider a DNN with $L+1$ layers, including an input layer, $L-1$ hidden layers and an output layer, and let each component of $\mathbf{p} = (p_1, p_2, \dots, p_{L+1})$, a vector of positive integers, be the number of neurons in the corresponding layer, where layers 1 and $L+1$ are the input and output layers, respectively; in our case, the dimension of the input features, $p_1 = r$, and the dimension of output, $p_{L+1} = 1$. As such, an $(L+1)$-layered neural network with an architecture $(L, \mathbf{p})$ can be expressed as a composite function, $g : \mathbb{R}^r \to \mathbb{R}^1$, with L folds, i.e., $g = g_L \circ g_{L-1} \circ \cdots \circ g_1$, where '$\circ$" denotes the composition of two functions, and the lth fold function

$$g_l(\cdot) = \sigma_l(\mathbf{W}_l \cdot + \mathbf{b}_l) : \mathbb{R}^{p_l} \to \mathbb{R}^{p_{l+1}} \text{ with } l = 1, \dots, L.$$

Here, $\mathbf{W}_l$ is a $p_{l+1} \times p_l$ weight matrix, $\mathbf{b}_l$ is a p_{l+1}-dimensional bias vector and "$\cdot$" represents an input from layer l. In the following, we use Θ to denote the set of parameters for the neural network containing all the weight matrices and bias vectors to be estimated. The function $\sigma_l : \mathbb{R}^{p_{l+1}} \to \mathbb{R}^{p_{l+1}}$

is an activation function, possibly nonlinear, that operates component-wise on a vector.

Different activation functions exist, with ReLU, i.e., $\max(0, \mathbf{a})$, being a commonly used one. Our focus is on neural networks that utilize ReLU functions for all layers, although it can be easily altered. We also concentrate on a specific class of DNNs, commonly used in the literature [170].

First, define a class of DNNs, say, $\mathcal{G}(L, \mathbf{p})$, which contains DNNs with architecture $(L, \mathbf{p})$ such that $\max_{l=1,\ldots,L}\{\|\mathbf{W}_l\|_\infty, \|\mathbf{b}_l\|_\infty\} < \infty$, where $\|\cdot\|_\infty$ denotes the sup-norm of a vector or matrix. DNNs with complex network architectures and a high number of parameters are prone to overfitting. To combat this issue, regularization techniques can be employed, such as adding a penalty term to the loss function (Setiono, 1997) or incorporating a dropout layer (Srivastava, 2014). Another option is to consider a class of s-sparse DNNs, imposing sparsity constraints on the weight matrices to improve interpretability and reduce overfitting:

$$\mathcal{G}(L, \mathbf{p}, s, G) = \{g \in \mathcal{G}(L, \mathbf{p}) : \sum_{l=1}^{L} \|\mathbf{W}_l\|_0 + \|\mathbf{b}_l\|_0 \le s, \|g\|_\infty \le G\}.$$

Here, $s \in \mathbb{N}_+$ (the set of positive integers), $G > 0$, $\|g\|_\infty = \sup\{|g(z)| : z \in \mathbb{D} \subset \mathbb{R}^r\}$ is the sup-norm of function g, and $\mathbb{D}$ is a bounded subset of $\mathbb{R}^r$.

With right censoring, we let U_i and C_i denote the survival and censored times for subject i, respectively. We observe $T_i = \min(U_i, C_i)$, and $\Delta_i = 1(U_i \le C_i)$, where $1(\cdot)$ is the indicator function, and assume the observed data $\mathcal{D} = \{(T_i, \Delta_i, \mathbf{x}_i, \mathbf{z}_i), i = 1, \ldots, n\}$ are independently and identically distributed (IID). To estimate g_0 in (3.1), we suggest using a DNN, denoted as $\mathcal{G}(L, \mathbf{p}, s, \infty)$, which takes $\mathbf{z} \in \mathbb{R}^r$ as input features and produces a scalar output. To handle the high-dimensional nature of $\boldsymbol{\beta}_0$, we propose a penalized estimation approach.

To proceed, we define the partial likelihood as

$$\ell(\boldsymbol{\beta}, g) = \frac{1}{n}\sum_{i=1}^{n} \Delta_i \Big[\boldsymbol{\beta}^\top \mathbf{x}_i + g(\mathbf{z_i}) - \log\Big\{\sum_{j \in R_i} \exp\big(\boldsymbol{\beta}^\top \mathbf{x}_j + g(\mathbf{z_j})\big)\Big\}\Big], \tag{3.2}$$

where $R_i = \{j : T_j \ge T_i\}$, the at-risk set at time T_i, and $g \in \mathcal{G}(L, \mathbf{p}, s, \infty)$. We would estimate $\boldsymbol{\beta}$ and $g(\cdot)$ by maximizing (3.2), where, to accommodate sparsity, we propose to use the SCAD penalty [49, 50] defined as

$$p'_\lambda(|\beta|) = \lambda\Big\{\mathrm{I}(|\beta| \le \lambda) + \frac{(a\lambda - |\beta|)_+}{(a-1)\lambda}\mathrm{I}(|\beta| > \lambda)\Big\}, \qquad a > 2,$$

yielding a penalized log partial likelihood,

$$PL(\boldsymbol{\beta}, g) = \ell(\boldsymbol{\beta}, g) - \sum_{j=1}^{p} p_\lambda(|\beta_j|).$$

The SCAD penalty is indeed a quadratic spline function with knots at λ and $a\lambda$, where $\lambda > 0$ is viewed as the tuning parameter controlling the sparsity of $\boldsymbol{\beta}$, and is assumed to converge to 0 as $n \to \infty$.

3.3 Estimation Procedure

We estimate $(\boldsymbol{\beta}_0, g_0)$ by maximizing $PL(\boldsymbol{\beta}, g)$, or, equivalently, minimizing the loss function which is defined as the negative penalized log partial likelihood:

$$Q(\boldsymbol{\beta}, g) = q(\boldsymbol{\beta}, g) + \sum_{j=1}^{p} p_\lambda(|\beta_j|), \tag{3.3}$$

where $q(\boldsymbol{\beta}, g) = -\ell(\boldsymbol{\beta}, g)$. That is, the estimate of $(\boldsymbol{\beta}_0, g_0)$ is obtained via

$$(\hat{\boldsymbol{\beta}}, \hat{g}) = \arg \min_{\boldsymbol{\beta}, g \in \mathbb{R}^p \times \mathcal{G}} Q(\boldsymbol{\beta}, g). \tag{3.4}$$

We present an optimization algorithm for solving (3.4) alternately. Our approach involves using the adaptive moment estimation (Adam) algorithm to estimate g given an estimate of $\boldsymbol{\beta}$. Subsequently, we use the resulting estimate $\hat{g}$ to estimate $\boldsymbol{\beta}$ via coordinate descent. The outline of our algorithm is as follows.

Step 1. Initialize $\boldsymbol{\beta}$ with $\hat{\boldsymbol{\beta}}^{(0)}$.

Step 2. Denote by $\hat{\boldsymbol{\beta}}^{(k-1)}$ the estimate of $\boldsymbol{\beta}$ at the $(k-1)$th iteration. Solve (3.4) for g, with $\boldsymbol{\beta}$ fixed at $\hat{\boldsymbol{\beta}}^{(k-1)}$, by using Adam (see Algorithm 2 below). Denote by $\hat{g}^{(k)}$ the estimate at the current iteration.

Step 3. With g fixed at $\hat{g}^{(k)}$, solve (3.4) for $\boldsymbol{\beta}$ by using the coordinate descent algorithm (see Algorithm 3 below). Denote by $\hat{\boldsymbol{\beta}}^{(k)}$ be the estimate at the current iteration.

Step 4. Repeat Steps 2 and 3 until convergence.

In Step 2, we employ an adapted Adam algorithm (Algorithm 1), a form of stochastic gradient descent [85], to estimate Θ (the weight matrices and bias vectors) in the neural network. To ensure numerical stability, a small positive constant ϵ_0 is added to the denominator. The learning rate for each parameter is determined adaptively based on estimates of the first and second moments of the gradients. Algorithm 1 is distinct from the traditional Adam method in that it updates the parameters in the neural network while maintaining $\boldsymbol{\beta}$ at its previous iteration, rather than updating all parameters simultaneously, as done in standard Adam. In Step 3, the coordinate descent algorithm for the Penalized DPLC can be derived following the method in [17]. Let $\boldsymbol{\xi} = \mathbf{X}\boldsymbol{\beta} \in \mathbb{R}^n$, where $\mathbf{X} = (\mathbf{x}_1, \ldots, \mathbf{x}_n)^\top$ is the covariate ($\mathbf{x}$) matrix of the n subjects in the data. We denote the gradient and Hessian of the function q with respect to $\boldsymbol{\beta}$ and $\boldsymbol{\xi}$ given the current estimate of the neural network, $\hat{g}^{(k)}$, as $q'(\boldsymbol{\beta}; \hat{g}^{(k)})$, $q''(\boldsymbol{\beta}; \hat{g}^{(k)})$, $q'(\boldsymbol{\xi}; \hat{g}^{(k)})$, and $q''(\boldsymbol{\xi}; \hat{g}^{(k)})$. To simplify notation, we will omit $\hat{g}^{(k)}$ in the following. The function $q(\boldsymbol{\beta})$ is approximated using a second order Taylor expansion around $\hat{\boldsymbol{\beta}}_{(t)}$:

Algorithm 2: Adam in alternating optimization

```
Input  : $r_1, r_2, \gamma, \hat{\boldsymbol{\beta}}^{(k-1)}, \iota$
Initialize $m^{(0)} \leftarrow 0$, $v^0 \leftarrow 0$, $\Theta^{(0)} \leftarrow 0$ and $t \leftarrow 1$
while $\|\hat{\Theta}^{(t)} - \hat{\Theta}^{(t-1)}\|_2 > \iota$ do
    $m^{(t)} \leftarrow r_1 \cdot m^{(t-1)} + (1 - r_1) \cdot \nabla_\Theta Q(\hat{\boldsymbol{\beta}}^{(k-1)}, \hat{g}^{(t)})$
    $v^{(t)} \leftarrow r_2 \cdot m^{(t-1)} + (1 - r_2) \cdot \nabla_\Theta Q(\hat{\boldsymbol{\beta}}^{(k-1)}, \hat{g}^{(t)})^2$
    $\hat{m}^{(t)} \leftarrow m^{(t)}/(1 - r_1^t)$, $\hat{v}^{(t)} \leftarrow v^{(t)}/(1 - r_2^t)$
    $\hat{\Theta}^{(t)} \leftarrow \hat{\Theta}^{(t-1)} - \gamma \hat{m}^{(t)}/(\sqrt{\hat{v}^{(t)}} + \epsilon_0)$
    $t \leftarrow t + 1$
Output: $\hat{g}^{(k)} \leftarrow g(\cdot \mid \hat{\Theta}^{(t)})$
```

$$
\begin{aligned}
q(\boldsymbol{\beta}) &\approx q(\hat{\boldsymbol{\beta}}_{(t)}) + (\boldsymbol{\beta} - \hat{\boldsymbol{\beta}}_{(t)})^\top q'(\hat{\boldsymbol{\beta}}_{(t)}) + (\boldsymbol{\beta} - \hat{\boldsymbol{\beta}}_{(t)})^\top q''(\hat{\boldsymbol{\beta}}_{(t)})(\boldsymbol{\beta} - \hat{\boldsymbol{\beta}}_{(t)})/2 \\
&= q(\hat{\boldsymbol{\beta}}_{(t)}) + (\boldsymbol{\xi} - \hat{\boldsymbol{\xi}}^{(t)})^\top q'(\hat{\boldsymbol{\xi}}^{(t)}) + (\boldsymbol{\xi} - \hat{\boldsymbol{\xi}}^{(t)})^\top q''(\hat{\boldsymbol{\xi}}^{(t)})(\boldsymbol{\xi} - \hat{\boldsymbol{\xi}}^{(t)})/2 \\
&= \frac{1}{2}(y(\hat{\boldsymbol{\xi}}^{(t)}) - \boldsymbol{\xi})^\top q''(\hat{\boldsymbol{\xi}}^{(t)})(y(\hat{\boldsymbol{\xi}}^{(t)}) - \boldsymbol{\xi}) + C(\hat{\boldsymbol{\xi}}^{(t)}, \hat{\boldsymbol{\beta}}_{(t)}),
\end{aligned}
$$

where $y(\hat{\boldsymbol{\xi}}^{(t)}) = \hat{\boldsymbol{\xi}}^{(t)} - q''(\hat{\boldsymbol{\xi}}^{(t)})^{-1} q'(\hat{\boldsymbol{\xi}}^{(t)})$ and $C(\hat{\boldsymbol{\xi}}^{(t)}, \hat{\boldsymbol{\beta}}_{(t)})$ does not depend on $\boldsymbol{\beta}$. The equalities hold as $q'(\boldsymbol{\beta}) = \mathbf{X}^\top q'(\boldsymbol{\xi})$ and $q''(\boldsymbol{\beta}) = \mathbf{X}^\top q''(\boldsymbol{\xi})\mathbf{X}$ by the chain rule. Then the loss function (3.3) at iteration t can be approximated by the penalized weighted sum of squares:

$$
Q(\boldsymbol{\beta}) \approx \frac{1}{2}(y(\hat{\boldsymbol{\xi}}^{(t)}) - \boldsymbol{\xi})^\top q''(\hat{\boldsymbol{\xi}}^{(t)})(y(\hat{\boldsymbol{\xi}}^{(t)}) - \boldsymbol{\xi}) + C(\hat{\boldsymbol{\xi}}^{(t)}, \hat{\boldsymbol{\beta}}^{(t)}) + \sum_{j=1}^{p} p_\lambda(|\beta_j|).
$$

To speed up the algorithm, we may replace $q''(\hat{\boldsymbol{\xi}}^{(t)})$ by a diagonal matrix, $\mathbf{W}(\hat{\boldsymbol{\xi}}^{(t)})$, with the diagonal entries of $q''(\hat{\boldsymbol{\xi}}^{(t)})$[143]:

$$\mathbf{W}(\hat{\boldsymbol{\xi}}^{(t)})_{m,m} = q''(\hat{\boldsymbol{\xi}}^{(t)})_{m,m} = \frac{1}{n}\sum_{i\in C_m}\Delta_i\left\{\frac{e^{\hat{\xi}_m^{(t)}+\hat{g}_m^{(k)}}\sum_{j\in R_i}e^{\hat{\xi}_j^{(t)}+\hat{g}_j^{(k)}} - (e^{\hat{\xi}_m^{(t)}+\hat{g}_m^{(k)}})^2}{(\sum_{j\in R_i}e^{\hat{\xi}_j^{(t)}+\hat{g}_j^{(k)}})^2}\right\},$$

where $C_m = \{i : T_i \leq T_m\}$ and $R_i = \{j : T_j \geq T_i\}$. In this case,

$$y(\hat{\boldsymbol{\xi}}^{(t)})_m = \hat{\boldsymbol{\xi}}_m^{(t)} + \frac{1}{n\mathbf{W}(\hat{\boldsymbol{\xi}}^{(t)})_{m,m}}\left\{\Delta_m - \sum_{i\in C_m}\Delta_i\left(\frac{e^{\hat{\xi}_m^{(t)}+\hat{g}_m^{(k)}}}{\sum_{j\in R_i}e^{\hat{\xi}_j^{(t)}+\hat{g}_j^{(k)}}}\right)\right\}.$$

In the iteration of coordinate descent, the parameters are updated individually; each parameter has a closed-form solution, making the computation manageable. We employ an adaptive rescaling technique [17]; with the SCAD penalty, the following SCAD-thresholding operator returns the univariate solution for the SCAD-penalized optimization:

$$f_{SCAD}(h, v; a, \lambda) = \begin{cases} \frac{S(h,\lambda)}{v}, & \text{if } |h| \leq 2\lambda \\ \frac{S(h,a\lambda/(a-1))}{v(1-1/(a-1))}, & \text{if } 2\lambda < |h| \leq a\lambda \\ h/v, & \text{if } |h| > a\lambda, \end{cases}$$

where $S(\cdot, \lambda)$ is the soft-thresholding operator with a threshold parameter, $\lambda > 0$ [43], i.e., $S(h, \lambda) = sign(h)(|h| - \lambda)_+$. Here, the sign function $sign(h)$ equals $h/|h|$ if $h \neq 0$, and 0 if $h = 0$; $(h)_+ = \max(h, 0)$. Let $\mathbf{r} = y(\boldsymbol{\xi}) - \boldsymbol{\xi}$ and $v_j = \mathbf{x}_j^\top \mathbf{W}(\boldsymbol{\xi})\mathbf{x}_j$. We define the following input at the t-th iteration for the SCAD-thresholding operator

$$h_j = \mathbf{x}_j^\top \mathbf{W}(\hat{\boldsymbol{\xi}}^{(t)})\mathbf{r} + v_j\beta_j^{(t)}.$$

The coordinate descent algorithm is presented in Algorithm 3.

3.4 Regularity Conditions and Statistical Properties

We impose sparsity on $\boldsymbol{\beta}_0 = (\beta_{10}, \ldots, \beta_{p0})^\top$. Without loss of generality, write $\boldsymbol{\beta}_0 = (\boldsymbol{\beta}_{10}^\top, \boldsymbol{\beta}_{20}^\top)^\top$ and assume $\boldsymbol{\beta}_{20} = \mathbf{0}$. To restrict the nonparametric function g_0, we assume that it belongs to a composite Hölder class of smooth functions [138]. First, with constants $a, M > 0$ and a positive integer d, we define a Hölder class of smooth functions as

$$\mathcal{H}_d^a(\mathbb{D}, M) = \{f : \mathbb{D} \subset \mathbb{R}^d \to \mathbb{R} : \sum_{v:|v|<a} \|\partial^v f\|_\infty + \sum_{v:|v|=\lfloor a \rfloor} \sup_{x,y\in\mathbb{D},x\neq y} \frac{|\partial^v f(x) - \partial^v f(y)|}{\|x - y\|_\infty^{a-\lfloor a \rfloor}} \leq M\},$$

Algorithm 3: Coordinate Descent in alternating optimization

```
Input  : $a$, $\lambda$, $\hat{\boldsymbol{\beta}}_{(0)} = \hat{\boldsymbol{\beta}}^{(k-1)}$, $\hat{g}^{(k)}$, $\iota$
Initialize $t \leftarrow 1$, $\hat{\boldsymbol{\xi}}^{(0)} \leftarrow \mathbf{X}\hat{\boldsymbol{\beta}}_{(0)}$, and $\mathbf{r} \leftarrow y(\hat{\boldsymbol{\xi}}^{(0)}) - \hat{\boldsymbol{\xi}}^{(0)}$
while $\|\hat{\boldsymbol{\beta}}_{(t)} - \hat{\boldsymbol{\beta}}_{(t-1)}\|_2 > \iota$ do
    for $j \leftarrow 1$ to $p$ do
        $h_j \leftarrow \mathbf{x}_j^\top \mathbf{W}(\hat{\boldsymbol{\xi}}^{(t-1)})\mathbf{r} + \upsilon_j \beta_{(t-1),j}$
        $\hat{\beta}_{(t),j} \leftarrow f_{SCAD}(h_j, \upsilon_j; a, \lambda)$
        $\mathbf{r} \leftarrow \mathbf{r} - (\hat{\beta}_{(t),j} - \hat{\beta}_{(t-1),j})\mathbf{x}_j$
    $\hat{\boldsymbol{\xi}}^{(t)} \leftarrow \mathbf{X}\hat{\boldsymbol{\beta}}_{(t)}$
    $t \leftarrow t + 1$
Output : $\hat{\boldsymbol{\beta}}^{(k)} \leftarrow \hat{\boldsymbol{\beta}}_{(t)}$
```

where $\mathbb{D}$ is a bounded subset of $\mathbb{R}^d$, $\lfloor a \rfloor$ is the largest integer smaller than a, $\partial^\upsilon := \partial^{\upsilon_1} \dots \partial^{\upsilon_r}$ with $\upsilon = (\upsilon_1, \dots, \upsilon_d) \in \mathbb{N}^d$, and $|\upsilon| := \sum_{j=1}^d \upsilon_j$.

For a positive integer q, let $\alpha = (\alpha_1, \dots, \alpha_q) \in \mathbb{R}_+^q$, and $\mathbf{d} = (d_1, \dots, d_{q+1}) \in \mathbb{N}_+^{q+1}$, $\tilde{\mathbf{d}} = (\tilde{d}_1, \dots, \tilde{d}_q) \in \mathbb{N}_+^q$ with $\tilde{d}_j \leq d_j$. We then define a composite Hölder smooth function class as

$$\mathcal{H}(q, \alpha, \mathbf{d}, \tilde{\mathbf{d}}, M) = \{f = f_q \circ \cdots \circ f_1 : f_i = (f_{i1}, \dots, f_{id_{i+1}})^\top, f_{ij} \in \mathcal{H}_{\tilde{d}_i}^{\alpha_i}([a_i, b_i]^{\tilde{d}_i}, M), |a_i|, |b_i| \leq M\}, \tag{3.5}$$

where $[a_i, b_i]$ is the bounded domain for each Hölder smooth function. There are two types of dimensional parameters, $\mathbf{d}$ and $\tilde{\mathbf{d}}$. The latter is defined as the *intrinsic dimension* [170], often much smaller than the feature dimension $\mathbf{d}$. We will prove that the convergence rate of DNN depends on the intrinsic dimension, $\tilde{\mathbf{d}}$, instead of $\mathbf{d}$, meaning a faster convergence rate than the other nonparametric estimators.

Throughout, $\mathbb{E}$ denotes the expectation of random variables; unless otherwise specified, for any function (random or nonrandom) f and a random vector, $\mathbf{v}$, we define $\mathbb{E}\{f(\mathbf{v})\} := \int f(\mathbf{t}) f_{\mathbf{v}}(\mathbf{t}) d\mathbf{t}$, where $f_{\mathbf{v}}(\cdot)$ is the density function of $\mathbf{v}$. Thus, the expectation is taken with respect to only the arguments of the f function. For a vector $\mathbf{a}$, define $||\mathbf{a}|| = (\mathbf{a}^\top \mathbf{a})^{1/2}$, and for a function g, define $\|g\|_{L^2}^2 = \mathbb{E}\{g^2(\mathbf{z})\}$. We denote $\tilde{\alpha}_i = \alpha_i \prod_{k=i+1}^q (\alpha_k \wedge 1)$ and $\gamma_n = \max_{i=1,\dots,q} n^{-\tilde{\alpha}_i/(2\tilde{\alpha}_i + \tilde{d}_i)}$, and assume the following conditions.

1. Considering a class of s-sparse DNNs or $\mathcal{G}(L, \mathbf{p}, s, G)$, we assume $L = O(\log n)$, $s = O(n\gamma_n^2 \log n)$ and $n\gamma_n^2 < \min_{l=1,\dots,L} p_l \leq \max_{l=1,\dots,L} p_l < n$.

2. With slightly overuse of notation, denote by $\mathbf{x}$ and $\mathbf{z}$ the random vectors underlying the observed IID copies of $\mathbf{x}_i$ and $\mathbf{z}_i$, respectively. Assume $(\mathbf{x}^\top, \mathbf{z}^\top)^\top$ take values in a bounded subset of $\mathbb{R}^{p+r}$ with a joint probability density function bounded away from zero, and $\boldsymbol{\beta}_0$ lies

in a compact set, i.e., $\boldsymbol{\beta}_0 \in \{\boldsymbol{\beta} \in \mathbb{R}^p : \|\boldsymbol{\beta}\| \leq B\}$.

3. Assume that the nonparametric function g_0 belongs to a mean 0 composite Hölder smooth class, i.e., $g_0 \in \mathcal{H}_0 \coloneqq \{g \in \mathcal{H}(q, \alpha, \mathbf{d}, \tilde{\mathbf{d}}, M) : \mathbb{E}\{g(\mathbf{z})\} = 0\}$ and the matrix $\mathbb{E}\{\mathbf{x} - \mathbb{E}(\mathbf{x}|\mathbf{z})\}^{\otimes 2}$ is nonsingular, where $\mathbf{a}^{\otimes 2} = \mathbf{a}\mathbf{a}^\top$ for a column vector $\mathbf{a}$.

4. Let τ be the maximal followup time. We assume that there exits a $\delta > 0$ such that $P(\Delta = 1|\mathbf{x}, \mathbf{z}) > \delta$ and $P(U > \tau|\mathbf{x}, \mathbf{z}) > \delta$ almost surely.

Condition 1 imposes a restriction on the architecture of neural networks, balancing the network's flexibility with the estimation accuracy [8, 9, 109, 120]. Condition 2 is commonly assumed for semiparametric partially linear models [68]. The Hölder smoothness in Condition 3 ensures that the function can be approximated by a DNN, while the zero expectation assumption ensures the identifiability of the deep partially linear Cox model [170]. In Condition 4, $P(\Delta = 1|\mathbf{x}, \mathbf{z}) > \delta$ ensures that there is a non-zero probability of observing an event, and $P(U > \tau|\mathbf{x}, \mathbf{z}) > \delta$ ensures that there are subjects still alive at the end of the study. Both of these assumptions guarantee that the partially linear Cox model can be estimated using the observed data.

For the SCAD penalty, we define $a_n = \max\{p'_\lambda(|\beta_{j0}| : \beta_{j0} \neq 0)\}$ and $b_n = \max\{p''_\lambda(|\beta_{j0}| : \beta_{j0} \neq 0)\}$. The following theorem establishes the existence and the convergence rates of $\hat{\boldsymbol{\beta}}$ and $\hat{g}$.

Theorem 1 *Under Conditions 1-4, and if $b_n \to 0$ (with properly chosen λ), then there exists a local maximizer $(\hat{\boldsymbol{\beta}}, \hat{g})$ of $PL(\boldsymbol{\beta}, g)$ satisfying $\mathbb{E}\{\hat{g}(\mathbf{z})\} = 0$, such that*

$$\|\hat{\boldsymbol{\beta}} - \boldsymbol{\beta}_0\| = O_p(\gamma_n \log^2 n + a_n)$$

and

$$\|\hat{g} - g_0\|_{L^2} = O_p(\gamma_n \log^2 n + a_n).$$

The theorem shows that the rate of convergence does not depend on the number of input features, but rather on the intrinsic dimension and smoothness of the function g_0, unlike other nonparametric estimators whose convergence rate also depends on the feature dimension. As a result, the DNN estimator may have an advantage when the intrinsic dimension of the true function is low.

3.5 Simulations

We conducted a series of simulations to assess the finite sample performance of our proposed estimator. For $i = 1, \dots, n$, we generated $(\mathbf{x}_i, \mathbf{z}_i)$ from a multivariate Gaussian distribution,

$$\mathcal{N}_{p+r}\left\{\mathbf{0}, \begin{bmatrix} 1 & 0.2 & \dots & 0.2 \\ \vdots & \vdots & \ddots & \vdots \\ 0.2 & 0.2 & \dots & 1 \end{bmatrix}\right\},$$

and then generated the true survival time U_i from an exponential distribution with a hazard

$$\mu \exp(\boldsymbol{\beta}_0^T \mathbf{x}_i + g_0(\mathbf{z}_i)),$$

where μ was chosen to be 0.003 and $\boldsymbol{\beta}_0 \in \mathbb{R}^p$ was a sparse vector simulated from the uniform distribution. The number of nonzero elements in $\boldsymbol{\beta}_0$ was s_β, chosen to be much less than the dimension of $\boldsymbol{\beta}_0$. The censored time C_i was simulated from a uniform distribution on $[0, \mathcal{C}]$, where $\mathcal{C}$ was chosen so that the censoring rate in the simulated data is around 30%.

We simulated data sets with varying sample sizes and feature sizes. Specifically, we fixed the clinic feature size, r, to be 8 and the number of nonzero radiomic features, s_β, to be 10, while varying the training sample size, n, to be 500 or 1500 and radiomic feature size, p, to be 600 or 1200. We assessed the performance of the model under these four scenarios with different numbers of training samples and feature sizes. For each simulation setup or configuration, a total of 100 independent simulated datasets were generated.

We set $g_0 : \mathbb{R}^8 \to \mathbb{R}$ to be

$$g_0(\mathbf{z}) = 0.68 \exp(z_1) - 0.45 \log\{(z_2 - z_3)^2\} + 0.32 \sin(z_4 z_5) - 0.45(z_6 - z_7 + z_8)^2 - 0.32,$$

and used a function from a neural network to approximate it. In our implementation, we tuned the number of hidden layers and the number of neurons in the hidden layers over a grid of values, i.e., 1 to 4 for the number of hidden layers and 2 to 16 for the number of neurons in the hidden layers. For the SCAD penalty, we set $a = 3.7$ as suggested by [49] from a Bayesian point of view and used grid search over $[0.5, 5]$ to find the best λ based on the Bayesian Information Criterion (BIC):

$$-2n\ell(\hat{\boldsymbol{\beta}}, \hat{g}) + \log n \cdot \hat{s}_\beta,$$

where $\hat{s}_\beta$ is the number of nonzero coefficient estimates. Figure B.1a displays the selection of λ for ten simulated datasets consisting of 500 training samples and 1200 features, and Figure B.1b shows the solution path for $\hat{\boldsymbol{\beta}}$ at various values of λ based on one randomly selected dataset.

In order to visually evaluate the accuracy of the DNN estimator in approximating g_0, Figure 3.1 displays contour plots of the true function and the average DNN estimates based on 100 simulated datasets with n varying from 500 to 1,500 and p ranging from 600 to 1,200. To create these plots, we fixed the values of the last six arguments of the function at their population means and varied the first two arguments. The results indicate that the DNN estimates provided a good approximation of the true function, with increasing accuracy observed as n increased for a fixed value of p.

We next compared the performance of the Penalized DPLC in prediction and selection to that of the SCAD-penalized Cox model [50], SCAD-penalized partially linear Cox model using polynomial splines [70], Cox boosting [13], random forests [76] and deep survival model [83]. The prediction performance was assessed using the C-Index [62], as shown in Figure 3.2. Our Penalized DPLC model outperformed other methods across various scenarios. The highest C-Index of 0.865 (IQR: 0.012) was achieved with 1500 samples and 600 features. As the feature size increased, the prediction performance decreased slightly, e.g., the median C-Index for Penalized DPLC decreased from 0.850 (IQR: 0.011) to 0.846 (IQR: 0.017) when the feature size increased from 600 to 1200 with 500 samples. Conversely, the prediction performance improved with more samples; the median C-Index for Penalized DPLC rose to 0.861 (IQR: 0.011) when the sample size increased to 1500, compared to 500 samples with 1200 features.

To evaluate the selection performance, we reported the number of selected features, false positive number (FPN), false positive rate (FPR), false negative number (FNN), and false negative rate (FNR). Let $\mathcal{S}$ represent the actual support of $\boldsymbol{\beta}$, $\hat{\mathcal{S}}$ the estimated support of $\hat{\boldsymbol{\beta}}$ (i.e., the selected features), and $Card(\cdot)$ the cardinality of a set. Then we define $\mathrm{FPN} = Card(\hat{\mathcal{S}} \backslash \mathcal{S})$, $\mathrm{FPR} = \mathrm{FPN}/\{p - Card(\mathcal{S})\}$, $\mathrm{FNN} = Card(\mathcal{S} \backslash \hat{\mathcal{S}})$, and $\mathrm{FNR} = \mathrm{FNN}/Card(\mathcal{S})$.

As seen in Table 3.1, the Penalized DPLC had an FNN ≤ 2 under the considered settings, indicating that less than two 'active' features among ten are missed, outperforming other methods (except for Cox Boosting) across all scenarios. Cox Boosting had an FNN of 1.22 (SE: 0.14), while the Penalized DPLC reported an FNN of 1.44 (SE: 0.10) with 500 samples and 1200 features. However, Cox Boosting had a higher FPN of 24.98 (SE: 1.21) compared to Penalized DPLC's FPN (Mean: 3.58, SE: 0.50), indicating an over-selection of features by Cox Boosting. The Penalized DPLC had a better FPN than other methods, except for the SCAD-penalized partially linear Cox model using polynomial splines. The average number of falsely selected features using Penalized DPLC was 1.90–3.58, compared to 1.42–4.38 for the partially linear Cox model with polynomial splines. The selection performance of Penalized DPLC improved with more samples and fewer features, achieving the best performance with 1500 samples and 600 features, with an FPR of 0.32% and FNR of 13.00%.

3.6 Application

We applied the Penalized DPLC to analyze a dataset from the NLST study, investigating what and how low-dose CT features were related to the mortality of lung cancer patients. The dataset includes a total of 368 subjects from NLST who were diagnosed with lung cancer and screened with low-dose CT; see Table 3.2. Out of these, 96 patients died during follow-up. The median age in the overall population was 63.5 years old (IQR: 59.0, 68.0), with 55% being male and over 90% being white. Most patients were in the early cancer stage, and hypertension was the most prevalent comorbidity (36%), followed by obstructive lung disease (24%) and prior pneumonia (21%).

To extract features from CT scans, we followed the image processing pipeline as outlined in Figure B.2. We first removed noise from the images through gray-scale normalization and adaptive histogram equalization. We then normalized the voxel intensity of each image to a standard range of 0 (black) to 255 (white) units and improved the contrast with adaptive histogram equalization [122]. Next, we identified the regions of interest (ROIs) and segmented the tumor regions based on their location and size. Finally, we used *pyradiomics* to extract texture features from the ROIs [159], including first-order features, shape-based features, and higher-order features [31]. Additionally, we applied image filtration using the Laplacian of Gaussian filter and a 3D LBP-based filter. The Laplacian of Gaussian filter highlights areas of gray level change [88], and the 3D LBP-based filter computes local binary patterns in 3D using spherical harmonics [7]. In total, 320 image features were extracted.

To compare the prediction and selection accuracy of the Penalized DPLC with other competing methods, we conducted 100 experiments. In each experiment, we tuned the number of hidden layers and the number of neurons in each hidden layer over the grids of [1, 2, 3, 4] and [2, 4, 8, 16], respectively, when constructing the DNN, and randomly divided the data into 80% for training and the remaining 20% for testing. To ensure that the censoring rate in the training and testing data remained the same as in the entire population, we split the data by stratifying the vital status of the patients.

As shown in Figure 3.4, the median C-Index for Penalized DPLC is 0.708 (IQR: 0.043), outperforming the other competing methods. Deep Survival (Median: 0.672, IQR: 0.065), Random Forests (Median: 0.656, IQR: 0.080), and Cox Boosting (Median: 0.668, IQR: 0.066) all had better prediction performance than the SCAD-penalized Cox model (Median: 0.655, IQR: 0.068) and the SCAD-penalized partially linear Cox model (Median: 0.633, IQR: 0.065).

Figures 3.3d– 3.3f illustrate the estimated effects of age, BMI, and pack years of smoking while holding other variables constant at their mean (for continuous variables) or mode (for categorical variables), as derived from the estimated $\hat{g}$ function. These contour plots clearly reveal the nonlinear relationships between age, BMI, and pack years of smoking and survival. The gradients of $\hat{g}$ for age, BMI, and pack years, stratified by gender, are presented in Figures 3.3a –3.3c, reflecting the local change in the log hazard for small changes in the corresponding variables. Figures 3.3a and 3.3c exhibit positive gradients for age and pack years, indicating that mortality increases with increasing age and pack years, consistent with the literature [155]. In contrast, Figure 3.3b shows that BMI has a protective effect on patient survival, in agreement with the obesity paradox [95]. Moreover, we observe that gender has a significant impact on lung cancer survival. As seen in the gradient figures, male patients exhibit a steeper increase in mortality risk compared to female patients for small increments in age and pack years, as shown in Figures 3.3a and 3.3c. On the other hand, Figure 3.3b highlights that an increased BMI has a stronger protective effect for female patients compared to male patients, consistent with previous findings of better survival outcomes for female patients [48].

The Penalized DPLC method has selected five radiomic features as risk factors: large dependence low gray level emphasis (LDLGLE), large area emphasis (LAE), large area low gray level emphasis (LALGLE), cluster shade, and contrast. Figure B.3 demonstrates the reproducibility of feature selection by the Penalized DPLC and the hazard ratios for the selected features. LDLGLE (HR: 1.07) and cluster shade (HR: 1.09) were selected 71 and 57 times out of 100 experiments, respectively. Although LALGLE (Frequency: 51, HR: 1.02) and contrast (Frequency: 41, HR: 1.02) were selected less frequently than the other texture features, they were still more frequently selected by the Penalized DPLC than by the alternative methods.

The use of CT scans to extract texture patterns from tumors has been shown to provide valuable information about their physiological properties [123, 112]. Radiomic features extracted from CT scans have been studied as predictors of survival outcomes in lung cancer patients in several studies, with promising results [116]. To address the analytical needs of the National Lung Screening Trial (NLST), we propose the Penalized DPLC model, which simultaneously selects and models the effects of prognostic radiomic features. Our adopted partial linear model assumes a log-linear relationship between radiomic features and hazards, allowing us to use the SCAD penalty to identify important image features. Meanwhile, clinical features with known associations with survival outcomes are modeled using a nonparametric function to account for their nonlinear effects. Despite this structured approach, we maintain the flexibility to model selected radiomic features using nonparametric functions like the clinical features. Our method provides a convenient and effective way to explore new predictors while fully characterizing the impact of established risk factors.

An application of the Penalized DPLC to the NLST provides insight into the relationship between CT scan texture patterns and patient survival outcomes. The model identifies several texture features that are related to survival outcomes with biologically interpretable results. The Penalized DPLC demonstrates a C-Index of 0.7, which is comparable to other reported values of 0.68 to 0.72 for survival prediction using radiomic and clinical features [53, 72].

There is significant potential for future work. Our modeling framework can be extended to incorporate alternative penalties, such as the LASSO and MCP [153], and can handle competing risk scenarios where multiple events are of interest [118]. We are currently utilizing a DNN estimator with a fixed and moderate dimension, which is suitable for our dataset where the number of clinical variables is moderate. However, it is feasible to develop DNN estimators that can handle high-dimensional predictors. Moreover, quantifying the uncertainty of the estimates remains a significant challenge. Further explorations in these areas are necessary.

Table 3.1: Selection Performance of Different Algorithms using Simulated Dataset

	Model	Selected Features[1]	FPN[2]	FPR (%)[3]	FNN[4]	FNR(%)[5]
n = 500, p = 600	Penalized DPLC	11.40 (0.38)	2.78 (0.36)	0.47 (0.06)	1.38 (0.10)	13.80 (1.03)
	SCAD	12.32 (0.59)	4.46 (0.48)	0.76 (0.08)	2.14 (0.17)	21.40 (1.74)
	SCAD spline	11.28 (0.48)	3.16 (0.40)	0.54 (0.07)	1.88 (0.14)	18.80 (1.42)
	Cox Boosting	34.92 (1.56)	26.14 (1.56)	4.43 (0.26)	1.22 (0.13)	12.20 (1.25)
	Random Forest	11.28 (0.48)	5.00 (0.46)	0.85 (0.08)	3.72 (0.16)	37.20 (1.64)
n = 500, p = 1200	Penalized DPLC	12.14 (0.53)	3.58 (0.50)	0.30 (0.04)	1.44 (0.10)	14.40 (0.95)
	SCAD	14.52 (0.89)	6.40 (0.83)	0.54 (0.07)	1.88 (0.16)	18.80 (1.56)
	SCAD spline	12.70 (0.56)	4.38 (0.49)	0.37 (0.04)	1.68 (0.15)	16.80 (1.47)
	Cox Boosting	33.76 (1.25)	24.98 (1.21)	2.10 (0.10)	1.22 (0.14)	12.20 (1.38)
	Random Forest	12.70 (0.56)	7.18 (0.53)	0.60 (0.04)	4.48 (0.15)	44.80 (1.46)
n = 1500, p = 600	Penalized DPLC	10.60 (0.34)	1.90 (0.33)	0.32 (0.06)	1.30 (0.09)	13.00 (0.87)
	SCAD	10.48 (0.42)	2.24 (0.36)	0.38 (0.06)	1.76 (0.13)	17.60 (1.30)
	SCAD spline	9.82 (0.30)	1.42 (0.23)	0.24 (0.04)	1.60 (0.13)	16.00 (1.34)
	Cox Boosting	33.18 (1.59)	24.30 (1.58)	4.12 (0.27)	1.12 (0.09)	11.20 (0.89)
	Random Forest	9.82 (0.30)	2.78 (0.31)	0.47 (0.05)	2.96 (0.16)	29.60 (1.56)
n = 1500, p = 1200	Penalized DPLC	10.74 (0.75)	2.64 (0.69)	0.22 (0.06)	1.90 (0.17)	19.00 (1.74)
	SCAD	10.18 (0.45)	2.28 (0.34)	0.19 (0.03)	2.10 (0.19)	21.00 (1.88)
	SCAD spline	10.24 (0.45)	2.26 (0.37)	0.19 (0.03)	2.02 (0.18)	20.20 (1.82)
	Cox Boosting	33.10 (1.64)	24.60 (1.61)	2.07 (0.14)	1.50 (0.15)	15.00 (1.46)
	Random Forest	10.24 (0.45)	3.86 (0.42)	0.32 (0.04)	3.62 (0.20)	36.20 (1.98)

[1] The true number of ‘active’ features in the simulated data sets is ten.

[2] False Positive Number (FPN) is the number of features that are ‘inactive’ but selected by the model as ‘active’ features. The mean and standard error of 100 experiments is reported.

[3] False Positive Rate (FPR) is the FPN divided by the true number of ‘inactive’ features. The number reported in the table is a percentage ($\times 100$).The mean and standard error of 100 experiments is reported.

[4] False Negative Number (FNN) is the number of features that are ‘active’ but selected by the model as ‘inactive’ features. The mean and standard error of 100 experiments is reported.

[5] False Negative Number (FNR) is the FNN divided by the true number of ‘active’ features. The number reported in the table is a percentage ($\times 100$).The mean and standard error of 100 experiments is reported.



Figure 3.1: **The Average Estimates of the Nonlinear Function using Simulated Data with Varying** n, p**.** The plots are made by varying the first two arguments fixing the other six arguments.



Figure 3.2: **Prediction Performance Based on 100 Simulated Data.**

Table 3.2: Clinical Characteristics of Patients from the National Lung Cancer Screen Trial

Characteristic	**Overall**, N = 368[1]	**Alive**, N = 272[1]	**Dead**, N = 96[1]
Median Follow-up Time (days)	2072 (1962, 2151)		
Age (yrs.)	63.5 (59.0, 68.0)	63.0 (59.0, 67.0)	66.0 (60.0, 70.0)
BMI	26.3 (24.3, 29.2)	26.3 (24.3, 29.2)	26.1 (24.1, 29.2)
Gender			
Male	201 (55%)	137 (50%)	64 (67%)
Female	167 (45%)	135 (50%)	32 (33%)
Race			
White	339 (92%)	251 (92%)	88 (92%)
Black	14 (3.8%)	11 (4.0%)	3 (3.1%)
Asian	8 (2.2%)	6 (2.2%)	2 (2.1%)
Other	6 (1.6%)	3 (1.1%)	3 (3.1%)
Unknow	1 (0.3%)	1 (0.4%)	0 (0%)
Cigarette Smoking Status			
Former	171 (46%)	135 (50%)	36 (38%)
Current	197 (54%)	137 (50%)	60 (62%)
Pack Years of Smoking	58 (46, 80)	57 (45, 80)	60 (49, 84)
Histology			
Adenocarcinoma	185 (50%)	137 (50%)	48 (50%)
Squamous Cell Carcinoma	73 (20%)	50 (18%)	23 (24%)
Large Cell Carcinoma	16 (4.3%)	9 (3.3%)	7 (7.3%)
Adenosquamous Carcinoma	8 (2.2%)	3 (1.1%)	5 (5.2%)
Neuroendocrine/Carcinoid Tumors	1 (0.3%)	1 (0.4%)	0 (0%)
Bronchioloalveolar Carcinoma	70 (19%)	59 (22%)	11 (11%)
NSCLC NOS	15 (4.1%)	13 (4.8%)	2 (2.1%)
Pathologic Stage			
IA	230 (62%)	188 (69%)	42 (44%)
IB	49 (13%)	36 (13%)	13 (14%)
IIA	11 (3.0%)	8 (2.9%)	3 (3.1%)
IIB	39 (11%)	26 (9.6%)	13 (14%)
IIIA	33 (9.0%)	13 (4.8%)	20 (21%)
IIIB	3 (0.8%)	1 (0.4%)	2 (2.1%)
IV	3 (0.8%)	0 (0%)	3 (3.1%)
Radiotherapy	27 (7.3%)	9 (3.3%)	18 (19%)
Chemotherapy	83 (23%)	49 (18%)	34 (35%)
Surgery Type			
Wedge/Multiple Wedge Resection	45 (12%)	30 (11%)	15 (16%)
Segmentectomy	14 (3.8%)	8 (2.9%)	6 (6.2%)
Lobectomy	287 (78%)	222 (82%)	65 (68%)
Bilobectomy	15 (4.1%)	9 (3.3%)	6 (6.2%)
Pneumonectomy	7 (1.9%)	3 (1.1%)	4 (4.2%)
Asthma	27 (7.3%)	18 (6.6%)	9 (9.4%)
Bronchitis	35 (9.5%)	23 (8.5%)	12 (12%)
COPD	39 (11%)	24 (8.8%)	15 (16%)
Diabetes	33 (9.0%)	20 (7.4%)	13 (14%)
Emphysema	48 (13%)	32 (12%)	16 (17%)
Heart Disease	52 (14%)	35 (13%)	17 (18%)
Hypertension	134 (36%)	98 (36%)	36 (38%)
Prior Pneumonia	77 (21%)	53 (19%)	24 (25%)
Obstructive Lung Disease	88 (24%)	58 (21%)	30 (31%)

[1] Median (IQR); n (%)



(a) Gradient for $\hat{g}$ of age

(b) Gradient for $\hat{g}$ of BMI

(c) Gradient for $\hat{g}$ of pack years of smoking

(d) $\hat{g}$ of age and BMI

(e) $\hat{g}$ of pack years of smoking and BMI

(f) $\hat{g}$ of age and pack years of smoking

Figure 3.3: **Estimated Nonlinear Function and Gradients using NLST:** The gradients for $\hat{g}$ of age, BMI, and pack years smoking history stratified by gender are plotted in (a), (b), and (c). $\hat{g}$ of age, BMI, and pack years of smoking is plotted in (d) and (e). The other variables are fixed at their sample means (for continuous variables) or modes (for categorical variables)



Figure 3.4: **Prediction Performance of 100 Experiments using Data from the National Lung Cancer Screen Trial:** During each experiment, 80% data is randomly selected as training data, and 20% data is selected as testing data. The censoring rate in the testing data and training data is controlled to be the same as that in the entire population.

CHAPTER 4

Estimating Heterogeneous Treatment Effects with Survival Outcomes via Deep Survival Learner

4.1 Introduction

Lung cancer is the leading cause of cancer-related deaths, resulting in over 1.8 million deaths worldwide in 2021 [161]. The primary subtype of lung cancer is non-small cell lung cancer (NSCLC), which accounts for 85% of all cases [115, 110]. For many years, surgery has been the standard treatment for patients with early-stage NSCLC [158]. However, numerous studies have demonstrated that the use of neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy can significantly improve survival rates after surgery [163, 32, 121, 54, 14, 106]. Therefore, several studies have suggested that adjuvant chemotherapy should become the standard treatment for patients with stage II to III cancer [32, 54]. The efficacy of perioperative chemotherapy can vary among different patients. For instance, Sandler et al. reported improved 5-year survival rates in women compared to men after adjuvant chemotherapy [134], while Morgensztern et al. observed higher mortality rates in patients over the age of 70 with adjuvant chemotherapy [113]. A better comprehension of the heterogeneous treatment effects across individuals and contexts can help clinicians tailor treatment regimens and optimize treatment decisions for each patient [11].

The Boston Lung Cancer Study (BLCS) is a prospective cohort study of lung cancer that has been ongoing since 1992 [65]. It has enrolled over 12,000 cases of lung cancer at Massachusetts General Hospital (MGH) and Dana-Farber Cancer Institute (DFCI). The BLCS cohort has collected extensive information on demographics, smoking history, occupational history, dietary habits, pathology, imaging, treatments, oncogenic (somatic driver) mutation status, and biosamples [66, 105, 162]. It is the first and most comprehensive survivor cohort, with the longest follow-up period, allowing for a thorough investigation of the factors influencing lung cancer treatment outcomes. The follow-up rate for the BLCS cohort has been high, approximately 95%, with near-complete ascertainment of deaths using the National Death Index and other resources [66, 162]. The BLCS provides a unique opportunity to estimate the heterogeneous treatment effects of perioperative chemotherapy in patients with early-stage (stage II/III) non-small cell lung cancer due to the availability of detailed individual-level patient information [60, 125, 165, 69, 148, 91, 80].

As BLCS is an observational study, it is challenging to establish causal relationships between treatments and outcomes directly. Instead, we can use the counterfactual framework proposed by Imbens and Rubin [74] to analyze the heterogeneous causal treatment effects. This framework involves estimating the Conditional Average Treatment Effect (CATE), which is defined as the conditional expectation of the Individual Treatment Effect (ITE) given the pre-treatment characteristics [1, 52]. In other words, the CATE describes how the treatment effect varies based on the patient's characteristics before treatment. Estimating CATE as a function of pre-treatment characteristics essentially estimates the interactions between treatment and these characteristics [77, 73]. However, the functional forms of CATE are very complex and difficult to be estimated using traditional statistical methods [4, 89].

Recent studies have explored flexible machine learning techniques for causal inference, known as causal machine learners, which offer promising ways of decomposing the estimation of CATE into sub-problems solvable using regression or machine learning methods [36, 37, 89]. Popular causal machine learners include S-, T-, X-, M-, and R-Learners. The S-Learner utilizes a single machine learning model fitted on the whole dataset to construct the estimator of CATE [167], whereas the T-Learner considers the heterogeneity between treatment and control groups and employs two machine learning models fitted separately on the treatment and control groups to estimate CATE [89]. Similarly, the X-Learner fits two models on the treatment and control groups, uses them to impute the Individual Treatment Effects (ITE) for each patient, and develops an estimator for CATE by regressing the imputed ITE on the patient characteristics [89]. The M-Learner applies inverse propensity weighting to modify the outcome and then uses the modified outcome to develop the estimator of CATE [125]. The R-Learner constructs the estimator based on a characterization of CATE in terms of the residual of treatment assignment and outcome [117]. In survival settings, Xu et al. [166] applied causal machine learners to estimate CATE from right-censored data and conducted extensive simulation studies to evaluate model performance under various scenarios. However, one significant limitation of these methods is their reliance on model structures and their vulnerability to model misspecifications that can lead to large error rates from underlying misspecified regression estimators [89]. Furthermore, when estimating CATE in survival settings, these methods tend to focus on the estimation of survival benefits at a single time point, ignoring the temporal dependence across different time points, which can result in an inefficient estimation of CATE over a time period [166]. Incorporating temporal dependence into these methods to improve the estimation of CATE in survival settings remains a challenging task.

In this work, we propose a new Deep Survival Learner (DSL) to address these challenges of estimating CATE in right-censored survival outcomes. The proposed DSL is an adaptation of the doubly-robust method, which incorporates Inverse Probability of Censoring Weights (IPCW) and develops a CATE estimator that is robust to model misspecifications [84, 87, 90]. Our contributions are as follows: First, we extend a doubly-robust learner to the survival setting and develop an estimator of CATE that is robust to model misspecifications using IPCW. Second, we jointly estimate CATE over an interval of time by applying the fusion penalty to the pseudo-outcome regression in DSL. This approach exploits the temporal structure of CATE in survival analysis by promoting similarity in successive estimates [154]. Third, we use Deep Neural Networks (DNNs) to model the complex relationships between CATE and baseline characteristics. DNNs can approximate any continuous function, and their convergence rate only depends on the characteristics of the true function. Therefore, they may have an advantage over other nonparametric estimators given the desirable properties of the true functions [38, 108, 138]. Fourth, we conduct a comprehensive simulation study to evaluate the performance of DSL under different scenarios. We systematically vary sample size as well as the model specifications of survival time and propensity score models to assess the robustness of DSL. Finally, we apply DSL to the BLCS dataset to study the heterogeneous causal treatment effects of perioperative chemotherapy for patients with NSCLC [65]. Our results are largely consistent with existing research.

In summary, the proposed DSL approach offers a promising estimation of CATE in right-censored survival outcomes. Our method is robust to model misspecifications, considers the temporal structure of CATE, and leverages DNNs to model the complex relationship between CATE and patient-level characteristics. We envision these features make DSL a valuable tool for identifying heterogeneous treatment effects in observational studies.

4.2 Methods

4.2.1 Notation

To accommodate the right censoring, we let T and C denote survival and censored time, respectively, and we observe $U = \min(T, C)$, and $\Delta = \mathbb{I}(T \leq C)$, where $\mathbb{I}(\cdot)$ is the indicator function. We assume the observed data $\mathcal{D} = \{(U_i, \Delta_i, X_i, W_i), i = 1, \ldots, n\}$ contain i.i.d. copies of (U, Δ, X, W), where $X_i \in \mathbb{R}^d$ denotes the pre-treatment characteristics, and $W_i \in \{0, 1\}$ denotes the treatment received (e.g., 0 = surgery alone and 1 = surgery plus chemotheorapy). We are interested in estimating the causal effect of treatment on the survival probability at a given time t_0 given $X = x$. Following the causal inference framework [74], we define the potential outcomes $\{T_i^0, T_i^1\}$ for each patient, where T_i^w is the potential outcome had the patient received treatment $w = 0, 1$; in practice, only $T_i = W_i T_i^1 + (1 - W_i) T_i^0$ is observable. We further define the individualized treatment effect is $\tau_i(t_0) = \mathbb{I}(T_i^1 > t_0) - \mathbb{I}(T_i^0 > t_0)$ and the CATE of the survival probability is a function of pre-treatment characteristics and time t_0,

$$\tau(x, t_0) = \mathbb{E}\{\tau_i(t_0)|X_i = x\} = \mathbb{E}\{\mathbb{I}(T_i^1 > t_0) - \mathbb{I}(T_i^0 > t_0)|X_i = x\}. \tag{4.1}$$

For notational ease, we denote by $Y_i(t_0) = \mathbb{I}(T_i > t_0)$, and by $Y_i^w(t_0) = \mathbb{I}(T_i^w > t_0)$ for $w = 0, 1$.

4.2.2 Construction of A Pseudo-outcome and Regularity Conditions

As for each individual T_i^0, T_i^1 cannot be observed simultaneously and because of censoring, the outcome $\tau_i(t_0)$ at any given t_0 is not observable. Under the conditions listed below, we aim to construct a pseudo-outcome so that it is computable and has the same expectation as $\tau_i(t_0)$, based on which we can estimate the CATE. Before proceeding, we make the following assumptions to ensure the estimability of $\tau(x, t_0)$.

Assumption 4.2.1 (Consistency) *The observable survival time, T_i is the same as the potential outcome with the actual treatment received, $T_i^{W_i}$. That is, $T_i = T_i^{W_i}$.*

Assumption 4.2.2 (Unconfoundedness/Ignorability) *The treatment to be received does not depend on the potential outcomes given pre-treatment characteristics, i.e.,*
$\{T_i^0, T_i^1\} \perp\!\!\!\perp W_i|X_i$, where $\perp\!\!\!\perp$ denotes independence.

Assumption 4.2.3 (Overlap) *The propensity score $e(x) = P(W_i = 1|X_i = x)$ is bounded away from zero and 1, i.e., $0 < e(x) < 1$, almost surely.*

Assumption 4.2.4 (Noninformative Censoring) *Censoring time is independent of survival time given treatment and pre-treatment characteristics, $T_i \perp\!\!\!\perp C_i|W_i, X_i$.*

Assumption 4.2.5 (Positivity) *There is a positive probability that subjects can be observed beyond time t_0, i.e., $P(C_i > t_0|W_i, X_i) > 0$*

Assumptions 4.2.1 - 4.2.3 are the standard causal assumptions to identify the conditional average treatment effects of W_i. These assumptions have been widely used in the literature on the heterogeneous treatment effects [89, 117]. Assumptions 4.2.4 and 4.2.5 are with respect to the censoring and ensure the estimability of the survival probability at t_0, which are commonly assumed in the survival literature [55].

Then we first consider a pseudo-outcome (in the theoretical sense) defined as

$$\varphi_i(t_0) = S(X_i, t_0, 1) - S(X_i, t_0, 0) + \frac{W_i - e(X_i)}{e(X_i)(1 - e(X_i))}\{Y_i(t_0) - S(X_i, t_0, W_i)\} \tag{4.2}$$

where $S(x,t_0,w)$ and $e(x)$ are working models for $\mathbb{E}\{Y_i(t_0)|X_i = x, W_i = w\}$ and $P(W_i = 1|X_i = x)$, respectively. We show that if either of them is correctly specified, that is, either $S(x,t_0,w) = \mathbb{E}\{Y_i(t_0)|X_i = x, W_i = w\}$ or $e(x) = P(W_i = 1|X_i = x)$ holds, $\mathbb{E}\{\varphi_i(t_0)|X_i = x\} = \mathbb{E}\{\tau_i(t_0)|X_i = x\}$, justifying the use of $\varphi_i(t_0)$ for estimating $\tau(x,t_0)$. To see this, we write $\varphi(t_0)$ as

$$\varphi_i(t_0) = S(X_i,t_0,1) - S(X_i,t_0,0) + \frac{W_i - e(X_i)}{e(X_i)(1-e(X_i))}\{Y_i(t_0) - S(X_i,t_0,W_i)\} \tag{4.3}$$

$$= \frac{W_iY_i(t_0)}{e(X_i)} - \frac{(1-W_i)Y_i(t_0)}{1-e(X_i)} + \frac{e(X_i)-W_i}{e(X_i)}S(X_i,t_0,1) + \frac{e(X_i)-W_i}{1-e(X_i)}S(X_i,t_0,0). \tag{4.4}$$

If $S(x,t_0,w)$ is correctly specified, i.e., $S(x,t_0,w) = \mathbb{E}\{Y_i(t_0)|X_i = x, W_i = w\} = \mathbb{E}\{Y_i^w(t_0)|X_i = x\}$, where the last equality is due to Assumptions 4.2.1 and 4.2.2, then it follows by Equation (4.3) that

$$\begin{aligned}\mathbb{E}\{\varphi_i(t_0)|X_i = x\} &= \mathbb{E}\{S(X_i,t_0,1) - S(X_i,t_0,0)|X_i = x\}\\ &\quad + \mathbb{E}\Big[\frac{W_i - e(X_i)}{e(X_i)(1-e(X_i))}\{Y_i(t_0) - S(X_i,t_0,W_i)|X_i = x\}\Big]\\ &= \mathbb{E}\{S(X_i,t_0,1) - S(X_i,t_0,0)|X_i = x\}\\ &= \mathbb{E}\{\mathbb{I}(T_i^1 > t_0) - \mathbb{I}(T_i^0 > t_0)|X_i = x\} = \mathbb{E}\{\tau_i(t_0)|X_i = x\},\end{aligned}$$

which holds because $\mathbb{E}\Big[\frac{W_i-e(X_i)}{e(X_i)(1-e(X_i))}\{Y_i(t_0) - S(X_i,t_0,W_i)|X_i = x\}\Big] = \mathbb{E}\Big[\frac{W_i-e(X_i)}{e(X_i)(1-e(X_i))}\mathbb{E}\{Y_i(t_0) - S(X_i,t_0,W_i)|W_i, X_i = x\}|X_i = x\Big]$ and $\mathbb{E}\{Y_i(t_0) - S(X_i,t_0,W_i)|W_i, X_i = x\} = 0$ when $S(x,t_0,w)$ is correctly specified.

On the other hand, if $e(X_i)$ is correctly specified, i.e., $e(x) = P(W_i = 1|X_i = x)$, then according to Equation (4.4),

$$\begin{aligned}\mathbb{E}\{\varphi_i(t_0)|X_i = x\} &= \mathbb{E}\Big\{\frac{W_iY_i(t_0)}{e(X_i)} - \frac{(1-W_i)Y_i(t_0)}{1-e(X_i)}|X_i = x\Big\}\\ &\quad + \mathbb{E}\Big\{\frac{e(X_i)-W_i}{e(X_i)}S(X_i,t_0,1) + \frac{e(X_i)-W_i}{1-e(X_i)}S(X_i,t_0,0)|X_i = x\Big\}\\ &= \mathbb{E}\Big\{\frac{W_iY_i(t_0)}{e(X_i)} - \frac{(1-W_i)Y_i(t_0)}{1-e(X_i)}|X_i = x\Big\}\\ &= \mathbb{E}\Big\{\frac{W_iY_i^1(t_0)}{e(X_i)} - \frac{(1-W_i)Y_i^0(t_0)}{1-e(X_i)}|X_i = x\Big\} = \mathbb{E}\{\tau_i(t_0)|X_i = x\},\end{aligned}$$

where the second-to-last equality holds because of Assumption 4.2.1 and the last equality holds because of Assumption 4.2.2.

Therefore, when either $S(x, t_0, w)$ or $e(x)$ is correctly specified (which can be well approximated by DNN in the next section), regressing $\varphi_i(t_0)$ on patient characteristics may give an unbiased estimate of CATE. Furthermore, t_0 can take values over an interval, giving a comprehensive evaluation of CATE over a range of time points (e.g. 1, 2 and 5 years) or an interval (e.g. from 1 to 5 years). We can construct a series of pseudo-outcomes at the grid points in the time interval of interest for each patient. A joint estimation of CATE across all the time points can leverage the similarity of CATE at the contiguous time points, because the treatment effects on the same patient are likely to be similar at these contiguous points. We will propose to apply the fusion penalty to promote the similarities between successive estimates of CATE [154], which confers much numerical stability and accuracy as shown in our simulations.

4.2.3 Deep Survival Learner of CATE

As the pseudo outcome $\varphi_i(t_0)$ involves unknown quantities, we propose to use DNN to estimate them and construct a DNN version of pseudo outcomes over a range of t_0 values, e.g., $t_{min} = t_{0,0} < t_{0,1} < \ldots < t_{0,j} < \ldots t_{0,J} = t_{max}$ over an interval $[t_{min}, t_{max}]$, where t_{min}, t_{max} are pre-chosen. That is, for a grid point of $t_{0,j}$, we compute an DNN estimate of $\varphi_i(t_{0,j})$, denoted by $\hat{\varphi}_i(t_{0,j})$, by plugging the DNN estimates of the survival function and the propensity score, $\hat{S}(X_i, t_0, W_i)$ and $\hat{e}(X_i)$, into (4.2). We further apply DNN to regress $\hat{\varphi}_i(t_{0,j})$ on patient characteristics and estimate CATE. We term our procedure a Deep Survival Learner (DSL), which essentially adapts a doubly-robust learner to survival settings [84].

We utilize DNN to learn the complex relationships between treatment received, survival outcomes, and patient characteristics. In addition, we propose adapting the fusion penalty to the DNN's loss function to promote the continuity of the CATE estimate with respect to time. To prevent overfitting, we employ K-fold cross-fitting during the estimation process, following the approach outlined in Kennedy et al. [84]. Specifically, we randomly partition the data into K folds and then sequentially construct the CATE estimator on each fold. The final CATE estimate is the average of the obtained estimates on each fold. The detailed algorithm for implementing DSL is presented below.

Stage 1. Divide the dataset $\mathcal{D}$ into K folds ($\mathcal{D}_1$, $\mathcal{D}_2$,...,$\mathcal{D}_K$).

For $k = 1, \ldots, K$, let $\mathcal{D}_{-k} = (\mathcal{D}_1, \ldots, \mathcal{D}_{k-1}, \mathcal{D}_{k+1}, \ldots, \mathcal{D}_K)$

Stage 2. (a) Use DNN to compute $\hat{e}(x)$, the estimated propensity score $P(W_i = 1|X_i = x)$, on $\mathcal{D}_{-k}$.

(b) Use DNN to compute $\hat{S}(x, t_0, w)$, the estimated survival function $\mathbb{E}\{Y_i(t_0)|X_i = x, W_i = w\}$, on $\mathcal{D}_{-k}$.

(c) Use DNN to compute $\hat{S}_C(x, c, w)$, the estimated survival function of censoring time, i.e., $\mathbb{E}\{\mathbb{I}(C_i > c)|X_i = x, W_i = w\}$, on $\mathcal{D}_{-k}$.

Stage 3. Pseudo-outcome regression: Compute the pseudo-outcomes for each subject at $t_{0,j}$ on $\mathcal{D}_k$:

$$\hat{\varphi}_i(t_{0,j}) = \hat{S}(X_i, t_{0,j}, 1) - \hat{S}(X_i, t_{0,j}, 0) + \frac{W_i - \hat{e}(X_i)}{\hat{e}(X_i)(1 - \hat{e}(X_i))}\{Y_i(t_{0,j}) - \hat{S}(X_i, t_{0,j}, W_i)\}. \tag{4.5}$$

Then use DNN to regress them on patient characteristics X_i and time $t_{0,j}$ on $\mathcal{D}_k$, yielding an estimator, $\hat{\tau}_k(x, t_0)$, of $\tau(x, t_0)$ on $\mathcal{D}_k$.

Stage 4. Cross-fitting: Repeat Stage 2 to Stage 3 until all the K folds data have been used to construct the estimator $\hat{\tau}_k(x, t_0)$. Use the average of K estimators $\hat{\tau}(x, t_0) = 1/K \sum_{k=1}^{K} \hat{\tau}_k(x, t_0)$ as the final estimator of $\tau(x, t_0)$.

Stages 2 and 3 involve the use of DNNs and will be detailed in the next section. In particular, we will detail the construction of pseudo outcomes via DNNs, i.e., $\hat{\varphi}_i(t_0)$, and the DSL estimate of CATE, $\hat{\tau}_k(x, t_0)$, by regressing $\hat{\varphi}_i(t_0)$ on the baseline characteristics and time. We will also introduce a fusion penalty to promote the continuity of the CATE estimate with respect to time, which proves to perform well. Our DNN-based estimator may achieve better convergence rates than other nonparametric estimators for CATE [38, 108, 138], as confirmed by our simulations.

4.3 Implementation of Deep Survival Learner

4.3.1 A general formulation of a DNN

We briefly introduce the general formulation of a feedforward neural network which is used in the Deep Survival Learner to construct the estimators. For an integer $L \geq 1$, we consider a neural network with $L+1$ layers, including one input layer, $L-1$ hidden layers, and one output layer. Let p_l be the number of neurons in the lth layer ($l = 1, \ldots, L+1$), where layer 1 and layer $L+1$ are the input layer and output layer, respectively. Accordingly, we define the width vector $\mathbf{p} = (p_1, p_2, \ldots, p_{L+1})$. Then an $(L + 1)$-layered neural network with the architecture $(L, \mathbf{p})$ is essentially an L-fold composite function, $\tau : \mathbb{R}^{p_1} \to \mathbb{R}^{p_{L+1}}$. It can be written as $g = g_L \circ g_{L-1} \circ \cdots \circ g_1$, where "$\circ$" denotes the composition of two functions. The lth fold function is

$$g_l(\cdot) = \sigma_l(\mathbf{W}_l \cdot + \mathbf{b}_l) : \mathbb{R}^{p_l} \to \mathbb{R}^{p_{l+1}} \text{ with } l = 1, \ldots, L$$

Here, $\mathbf{W}_l$ is a $p_{l+1} \times p_l$ weight matrix, $\mathbf{b}_l$ is a p_{l+1} dimensional bias vector, and "$\cdot$" represents the input from the previous layer. In the following, we use $\mathbf{\Theta}$ to denote the set of parameters for the neural network containing all the weight matrices and bias vectors, which depend on the network structures, including the number of hidden layers and the number of neurons in each layer. In practice, we tune the layer and neuron numbers by cross-validation. The function $\sigma_l : \mathbb{R}^{p_{l+1}} \to \mathbb{R}^{p_{l+1}}$ is an activation function. Typical choices of $\sigma_l(\mathbf{x})$ include a linear function of $\mathbf{x}$, a ReLU function, i.e., $\max(0, \mathbf{x})$, and a softmax function, i.e., $\exp(\mathbf{x})/\|\exp(\mathbf{x})\|_1$, where max and $\exp$ operate componentwise. Figure 4.1 gives an example of a four-layered DNN.



Figure 4.1: **An Example of Four-Layered DNN.**

We define a class of DNNs, $\mathcal{G}(L, \mathbf{p})$, with architecture $(L, \mathbf{p})$ such that $\max_{l=1,\dots,L}\{\|\mathbf{W}_l\|_\infty, \|\mathbf{b}_l\|_\infty\} < \infty$, where $\|\cdot\|_\infty$ denotes the sup-norm of a vector or matrix. DNNs with complex network architectures and a high number of parameters are prone to overfitting. We therefore consider a class of s-sparse DNNs, imposing sparsity constraints on the weight matrices to improve interpretability and reduce overfitting:

$$\mathcal{G}(L, \mathbf{p}, s, G) = \{g \in \mathcal{G}(L, \mathbf{p}) : \sum_{l=1}^{L} \|\mathbf{W}_l\|_0 + \|\mathbf{b}_l\|_0 \le s, \|g\|_\infty \le G\}.$$

Here, $s \in \mathbb{N}_+$ (the set of positive integers), $G > 0$, $\|g\|_\infty = \sup\{|g(z)| : z \in \mathbb{D} \subset \mathbb{R}^{p_1}\}$ is the sup-norm of function g, and $\mathbb{D}$ is a bounded subset of $\mathbb{R}^{p_1}$.

When using DNNs to approximate the nonparametric functions in the models, we assume that these functions belong to a composite Hölder class of smooth functions [138] for theoretical convenience. First, with constants $a, M > 0$ and a positive integer d, we define a Hölder class of smooth functions as

$$\mathcal{H}_d^a(\mathbb{D}, M) = \{f : \mathbb{D} \subset \mathbb{R}^d \to \mathbb{R} : \sum_{\upsilon:|\upsilon|<a} \|\partial^\upsilon f\|_\infty + \sum_{\upsilon:|\upsilon|=\lfloor a \rfloor} \sup_{x,y\in\mathbb{D},x\ne y} \frac{|\partial^\upsilon f(x) - \partial^\upsilon f(y)|}{\|x-y\|_\infty^{a-\lfloor a \rfloor}} \le M\},$$

where $\mathbb{D}$ is a bounded subset of $\mathbb{R}^d$, $\lfloor a \rfloor$ is the largest integer smaller than a, $\partial^\upsilon := \partial^{\upsilon_1} \dots \partial^{\upsilon_r}$ with $\upsilon = (\upsilon_1, \dots, \upsilon_d) \in \mathbb{N}^d$, and $|\upsilon| := \sum_{j=1}^{d} \upsilon_j$. For a positive integer q, let $\alpha = (\alpha_1, \dots, \alpha_q) \in \mathbb{R}_+^q$, and $\mathbf{d} = (d_1, \dots, d_{q+1}) \in \mathbb{N}_+^{q+1}$, $\tilde{\mathbf{d}} = (\tilde{d}_1, \dots, \tilde{d}_q) \in \mathbb{N}_+^q$ with $\tilde{d}_j \le d_j$. We then define a composite

Hölder smooth function class as

$$\mathcal{H}(q, \alpha, \mathbf{d}, \tilde{\mathbf{d}}, M) = \{f = f_q \circ \cdots \circ f_1 : f_i = (f_{i1}, \ldots, f_{id_{i+1}})^\top, f_{ij} \in \mathcal{H}_{\tilde{d}_i}^{\alpha_i}([a_i, b_i]^{\tilde{d}_i}, M), |a_i|, |b_i| \leq M\}, \tag{4.6}$$

where $[a_i, b_i]$ is the bounded domain for each Hölder smooth function. There are two types of dimensional parameters, $\mathbf{d}$ and $\tilde{\mathbf{d}}$. The latter is defined as the *intrinsic dimension* [170], often much smaller than the feature dimension $\mathbf{d}$.

4.3.2 DNN estimation of survival functions

In Stage 2 of the DSL algorithm, we utilize a DNN approach [83] to construct the estimator $\hat{S}(x, t_0, w)$. Specifically, we use DNN to estimate the nonparametric risk function in a Cox model:

$$\lambda(t|X_i = x, W_i = w) = \lambda_0(t) \exp\{g_w(x)\} \tag{4.7}$$

We assume that the nonparametric risk function $g_w(x)$ belongs to the class of composite Hölder smooth function, i.e., $g_w(x) \in \mathcal{H}(q, \alpha, \mathbf{d}, \tilde{\mathbf{d}}, M)$. For identifiability, we assume $g_w(0) = 0$ for $w = 0, 1$. We use the s-sparse DNNs, $g(x; \mathbf{\Theta}_w) \in \mathcal{G}(L, \mathbf{p}, s, G)$, to approximate $g_w(x)$, where $g(x; \mathbf{\Theta}_w)$ is the DNN-constructed risk function governed by the parameter of $\mathbf{\Theta}_w$ under treatment $w = 0, 1$. That is, we estimate two DNNs, where $g(x; \mathbf{\Theta}_0)$, and $g(x; \mathbf{\Theta}_1)$ are the log relative risk functions for patients in the control and treatment group, respectively. To estimate $\mathbf{\Theta} = (\mathbf{\Theta}_0, \mathbf{\Theta}_1)$ using data $\mathcal{D}_{-k}$ (as specified in the DSL algorithm), we minimize the negative partial likelihood defined (4.8) associated with the Cox proportional hazards model:

$$\ell(\mathbf{\Theta}) = -\sum_{i \in \mathcal{D}_{-k}} \Delta_i \Big[g(X_i; \mathbf{\Theta}_{W_i}) - \log\Big\{\sum_{j \in \mathcal{D}_{-k} \cap R(U_i)} g(X_j; \mathbf{\Theta}_{W_j})\Big\}\Big], \tag{4.8}$$

where $R(t) = \{j : U_j \geq t\}$ is the at-risk set at time t. Let $\hat{\mathbf{\Theta}} = (\hat{\mathbf{\Theta}}_0, \hat{\mathbf{\Theta}}_1)$ be the minimizer of (4.8). For simplicity, we write the estimated risk function as $\hat{g}_w(x) = g(x; \hat{\mathbf{\Theta}}_w)$. We use Adam to minimize the negative partial likelihood function [85]. To estimate the baseline hazard λ_0, we use the Breslow estimator [100]

$$\hat{\Lambda}_0(t) = \sum_{i \in \mathcal{D}_{-k} : U_i \leq t} \frac{\Delta_i}{\sum_{j \in \mathcal{D}_{-k} \cap R(U_i)} \exp\{\hat{g}_{W_j}(X_j)\}} \tag{4.9}$$

where $\hat{\Lambda}_0(t)$ is the cumulative baseline hazard function. Then the estimator for $S(X_i, t_0, W_i)$ can be written as $\hat{S}(X_i, t_0, W_i) = \exp\{-e^{\hat{g}_{W_i}(X_i)} \hat{\Lambda}_0(t_0)\}$. Similarly, we can construct a DNN-based estimator, $\hat{S}_C(X_i, t_0, W_i)$, of the survival function of censoring time by "flipping" the event indicator

Δ to censoring indicator $\Delta_c = 1 - \Delta$.

4.3.3 DNN estimation of propensity score

To estimate the propensity score, we employ a DNN extension of logistic regression given by:

$$\mathrm{logit}\mathrm{P}(W_i = 1 \mid X_i = x) = g(x).$$

Here, $\mathrm{logit}(p) = \log p/(1-p)$ with $p \in (0,1)$, represents the logit link function, and $g \in \mathcal{H}(q, \alpha, \mathbf{d}, \tilde{\mathbf{d}}, M)$, where we use a deep neural network, $g(X_i, \mathbf{\Theta}) \in \mathcal{G}(L, \mathbf{p}, s, G)$, to approximate g. To train this network using data $\mathcal{D}_{-k}$, we minimize the cross-entropy loss function given by:

$$\ell(\mathbf{\Theta}) = -\sum_{i \in \mathcal{D}_{-k}} \left[\frac{W_i}{1 + \exp\{-g(X_i; \mathbf{\Theta})\}} + \frac{1 - W_i}{1 + \exp\{g(X_i; \mathbf{\Theta})\}} \right]. \tag{4.10}$$

We use the Adam optimizer [85] to minimize the loss function and denote by $\hat{\mathbf{\Theta}}$ the minimizer. We estimate the propensity score by $\hat{e}(X_i) = 1/[1 + \exp\{-g(X_i; \hat{\mathbf{\Theta}})\}]$.

4.3.4 DNN estimation of CATE

In the third stage of the DSL algorithm, the pseudo-outcomes, $\varphi_i(t_{0,j})$ in (4.5), need to be computed for each patient. However, we cannot construct the pseudo-outcome for every patient at each given time point because $Y_i(t_{0,j})$ is not computable at each $t_{0,j}$ due to censoring. Introduce the effective censoring indicator $\Delta_i(t_{0,j}) = \mathbb{I}\{C_i \geq (T_i \wedge t_{0,j})\} = \Delta_i \vee \mathbb{I}\{U_i \geq t_{0,j}\}$. If and only if $\Delta_i(t_{0,j}) = 1$, that is, if the patient is observed to be alive at $t_{0,j}$ or the exact failure time is observed, can $Y_i(t_{0,j}) \equiv \mathbb{I}(T_i > t_{0,j})$ be determined. Therefore, we focus on the cases with $\Delta_i(t_{0,j}) = 1$ when computing CATE at $t_{0,j}$ and use IPCW to adjust for the effective censoring [87, 90].

Assuming the true CATE belongs to Hölder class of smooth function, $\tau(x, t_0) \in \mathcal{H}(q, \alpha, \mathbf{d}, \tilde{\mathbf{d}}, M)$, we use DNN to construct the estimator of CATE. Unlike the other causal machine learners, our proposed DSL estimator is a function of both pre-treatment characteristics and time. That is, the input of DNN is $(x, t_0) \in \mathbb{R}^d \times \mathbb{R}_+$. With slight overuse of notation, we let $\tau_k(x, t_0; \mathbf{\Theta}) \in \mathcal{G}(L, \mathbf{p}, s, G)$ denote the DNN trained on the $\mathcal{D}_k$ fold of data with parameters $\mathbf{\Theta}$. To promote the continuity of $\tau_k(x, t_0; \mathbf{\Theta})$ with respect to t_0, we apply the fusion penalty to the loss function(4.11) where λ_f is the tuning parameter for fusion penalty [154]. The intuition behind this is that the treatment effects at two contiguous time points should be similar. We propose to estimate the parameters in the DNNs,

$\mathbf{\Theta}$, by minimizing the fusion penalized loss function

$$\begin{aligned}\ell(\mathbf{\Theta}) &= \sum_{i\in\mathcal{D}_k}\sum_{j=1}^{J}\frac{\Delta_i(t_{0,j})}{\hat{S}_C(X_i, U_i\wedge t_{0,j}, W_i)}\Big\{\varphi_i(t_{0,j}) - \tau_k(X_i, t_{0,j}; \mathbf{\Theta})\Big\}^2 \\ &+\lambda_f\sum_{i\in\mathcal{D}_k}\sum_{j=1}^{J-1}\Delta_i(t_{0,j+1})\Delta_i(t_{0,j})|\tau_k(X_i, t_{0,j+1}; \mathbf{\Theta}) - \tau_k(X_i, t_{0,j}; \mathbf{\Theta})|.\end{aligned} \tag{4.11}$$

We again use Adam for optimization and tune the penalization parameter λ_f by cross-validation. We will exemplify the choice of tuning parameters in the simulation study and the real data application.

4.4 Simulation

To examine the double robustness property of DSL, we conducted simulations to evaluate its performance when either the survival model or the propensity score model is misspecified. In cases where both models are correctly specified, we compared the efficiency of DSL to other causal machine learners, including the S-, T-, X-, M-, and R-Learners mentioned in the introduction section. Furthermore, we evaluated the robustness of DSL in situations where both models are misspecified. We assessed the model performance in each scenario by varying the training sample size.

For $i = 1, \ldots, n$, we generated $X_i = (X_{i,1}, \ldots, X_{i,7}) \in \mathbb{R}^7$ from a multivariate Gaussian distribution,

$$\mathcal{N}_7\left\{\mathbf{0}, \begin{bmatrix} 1 & 0.2 & \ldots & 0.2 \\ \vdots & \vdots & \ddots & \vdots \\ 0.2 & 0.2 & \ldots & 1 \end{bmatrix}\right\},$$

Specifically, consider the following four data-generating processes.

Case 1 Both the survival time model and propensity score model are correctly specified. Specifically, the survival time is generated from a Cox-exponential model.

$$\begin{aligned}\lambda(t|X_i, W_i) = \lambda_0\exp[&-0.85 - 1.2\mathbb{I}(X_{i,1} > 0) + 1.5\sqrt{|X_{i,2}|} + 0.2X_{i,3} \\ &+ \{1.7 - 0.8\mathbb{I}(X_{i,1} > 0) - 0.7\sqrt{|X_{i,2}|}\}W_i]\end{aligned}$$

The propensity score is $e(X_i) = 1/\{1 + \exp(-X_{i,7} + 1)\}$. The treatment rate is around 0.3.

Case 2 The survival time model is incorrectly specified, but the propensity score model is correctly specified. Specifically, the survival time is generated from an accelerated failure time model

$$\log(T_i) = -1 - 1.2\mathbb{I}(X_{i,1} > 0) + 1.5\sqrt{|X_{i,2}|} + 0.2X_{i,3} \\ + \{1.7 - 0.8\mathbb{I}(X_{i,1} > 0) - 0.7\sqrt{|X_{i,2}|}\}W_i + \epsilon_i$$

where ϵ_i follows a standard Gaussian distribution. The propensity score is $e(X_i) = 1/\{1 + \exp(-X_{i,7} + 1)\}$. The treatment rate is around 0.3.

Case 3 The survival time model is correctly specified, but the propensity score model is incorrectly specified. The survival time is generated from a Cox-exponential model

$$\lambda(t|X_i, W_i) = \lambda_0 \exp[-0.85 - 1.2\mathbb{I}(X_{i,1} > 0) + 1.5\sqrt{|X_{i,2}|} + 0.2X_{i,3} \\ + \{1.7 - 0.8\mathbb{I}(X_{i,1} > 0) - 0.7\sqrt{|X_{i,2}|}\}W_i]$$

The propensity score is $e(X_i) = \phi(1.3X_{i,7}; \mu, \sigma)$, where $\phi(x; \mu, \sigma)$ is the probability density function of gaussian distribution with mean μ and variance σ^2. We set $\mu = 0$ and $\sigma^2 = 6.25$ so the treatment rate is around 0.3.

Case 4 Both the survival time model and propensity score model are incorrectly specified. The survival time is generated from an accelerated failure time model

$$\log(T_i) = -1 - 1.2\mathbb{I}(X_{i,1} > 0) + 1.5\sqrt{|X_{i,2}|} + 0.2X_{i,3} \\ + \{1.7 - 0.8\mathbb{I}(X_{i,1} > 0) - 0.7\sqrt{|X_{i,2}|}\}W_i + \epsilon_i$$

where ϵ_i follows a standard Gaussian distribution. The propensity score is $e(X_i) = \phi(1.3X_{i,7}; \mu, \sigma)$ and μ is set to be 0 and σ^2 is set to be 6.25.

In all the scenarios, the censoring time is generated from a Cox-exponential model.

$$\lambda_C(t|X_i, W_i) = \lambda_0^C \exp[-0.33 - 0.6\mathbb{I}(X_{i,4} > 0) + 0.4\sqrt{|X_{i,5}|} + 0.2X_{i,6} \\ + \{1.2 + 0.5\mathbb{I}(X_{i,4} > 0) - 0.5\sqrt{|X_{i,5}|}\}W_i]$$

The baseline hazards for survival time, λ_0, and censoring time, λ_0^C, are set so that the censoring rate is around 0.45. In each case, the model is fitted on the training samples and assessed on the testing samples. The training sample sizes vary between 270, 800, and 2400, while the testing sample size is 600. We estimate $\tau(x, t_0)$ from the 20th percentile of the observed time to the 80th percentile of the observed time. We use the integrated mean squared error (IMSE), defined as $\int_{t_{min}}^{t_{max}} 1/n\{\tau(x, t_0) - \hat{\tau}(x, t_0)\}^2 dt_0$, to assess the model performance. For each simulation configuration, a total of 100 datasets were simulated.

In the numerical implementation, we use 2-fold ($K = 2$) cross-fitting to train DSL. We choose $K = 2$-to balance the computational burden and performance. We tune the structure of DeepSurv using cross-validation. Specifically, we tuned the number of hidden layers and the number of neurons in the hidden layers over a grid of values, i.e., 1 to 2 for the number of hidden layers and 2 to 16 for the number of neurons in the hidden layers. Each hidden layer is followed by a dropout layer, and we tune the dropout rate to be 0.3 or 0.5. Finally, we tune the learning rate of the Adam optimizer over the grids from 0.001 to 0.01. For the DNN-based estimator $\hat{\tau}(x, t_0)$, we tune the hyperparameters, including the number of hidden layers, the number of neurons in the hidden layer, the dropout rate and learning rate using the same strategy as we do for the DeepSurv model. Additionally, we tune the parameter λ_f for the fusion penalty over a grid of points from 0.005 to 5. The DNNs are implemented using `PyTorch`.

We compare the DSL to other causal machine learners, including S-, T-, and X-Learner [89, 166]. For S-Learner, we use penalized Cox model with the elastic net penalty to model the survival probability at time t_0 given pre-treatment characteristics (X) and treatment received (w), $\hat{S}(X, t_0, W)$. Then the CATE, $\tau(X, t_0)$, is estimated by $\hat{S}(X, t_0, 1) - \hat{S}(X, t_0, 0)$. The penalized Cox model is implemented using the R package `glmnet` [150]. The penalization parameter is tuned over the grids from 0.007 to 0.9. For T-Learner, we trained two random survival forests models on the treatment group and control group [76]. Then we estimate the survival probability at time t_0 given pre-treatment characteristics on the treatment group ($\hat{S}_1(x, t_0)$) and control group ($\hat{S}_0(x, t_0)$). $\hat{\tau}(x, t_0)$ is then estimated as the difference of survival probability between the treatment group and control group, $\hat{S}_1(x, t_0) - \hat{S}_0(x, t_0)$. The random survival forests model is implemented using the R package `randomForestSRC` [75]. We tune the minimum size of the terminal node in the random forests over the grids from 1 to 100. The number of variables to possibly split at each node is tuned from 1 to 7. Similar to T-Learner, X-Learner also uses random survival forests to fit the model for survival probability on the treatment group and control. We then calculate the pseudo-outcomes and use the XGBoost to fit the pseudo-outcome regression [28]. The XGBoost is implemented using the R package `xgboost`. We tune the learning rate of XGBoost from 0.01 to 0.99.

The results of the simulation study are shown in Table 4.1 based on 100 experiments for each setting. Models are trained using the training samples with various sizes and tested on the testing data. We report the mean and 95% confidence interval of IMSE. In the first case, where both the model of survival time T and the model of propensity score W are correctly specified, DLS outperforms other models across various scenarios. The model performance increases as the sample size increase. The best performance is achieved when the model is trained on 2,400 samples with an average IMSE of 0.234 (95% CI: 0.229, 0.239).

When the survival model is correctly specified, but the propensity score model is incorrectly specified, the performance of DSL is also better than the other models. The IMSE decreases from 0.297 (95% CI: 0.289, 0.305) to 0.214 (95% CI: 0.210, 0.218) as the training sample size increases. Similarly, DSL trained on 270 (mean: 0.240, 95% CI: 0.234, 0.247) or 800 (mean: 0.210, 95% CI: 0.206, 0.214) samples achieves better performance than the other methods when the propensity score is correctly specified, but the survival model is incorrectly specified. Except that the RSF-T-Learner achieves slightly better performance (mean: 0.185, 95% CI: 0.179, 0.191) than DSL (mean: 0.191, 95% CI: 0.188, 0.194) when the number of training samples is 2,400.

Finally, when both the survival model and the propensity score model are incorrectly specified, DSL achieves better performance than the Cox-S-Learner and the XGBoost-X-Learner. There is no significant difference between DSL and RSF-T-Learner (mean: 0.259, 95% CI: 0.249, 0.270 vs. mean: 0.253, 95% CI: 0.237, 0.269) when the training sample size is 270. However, the performance of RSF-T-Learner is better than that of DSL when we increase the training sample size to 800 and 2,400, respectively. The IMSE of DSL is 0.221 (95% CI: 0.215, 0.227) when the training sample size is 800 and 0.206 (95% CI: 0.202, 0.210) when the training sample size is 2400. On the other hand, RSF-T-Learner achieves the IMSE of 0.195 (95%: 0.182, 0.208) and 0.193 (95% CI: 0.191, 0.195) trained on 800 and 2,400 samples, respectively.

To summarize, larger training samples lead to better DSL performance. Correctly specified survival and propensity score models result in DSL providing a more efficient estimator with less variation in IMSE over time, due to incorporating temporal dependence of CATE in estimation. DSL outperforms other methods, even with misspecified models, thanks to its double-robustness and use of DNNs as base learners.

4.5 Boston Lung Cancer Study

We apply the proposed method to study the heterogeneous treatment effects of perioperative chemotherapy using data from the Boston Lung Cance Study. We are interested in the causal effect of perioperative chemotherapy on the survival time of patients with early-stage (Stage II/III) NSCLC. According to the descriptive analysis shown in Table 4.2, we observe 521 (66%) of death among the 784 patients. The median survival time in the study population is 1,951 days (95% CI: 1,699, 2,219). Let the group of patients who received surgery + chemotherapy be the treatment group and the group of patients who only received surgery be the control group. There are 214 patients (27%) in the treatment group. Patients in the treatment group are younger than patients in the control group (median: 64, IQR: 58, 71 vs. median: 68, IQR: 60, 75). There are more male patients in the treatment group (116, 54%) compared to the control group (274, 48%). Overall, we find better survival outcomes for the treatment group than the control group. More death is

Table 4.1: Integrated Mean Squared Error using Different Methods

		Deep Survival Learner	Cox-S-Learner	RSF-T-Learner	XGBoost-X-Learner
Correct T Correct W	n = 270	0.330 (0.315, 0.344)	0.363 (0.339, 0.386)	0.442 (0.413, 0.472)	0.595 (0.583, 0.608)
	n = 800	0.261 (0.255, 0.268)	0.292 (0.281, 0.304)	0.351 (0.326, 0.376)	0.479 (0.473, 0.484)
	n = 2400	0.234 (0.229, 0.239)	0.278 (0.271, 0.286)	0.256 (0.253, 0.260)	0.463 (0.456, 0.470)
Correct T Wrong W	n = 270	0.297 (0.289, 0.305)	0.339 (0.319, 0.360)	0.409 (0.385, 0.433)	0.579 (0.569, 0.589)
	n = 800	0.244 (0.238, 0.250)	0.292 (0.279, 0.305)	0.352 (0.333, 0.372)	0.477 (0.470, 0.484)
	n = 2400	0.214 (0.210, 0.218)	0.264 (0.258, 0.270)	0.260 (0.256, 0.263)	0.469 (0.460, 0.478)
Wrong T Correct W	n = 270	0.240 (0.234, 0.247)	0.291 (0.272, 0.309)	0.267 (0.256, 0.278)	0.523 (0.502, 0.543)
	n = 800	0.210 (0.206, 0.214)	0.244 (0.234, 0.253)	0.218 (0.211, 0.224)	0.382 (0.372, 0.392)
	n = 2400	0.191 (0.188, 0.194)	0.227 (0.222, 0.233)	0.185 (0.179, 0.191)	0.321 (0.316, 0.326)
Wrong T Wrong W	n = 270	0.259 (0.249, 0.270)	0.258 (0.241, 0.274)	0.253 (0.237, 0.269)	0.415 (0.407, 0.423)
	n = 800	0.221 (0.215, 0.227)	0.230 (0.221, 0.238)	0.195 (0.182, 0.208)	0.327 (0.322, 0.332)
	n = 2400	0.206 (0.202, 0.210)	0.238 (0.233, 0.243)	0.193 (0.191, 0.195)	0.337 (0.328, 0.345)

[1] Four different scenarios are presented, corresponding to different combinations of correct or incorrect survival time T and propensity score W models.
[2] The average and 95% confidence interval of IMSE across 100 experiments are reported.

observed in the control group (411, 72%) than in the treatment group (110, 51%). The median survival time for patients in the treatment group is 2,379 days (95% CI: 1,928, 3,145), while it is 1,736 (1,478, 2,121) in the control group. The Kaplan-Meier curves (Figure 4.2) also show a better survival probability for the treatment group.

We apply DSL to this dataset and use 2-fold cross-fitting to train the model as we did in the simulation study. We choose to split data into two folds instead of more folds to reduce the computation burden of the estimation procedure. Additionally, the results of the simulation experiments show that 2-fold cross-fitting can already give good results, and there is no need to increase the number of folds. We tune the hyperparameters in DSL as we did in the simulation study. The DeepSurv model for survival time trained on the first fold has two hidden layers. Each layer has two neurons. The two dropout layer following the hidden layers have dropout rates of 0.5 and 0.3, respectively. In the second fold, the model for survival time also has two layers. Both hidden layers have 16 neurons. The following dropout layers have a dropout rate of 0.3. The learning rate is 0.05. For the DeepSurv model of censoring time, the model trained on the first fold has two hidden layers. The first hidden layer has two neurons, and the second hidden layer has 16 layers. The dropout layers have a dropout rate of 0.3. The learning rate is 0.001. In the second fold, the model has two hidden layers. The first layer has four neurons, and the second layer has two neurons. The dropout layer has a dropout rate of 0.3. The learning rate is 0.001. Finally, the DNN-based estimator of CATE trained on the first fold has two layers. The first layer has four neurons, and the second layer has 16 neurons. The following dropout layers have a dropout rate of 0.3. The fusion

Table 4.2: Clinical Characteristics of Patients from the Boston Lung Cancer Cohort

Characteristic	**Overall**	**Surgery**	**Surgery + Chemotherapy**
	(N = 784)[1]	**(N = 570)**[1]	**(N = 214)**[1]
Death	521 (66%)	411 (72%)	110 (51%)
Median Survival Time (years)	5.4 (4.7, 6.1)	4.8 (4.1, 5.8)	6.5 (5.3, 8.6)
Age at disgonsis (yrs)	67 (59, 74)	68 (60, 75)	64 (58, 71)
Unknown	19	12	7
Height (m)	1.69 (1.61, 1.75)	1.68 (1.60, 1.75)	1.70 (1.63, 1.78)
Unknown	57	52	5
Weight (kg)	75 (64, 86)	74 (64, 86)	76 (65, 88)
Unknown	60	53	7
Smoking Intensity (cigarettes/day)	20 (15, 30)	20 (15, 30)	20 (10, 30)
Unknown	24	22	2
Tumor Stage			
II	445 (57%)	333 (58%)	112 (52%)
III	339 (43%)	237 (42%)	102 (48%)
Gender			
Female	394 (50%)	296 (52%)	98 (46%)
Male	390 (50%)	274 (48%)	116 (54%)
Race			
American Indian/Alaska Native	2 (0.3%)	2 (0.4%)	0 (0%)
Asian	15 (1.9%)	7 (1.2%)	8 (3.8%)
Black	8 (1.0%)	5 (0.9%)	3 (1.4%)
Mixed	3 (0.4%)	1 (0.2%)	2 (0.9%)
Other	4 (0.5%)	4 (0.7%)	0 (0%)
White	746 (96%)	547 (97%)	199 (94%)
Unknown	6	4	2
Ethnicity			
Hispanic	18 (2.6%)	12 (2.4%)	6 (3.1%)
Non-Hispanic	671 (97%)	482 (98%)	189 (97%)
Unknown	95	76	19
Smoking Status			
Current Smoker	213 (27%)	166 (29%)	47 (22%)
Former Smoker	490 (62%)	353 (62%)	137 (64%)
Never Smoker	81 (10%)	51 (8.9%)	30 (14%)

[1] Median (IQR); n (%)



Figure 4.2: **Kaplan-Meier curves by treatment group**

penalty parameter is 2.3, and the learning rate is 0.001. Trained on the second fold, the model has the same structure as the model in the first fold, except that the fusion penalty parameter is 0.23.

We estimate CATE at the time points ranging from the 10th percentile of the survival time (1 year) to the 90th percentile of the survival time (12 years). Figure 4.3 shows the estimated CATE with respect to pre-treatment characteristics, including gender, tumor stage, race, age, BMI, and smoking intensity. The estimated CATE at time t_0 is the difference in t_0 survival rate comparing the patient when he receives surgery and perioperative chemotherapy to when he only receives surgery. We find positive CATE over time of interest across different characteristics, indicating that perioperative chemotherapy can improve the survival probability of early-stage NSCLC patients. Fixing other variables at their mean or mode, the increment in the 1-, 3-, and 5-year survival rate after perioperative chemotherapy is 6.7%, 6.4%, and 6.0% for female patients, while it is 6.2%, 5.9%, and 5.7% for male patients (Figure 4.3(a)). When it comes to the cancer stage (Figure 4.3 (b)), the increment in the 1-, 3-, and 5-year survival rate after perioperative chemotherapy is 6.8%, 6.4%, and 6.0% for patients with stage II NSCLC. However, for patients with stage III NSCLC, the increment in the 1-, 3-, and 5-year survival rate is 5.6%, 5.4%, and 5.2%, respectively. In Figure 4.3 (c), Black patients show the highest increment in the 1-, 3-, and 5-year survival rate (7.2%, 6.9%, 6.6%) compared to White (6.8%, 6.4%, 6.0%) and Asian patients (5.7%, 5.3% and 5.2%). Additionally, our study shows that the increment of 1-, 3-, and 5-year survival rate after perioperative chemotherapy for patients at the age of 65 years old is 7.0%, 6.7%, and 6.3% fixing other variables at their mean or mode, while it is 5.1%, 5.0%, and 5.0% for patients at the age of 75 years old (Figure 4.3 (d)). Furthermore, patients with higher BMI have higher estimated CATE, as shown in Figure 4.3 (e). Patients with a BMI of 22 show a 4.8%, 4.9%, and 4.9% increment in 1-, 3-, and 5-year survival rates, respectively, after perioperative chemotherapy. In contrast, patients with a BMI of 32 show a 7.6%, 7.4%, and 7.1% increment in 1-, 3-, and 5-year survival rates. Finally, Figure 4.3 (g) shows that the increment of 1-, 3-, and 5-year survival rate after perioperative chemotherapy for patients who smoke 10 cigarettes per day is 7.3%, 7.0%, and 6.7%, while it is 6.2%, 5.9%, 5.5% for patients who smoke 30 cigarettes per day.

Our findings are consistent with the existing literature. For example, our results show that perioperative chemotherapy is more effective for female patients than male patients, which is consistent with the existing literature. Leiter et al. found more benefits for female patients after adjuvant chemotherapy than their male counterparts [96]. Sandler et al. also found improved survival with adjuvant chemotherapy for women relative to men [134]. Additionally, our study shows that younger patients have a better survival improvement after perioperative chemotherapy than older patients. Morgensztern et al. found a more increased risk of early mortality with adjuvant chemotherapy and a prolonged stay postoperatively for older patients [113]. This may be because the toxicity of chemotherapy is more pronounced in elderly patients [136]. Furthermore, we find that patients with higher BMI benefit more from perioperative chemotherapy. This finding is in agreement with the obesity paradox for lung cancer patients [133]. We also find that patients with less smoking intensity have a higher increment in survival probability after perioperative chemotherapy, which is confirmed by other studies [169]. In addition, black patients show a better treatment effect than White and Asian patients in our study. However, many studies have shown higher mortality from lung cancer among black patients [59, 5]. Therefore, the high mortality for black patients may be due to the racial disparities in the treatment of lung cancer [23, 5].

4.6 Conclusion

In this chapter, we develop a new causal deep learning algorithm, Deep Survival Learner (DSL), by adapting a doubly-robust estimator of conditional average treatment effects with survival outcomes in observational studies. Extensive simulation studies have been conducted to understand the finite sample behaviors of the proposed method. DSL outperforms other competing metalearner algorithms when either the survival model or the propensity score model is correctly specified. The simulation results also show that the performance of DSL is comparable to other methods when both of the models are incorrectly specified.

Applying DSL to the Boston Lung Cancer study, we study the heterogeneous treatment effects of perioperative chemotherapy for early-stage lung cancer patients. We find that young female patients with Stage II NSCLC benefit more from perioperative chemotherapy than others. We also find that the treatment effects of perioperative chemotherapy are better for patients with higher



Figure 4.3: **Estimated conditional treatment effects**

BMI and lower smoking intensity. What's more, black patients have better survival outcomes after perioperative chemotherapy. The results are largely consistent with the existing literature [131, 130, 96, 134, 113, 136, 133, 169].

Large-scale simulation studies and applications to the Boston Lung Cancer Study have demonstrated the ability of the proposed DSL to estimate the heterogeneity of treatment effects across different patients and contexts. In this chapter, a simple feedforward neural network with numerical inputs is used to estimate CATE. However, other complex-structured neural networks can be used to analyze more complicated biomedical data. For example, we can apply convolutional neural networks (CNN), which take imaging inputs, to extract useful information regarding treatment effects from medical images. Additionally, it is interesting to apply the proposed model to high-dimensional settings and select important pre-treatment characteristics regarding the treatment effects. Finally, the best way to quantify the uncertainty of the estimates is still unknown. We will pursue this in the future.

APPENDIX A

Individualized Risk Assessment of Preoperative Opioid Use by Interpretable Neural Network Regression

A.1 Architecture of DNN



Figure A.1: **Architecture of DNN for the AOS Data. Input:** preoperative characteristics are classified into three inputs: Z_1 are un-modifiable characteristics, such as gender and race; Z_2 are modifiable characteristics, such as BMI and smoking; Z_3 are pain-related characteristics, such as Fibromyalgia Survey Score and pain severity. **Layers:** each category of inputs goes through the same structure: two hidden layers with a ReLu activation function. The first hidden layer has 500 neurons and the second hidden layer has 125 neurons. The three structures are concatenated and passed onto a layer with 15 hidden neurons and a ReLu activation function. **Output:** estimated probability of preoperative opioid use.

A.2 Sensitivity Analysis

Because stochastic gradient descent is sensitive to the choice of learning rates (LR), we use grid search to tune the learning rate. For the real data analysis, we tune the learning rate over a range from 0.005 to 0.1 with 20 equally spaced grid points, and find that $LR = 0.01$ seems to strike a balance between stability and computational readiness. We also implement the adaptive SGD to analyze our data. Specifically, we have implemented three popular adaptive SGD algorithms, namely, "Adagrad", "Adadelta" and "Adam." Adagrad adapts the learning rate based on a sequence of subgradients [44] to improve the robustness of SGD and avoid tuning the learning rate manually [40], while Adadelta [168] and Adam [85] only store an exponentially decaying average of subgradients [168]. We conduct 100 experiments to compare the prediction performance using different optimizers. In each experiment, we randomly split data into the training and testing parts, and use the balanced subsampling strategy described in Section 5.2 to assess the performance on the testing data. The means and standard errors (se) of different metrics are summarized in Table A.1. We find that all four methods give similar performances, though SGD with a fixed $LR = 0.01$ and Adam give the same C-statistic and sensitivity, slightly better than those obtained by Adagrad and Adadelta; all of these methods give the same balance accuracy.

Table A.1: Prediction Performance of INNER Using different Optimizers

	SGD (LR=0.01)	**Adagrad**	**Adadelta**	**Adam**
C-statistic	0.78 (0.0006)	0.77 (0.0005)	0.76 (0.0006)	0.78 (0.0006)
Accuracy	0.72 (0.0029)	0.73 (0.0011)	0.73 (0.0006)	0.72 (0.0009)
Sensitivity	0.69 (0.0052)	0.66 (0.0022)	0.66 (0.0012)	0.69 (0.0020)
Specificity	0.73 (0.0052)	0.76 (0.0019)	0.76 (0.0010)	0.73 (0.0017)
Balance Accuracy	0.71 (0.0008)	0.71 (0.0006)	0.71 (0.0005)	0.71 (0.0006)

[a.] used the balanced subsampling strategy and a threshold of 0.5

[b.] based on 100 random splits

The number of iterations is chosen to ensure the convergence of the algorithm (as shown in Fig A.2). We have also varied the batch sizes and number of iterations to examine the stability of the results and find a batch size of 64 and an epoch of 200 give a reasonable performance. We have conducted sensitivity analysis to assess the robustness of SGD towards the choices of these hyperparameters, and we find that the model's C-statistic is fairly robust to them. Specifically, by varying the learning rate from 0.0075 to 0.0125, the batch size from 32 to 128 and the number of iterations from 200 to 250, the C-statistic of the obtained INNER model is around 0.78.

We have conducted additional sensitivity analyses to examine the performance of the model under various initialization schemes for the weights $\mathbf{W}$ and the biases $\mathbf{b}$ in the neural networks. We have explored using different weights, such as uniform and normal weights, for the initial weights

Table A.2: Average C-statistics (se) of INNER with Various Learning Rates, Batch Sizes and Epochs

		LR =0.0075	**LR = 0.01**	**LR = 0.0125**
BS = 32	Epoch = 150	0.78 (0.0005)	0.78 (0.0006)	0.78 (0.0006)
	Epoch = 200	0.78 (0.0005)	0.78 (0.0007)	0.78 (0.0006)
	Epoch = 250	0.78 (0.0005)	0.78 (0.0007)	0.78 (0.0006)
BS = 64	Epoch = 150	0.78 (0.0006)	0.78 (0.0007)	0.78 (0.0007)
	Epoch = 200	0.78 (0.0005)	0.78 (0.0006)	0.78 (0.0006)
	Epoch = 250	0.78 (0.0005)	0.78 (0.0006)	0.78 (0.0005)
BS =128	Epoch = 150	0.78 (0.0006)	0.78 (0.0006)	0.78 (0.0006)
	Epoch = 200	0.78 (0.0006)	0.78 (0.0006)	0.78 (0.0006)
	Epoch = 250	0.78 (0.0006)	0.78 (0.0005)	0.78 (0.0006)

[a.] used the balanced subsampling strategy and a threshold of 0.5

[b.] used SGD for optimization

[c.] based on 100 experiments

[56, 64]. In particular, we have studied two versions of uniform weights: for a weight matrix $\mathbf{W}_l \in \mathbf{R}^{k_{l+1} \times k_l}$, where k_l and k_{l+1} are the numbers of input and output units of the lth layer, we initialize it with Uniform$\{-\sqrt{6/(k_l + k_{l+1})}, \sqrt{6/(k_l + k_{l+1})}\}$ following [56] (labeled as “Glorot uniform” in Table A.3, which reports the sensitivity analysis results); we also initialize the weight matrix with Uniform$(-\sqrt{6/k_l}, \sqrt{6/k_l})$ following [64] (labeled as “He uniform” in Table A.3). For the normal weights, we use Normal$(0, 2/(k_l + k_{l+1}))$ as the initial weights following [56] (labeled as “Glorot normal” in Table A.3). Finally, for the bias vector $\mathbf{b}$, we initialize it to be either all 0’s or 1’s for its components (labeled as “Zeros” or “Ones” in the column of bias initialization in Table A.3). For each set-up, we find that the C-statistic of the model is fairly constant, which is 0.78 with varied initialized values of weights and biases.

Table A.3: Average (se) C-statistics with different Initializations of Weights and Biases

Weight Initialization	Bias Initialization	**C-statistic**
Glorot uniform	Zeros	0.78 (0.0006)
	Ones	0.78 (0.0006)
Glorot normal	Zeros	0.78 (0.0005)
	Ones	0.78 (0.0005)
He uniform	Zeros	0.78 (0.0008)
	Ones	0.78 (0.0006)

[a.] used the balanced subsampling strategy and a threshold of 0.5

[b.] used SGD for optimization

[c.] based on 100 experiments



Figure A.2: **Learning Curve of INNER: Cross Entropy Loss Against Iteration For Training and Validation Data**

A.3 Subpopulations with High Risks

We have made scatter plots of $\log(\text{POT})$ and $\log(\text{BOT})$ (Fig A.3) for the three groups mentioned in Section 5.4. The population means (standard deviation (std)) of $\log(\text{POT})$ and $\log(\text{BOT})$ are 0.26 (0.09) and -2.32 (0.63) respectively. In Fig A.3(a), we focus on a group of patients identified by demographic risk factors, i.e., African American male patients younger than 20 years old; these patients on average have a higher $\log(\text{POT})$ (mean: 0.29, std: 0.14) but a lower $\log(\text{BOT})$ (mean: -2.64, std: 0.46), indicating their sensitivity to pain but lower tendency to take opioids without pains. Fig A.3(b) depicts BOT and POT for patients who have worsened physical conditions, i.e., with BMI greater than or equal to 32, ASA scores between three and four, Fibromyalgia survey scores greater than 13, Charlson comorbidity index greater than or equal to one, and sleep apnea; these patients have a higher $\log(\text{BOT})$ (mean: -1.33, std: 0.46) and higher $\log(\text{POT})$ (mean: 0.29, std: 0.07) compared to the entire population, indicating they are both sensitive to pain and likely to take preoperative opioids even with no pains reported. Finally, Fig A.3(c) focuses on patients who have substance use and co-occurring mental disorders, such as illicit drug use history, tobacco consumption, anxiety and depression. These patients have a smaller $\log(\text{BOT})$ (mean: -1.51, std: 0.46) on average compared to those in Fig A.3(b) and the highest $\log(\text{POT})$ (mean: 0.30, std: 0.07) among the three groups.



(a) (b) (c)

Figure A.3: **Distributions of BOT and POT for three groups. (a)**: Patients are chosen based on demographics, including gender, race and age;**(b)**: Patients are chosen based on physical condition risk factors, including BMI, ASA scores, Fibromyalgia survey scores, Charlson comorbidity index and sleep apnea;**(c)**: Patients are chosen based on substance use and co-occurring mental disorders, including illicit drug use history, tobacco consumption, depression and anxiety. The horizontal and vertical lines represent the population means of $\log(\text{POT})$ and $\log(\text{BOT})$, respectively; the numbers in each plot refer to the means and standard deviations.

Table A.4: Comparisons of the Prediction Performance using the AOS Data

	Deep Neural Network	**Logistic Regression**	**Interpretable Neural Network Regression**
Preoperative Opioid Prevalence: 0.23			
C-statistic	0.78 (0.0006)	0.62 (0.0094)	0.78 (0.0006)
Threshold = 0.50			
Accuracy	0.80 (0.0004)	0.70 (0.0116)	0.80 (0.0004)
Sensitivity	0.33 (0.0049)	0.43 (0.0331)	0.31 (0.0057)
Specificity	0.94 (0.0016)	0.78 (0.0238)	0.94 (0.0018)
Balance Accuracy	0.63 (0.0017)	0.61 (0.0071)	0.63 (0.002)
Threshold = 0.23			
Accuracy	0.72 (0.0021)	0.69 (0.0123)	0.73 (0.0030)
Sensitivity	0.69 (0.0039)	0.44 (0.0336)	0.68 (0.0055)
Specificity	0.73 (0.0038)	0.77 (0.025)	0.74 (0.0054)
Balance Accuracy	0.71 (0.0006)	0.61 (0.007)	0.71 (0.0007)
Preoperative Opioid Prevalence: 0.50			
C-statistic	0.78 (0.0006)	0.73 (0.0027)	0.78 (0.0006)
Threshold = 0.50			
Accuracy	0.73 (0.0017)	0.63 (0.0129)	0.72 (0.0029)
Sensitivity	0.69 (0.0043)	0.67 (0.0261)	0.69 (0.0052)
Specificity	0.73 (0.0034)	0.62 (0.0238)	0.73 (0.0052)
Balance Accuracy	0.71 (0.0007)	0.64 (0.0049)	0.71 (0.0008)
Threshold = 0.23			
Accuracy	0.46 (0.0044)	0.50 (0.0130)	0.41 (0.0056)
Sensitivity	0.93 (0.0024)	0.84 (0.0154)	0.95 (0.0022)
Specificity	0.31 (0.0064)	0.39 (0.0211)	0.24 (0.0080)
Balance Accuracy	0.62 (0.0021)	0.61 (0.0047)	0.60 (0.0030)

[a.] prediction power of each model with the best architectures (DNN and INNER) under different sampling strategies and threshold; for the comparison of different architectures, refer to Appendix Table A.5 and Appendix Table A.6

[b.] based on 100 experiments for each metric

[c.] in the AOS data, the prevalence of preoperative opioid is 0.23, and the prevalence is around 0.23 for the training data; we use the balanced subsampling strategy to adjust the prevalence of preoperative opioid to be 0.50 in the training data

Table A.5: Tuning the Architecture of INNER with the AOS Data

	Three Layers **250 Neurons**	**Four Layers** **500 Neurons**	**Five Layers** **500 Neurons**
Preoperative Opioid Prevalence: 0.23			
C-statistic	0.78 (0.0006)	0.78 (0.0007)	0.77 (0.0005)
Threshold = 0.50			
Accuracy	0.80 (0.0004)	0.79 (0.0005)	0.79 (0.0004)
Sensitivity	0.31 (0.0057)	0.32 (0.0063)	0.32 (0.0061)
Specificity	0.94 (0.0018)	0.94 (0.0021)	0.93 (0.0019)
Balance Accuracy	0.63 (0.0020)	0.63 (0.0021)	0.63 (0.0021)
Threshold = 0.23			
Accuracy	0.73 (0.0030)	0.72 (0.0031)	0.72 (0.0022)
Sensitivity	0.68 (0.0055)	0.68 (0.0054)	0.68 (0.0043)
Specificity	0.74 (0.0054)	0.73 (0.0055)	0.74 (0.0041)
Balance Accuracy	0.71 (0.0007)	0.71 (0.0008)	0.71 (0.0005)
Preoperative Opioid Prevalence: 0.50			
C-statistic	0.78 (0.0006)	0.78 (0.0006)	0.78 (0.0006)
Threshold = 0.50			
Accuracy	0.72 (0.0029)	0.73 (0.0026)	0.72 (0.0020)
Sensitivity	0.69 (0.0052)	0.69 (0.0048)	0.69 (0.0037)
Specificity	0.73 (0.0052)	0.75 (0.0047)	0.73 (0.0036)
Balance Accuracy	0.71 (0.0008)	0.71 (0.0008)	0.71 (0.0005)
Threshold = 0.23			
Accuracy	0.41 (0.0056)	0.42 (0.0057)	0.43 (0.0050)
Sensitivity	0.95 (0.0022)	0.95 (0.0023)	0.94 (0.0021)
Specificity	0.24 (0.0080)	0.26 (0.0081)	0.28 (0.0071)
Balance Accuracy	0.60 (0.0030)	0.60 (0.0030)	0.61 (0.0026)

[a.] the first column is for the best INNER architecture as reported in Table 2.4 and Appendix Table A.4

[b.] the other columns refer to the other more complicated INNERs, with more hidden layers or more neurons in each hidden layers

[c.] the column names are the number of hidden layers and the number of neurons in the first hidden layers for $F_L(\mathbf{Z}_i; \boldsymbol{\alpha})$ and $F_L(\mathbf{Z}_i; \boldsymbol{\alpha})$

[d.] in the AOS data, the prevalence of preoperative opioid use is 0.23; uses a balanced subsampling strategy by over-sampling cases; adjusts the prevalence of preoperative opioid use to be 0.50 in the training data

Table A.6: Tuning the Architecture of DNN for AOS Data

	Two Layers 500 Neurons	**Three Layer 250 Neurons**	**Three Layer 500 Neurons**
Preoperative Opioid Prevalence: 0.23			
C-statistic	0.78 (0.0006)	0.79 (0.0006)	0.79 (0.0005)
Threshold = 0.50			
Accuracy	0.80 (0.0004)	0.79 (0.0004)	0.79 (0.0004)
Sensitivity	0.33 (0.0049)	0.34 (0.0054)	0.32 (0.0068)
Specificity	0.94 (0.0016)	0.93 (0.0018)	0.94 (0.0020)
Balance Accuracy	0.63 (0.0017)	0.63 (0.0018)	0.63 (0.0024)
Threshold = 0.23			
Accuracy	0.72 (0.0021)	0.72 (0.0022)	0.72 (0.0024)
Sensitivity	0.69 (0.0039)	0.70 (0.0038)	0.69 (0.0049)
Specificity	0.73 (0.0038)	0.72 (0.0040)	0.73 (0.0046)
Balance Accuracy	0.71 (0.0006)	0.71 (0.0006)	0.71 (0.0005)
Preoperative Opioid Prevalence: 0.50			
C-statistic	0.78 (0.0006)	0.78 (0.0006)	0.78 (0.0005)
Threshold = 0.50			
Accuracy	0.73 (0.0017)	0.72 (0.0025)	0.72 (0.0023)
Sensitivity	0.69 (0.0043)	0.70 (0.0039)	0.70 (0.0043)
Specificity	0.73 (0.0034)	0.72 (0.0043)	0.73 (0.0042)
Balance Accuracy	0.71 (0.0007)	0.71 (0.0007)	0.71 (0.0005)
Threshold = 0.23			
Accuracy	0.46 (0.0044)	0.45 (0.0044)	0.45 (0.0052)
Sensitivity	0.93 (0.0024)	0.94 (0.0020)	0.93 (0.0023)
Specificity	0.31 (0.0064)	0.30 (0.0062)	0.31 (0.0074)
Balance Accuracy	0.62 (0.0021)	0.62 (0.0022)	0.62 (0.0026)

[a.] the first column is for the best DNN architecture as reported in Table 2.4 and Appendix Table A.4

[b.] the other columns refer to the other more complicated DNNs, with more hidden layers or more neurons

[c.] the column names are the number of hidden layers and the number of neurons in the first hidden layers before concatenation

[d.] in the AOS data, the prevalence of preoperative opioid use is 0.23; uses a balanced subsampling strategy by over-sampling cases; adjusts the prevalence of preoperative opioid use to be 0.50 in the training data

APPENDIX B

Penalized Deep Partially Linear Cox Models with Application to CT Scans of Lung Cancer Patients

B.1 Notation

Denote $a_n \lesssim b_n$ as $a_b \leq cb_n$ for some $c > 0$ when n is sufficiently large; $a_n \asymp b_n$ if $a_n \lesssim b_n$ and $b_n \lesssim a_n$. Let $\eta(\cdot,\cdot) = (\boldsymbol{\beta}^\top \cdot, g(\cdot)) : \mathbb{R}^p \times \mathbb{R}^r \to \mathbb{R}^2$ denote the collection of a linear operator and a nonlinear operator. In this section, denote by $\mathbf{v} = (\mathbf{x}^\top, \mathbf{z}^\top)^\top$ the random vector underlying the observed IID data of $\mathbf{v}_i = (\mathbf{x}_i^\top, \mathbf{z}_i^\top)^\top$, and (T, Δ) the random vector underlying the observed IID data of $(T_i, \Delta_i), i = 1, \ldots, n$. Define $\xi_\eta(\mathbf{v}) = \boldsymbol{\beta}^\top \mathbf{x} + g(\mathbf{z})$. Denote the truth of $\eta(\cdot,\cdot)$ by $\eta_0(\cdot,\cdot) = (\boldsymbol{\beta_0}^\top \cdot, g_0(\cdot))$. For two operators, say, $\eta_1(\cdot,\cdot) = (\boldsymbol{\beta}_1^\top \cdot, g_1(\cdot))$ and $\eta_2(\cdot,\cdot) = (\boldsymbol{\beta}_2^\top \cdot, g_2(\cdot))$, define their distance as

$$d^2(\eta_1, \eta_2) := \mathbb{E}[\{\xi_{\eta_1}(\mathbf{v}) - \xi_{\eta_2}(\mathbf{v})\}^2] = \int \{\xi_{\eta_1}(\mathbf{t}) - \xi_{\eta_2}(\mathbf{t})\}^2 f_{\mathbf{v}}(\mathbf{t}) d\mathbf{t},$$

and the corresponding norm

$$\|\eta\|^2 := \mathbb{E}[\xi_\eta^2(\mathbf{v})] = \int \xi_\eta^2(\mathbf{t}) f_{\mathbf{v}}(\mathbf{t}) d\mathbf{t}.$$

For the notational ease, we write $\eta = (\boldsymbol{\beta}, g)$ in the following.

With $Y(t) = 1(T \geq t)$ and $Y_i(t) = 1(T_i \geq t)$, define

$$S_{0n}(t, \eta) = \frac{1}{n} \sum_{i=1}^n Y_i(t) \exp\{\xi_\eta(\mathbf{v}_i)\}, \qquad S_0(t, \eta) = \mathbb{E}[Y(t) \exp\{\xi_\eta(\mathbf{v})\}],$$

and for any vector function $\mathbf{h}$ of $\mathbf{v}$ define

$$S_{1n}(t, \eta, \mathbf{h}) = \frac{1}{n} \sum_{i=1}^n Y_i(t) \mathbf{h}(\mathbf{v}_i) \exp\{\xi_\eta(\mathbf{v}_i)\}, \qquad S_1(t, \eta, \mathbf{h}) = \mathbb{E}[Y(t) \mathbf{h}(\mathbf{v}) \exp\{\xi_\eta(\mathbf{v})\}],$$

where the expectation is taken with respect to the joint distribution of T and $\mathbf{v}$.

Let

$$l_n(t, \mathbf{v}, \eta) = \xi_\eta(\mathbf{v}) - \log S_{0n}(t, \eta), \qquad l_0(t, \mathbf{v}, \eta) = \xi_\eta(\mathbf{v}) - \log S_0(t, \eta).$$

Then the partial likelihood in (4.8) can be written as

$$\ell(\eta) = \frac{1}{n} \sum_{i=1}^{n} \{\Delta_i l_n(T_i, \mathbf{v}_i, \eta) - \Delta_i \log n\}.$$

Since $\sum_{i=1}^{n} \Delta_i \log n$ does not involve unknown parameters and can be dropped in optimization, we replace below $\ell(\eta)$ by $\frac{1}{n} \sum_{i=1}^{n} \{\Delta_i l_n(T_i, \mathbf{v}_i, \eta)\}$.

Finally, for any function h of $(\mathbf{v}, \Delta, T)$, where (Δ, T) is the random vector underlying (Δ_i, T_i), define

$$\mathbb{P}_n\{h(\mathbf{v}, \Delta, T)\} = \frac{1}{n} \sum_{i=1}^{n} h(\mathbf{v}_i, \Delta_i, T_i), \qquad \mathbb{P}\{h(\mathbf{v}, \Delta, T)\} = \mathbb{E}\{h(\mathbf{v}, \Delta, T)\},$$

and in particular, we define $L_n(\eta) = \mathbb{P}_n\{\Delta l_n(T, \mathbf{v}, \eta)\}$ and $L_0(\eta) = \mathbb{P}\{\Delta l_0(T, \mathbf{v}, \eta)\}$. Here, the expectation is taken with respect to the joint distribution of T, Δ and $\mathbf{v}$.

B.2 Proof of Theorem 1

Define $\alpha_n = \gamma_n \log^2 n + a_n = \tau_n + a_n$. For some $D > 0$, let $\mathbb{R}^p_D := \{\boldsymbol{\beta} \in \mathbb{R}^p : \|\boldsymbol{\beta}\|_\infty < D\}$ and $\mathcal{G}_D := \mathcal{G}(L, \mathbf{p}, s, D)$, and define

$$\hat{\eta}_D = \underset{\eta \in \mathbb{R}^p_D \times \mathcal{G}_D}{\operatorname{argmax}} \; PL(\eta).$$

Further, denote by $\hat{\eta} = (\hat{\boldsymbol{\beta}}, \hat{g})$ a local maximizer of $PL(\eta)$ over $\mathbb{R}^p \times \mathcal{G}$, that is, by setting $D = \infty$ in $\mathbb{R}^p_D$ and $\mathcal{G}_D$. As in [170], it can be shown that if $\max(||\beta||, ||g||_\infty) \to \infty$, $PL(\eta) \to -\infty$; hence, when D is sufficiently large, $\hat{\eta} = \hat{\eta}_D$ almost surely. Therefore, in the following, we show that $d(\hat{\eta}_D, \eta_0) = O_p(\alpha_n)$, when D is sufficiently large.

To do so, it suffices to show that for any $\epsilon > 0$, there exists a C such that

$$\mathrm{P}\left\{ \sup_{\eta \in \mathcal{N}_c} PL(\eta) < PL(\eta_0) \right\} \geq 1 - \epsilon, \tag{B.1}$$

where $\mathcal{N}_c = \{\eta \in \mathbb{R}^p_D \times \mathcal{G}_D : d(\eta, \eta_0) = C\alpha_n\}$. If it holds, it implies with probability at least $1 - \epsilon$ that there exists a $C > 0$ such that a local maximum exists and is inside the ball $\mathcal{N}_c$. Hence, there exists a local maximizer such that $d(\hat{\eta}, \eta_0) = O_p(\alpha_n)$.

Without loss of generality, we assume that η satisfies $\mathbb{E}\{\xi_\eta(\mathbf{v})\} = \mathbb{E}\{\xi_{\eta_0}(\mathbf{v})\}$, implying $\mathbb{E}\{g(\mathbf{z})\} = 0$; if not, we can always centralize it. To see this, consider any $\eta = (\beta, g)$ in the ball $B_C = \{\eta \in \mathbb{R}^p_D \times \mathcal{G}_D : d(\eta, \eta_0) \leq C\alpha_n\}$, its centralization $\eta' = (\beta, g - \mathbb{E}\{\xi_\eta(\mathbf{v}) - \xi_{\eta_0}(\mathbf{v})\})$ is also in the ball B_C, satisfying $\mathbb{E}\{\xi_{\eta'}(\mathbf{v})\} = \mathbb{E}\{\xi_{\eta_0}(\mathbf{v})\}$ and $PL(\eta') = PL(\eta)$.

Because of the sparsity of the β-coefficients, we arrange the indices of the covariates $(x_1, \ldots, x_p)$ so that $\beta_{j0} = 0$ when $j > s_\beta$. We consider

$$\begin{aligned} & PL(\eta) - PL(\eta_0) \\ = \;& \{L_n(\eta) - L_n(\eta_0)\} - \sum_{j=1}^{p} \{p_\lambda(|\beta_j|) - p_\lambda(|\beta_{j0}|)\} \\ \leq \;& \{L_n(\eta) - L_n(\eta_0)\} - \sum_{j=1}^{s_\beta} \{p_\lambda(|\beta_j|) - p_\lambda(|\beta_{j0}|)\}, \end{aligned} \tag{B.2}$$

where the inequality holds because $p_\lambda(|\beta_j|) - p_\lambda(0) > 0$ when $j > s_\beta$.

We first deal with

$$\begin{aligned} L_n(\eta) - L_n(\eta_0) =& \{L_0(\eta) - L_0(\eta_0)\} \\ & + \{L_n(\eta) - L_0(\eta)\} - \{L_n(\eta_0) - L_0(\eta_0)\}. \end{aligned} \tag{B.3}$$

According to Lemma 2 in [170], we know that

$$L_0(\eta) - L_0(\eta_0) \asymp -d^2(\eta, \eta_0).$$

Since $d(\eta, \eta_0) = C\alpha_n$, the first term in the right hand side of B.3 is of the order $C^2\alpha_n^2$.

After some calculation,

$$\begin{aligned} (L_n - L_0)(\eta) - (L_n - L_0)(\eta_0) =& (\mathbb{P}_n - \mathbb{P})\{\Delta l_0(T, \mathbf{v}, \eta) - \Delta l_0(T, \mathbf{v}, \eta_0)\} \\ & + \mathbb{P}_n\Big\{\Delta \log \frac{R_0(T, \eta)}{R_0(T, \eta_0)} - \Delta \log \frac{R_{0n}(T, \eta)}{R_{0n}(T, \eta_0)}\Big\} \\ =& I + II. \end{aligned} \tag{B.4}$$

According to the proof of Theorem 3.1 in [170], with $\mathcal{A}_\delta = \{(\beta, g) \in \mathbb{R}^p_D \times \mathcal{G}_D : \delta/2 \leq d(\eta, \eta_0) \leq \delta\}$, it follows that

$$\sup_{\eta \in \mathcal{A}_\delta} |I| = O(n^{-1/2}\phi_n(\delta)),$$

$$\sup_{\eta \in \mathcal{A}_\delta} |II| \leq O(n^{-1/2}\phi_n(\delta)),$$

where $\phi_n(\delta) = \delta\sqrt{s\log\frac{\mathcal{U}}{\delta}} + \frac{s}{\sqrt{n}}\log\frac{\mathcal{U}}{\delta}$ and $\mathcal{U} = L\prod_{l=1}^{L}(p_l+1)\sum_{l=1}^{L}p_lp_{l+1}$.Then by Assumption 1, when $\delta = C(\tau_n + a_n)$, we can show that $n^{-1/2}\phi_n\{C(\tau_n + a_n)\} \leq C(\tau_n + a_n)^2 = C\alpha_n^2$.

By the Taylor expansion and the Cauchy-Schwarz inequality, the second term on the right-hand side of (B.2) is bounded by

$$\sqrt{s_\beta}a_n\|\boldsymbol{\beta} - \boldsymbol{\beta_0}\| + \frac{1}{2}b_n\|\boldsymbol{\beta} - \boldsymbol{\beta_0}\|^2.$$

Since $d(\eta, \eta_0) = C\alpha_n$, and therefore $\|\boldsymbol{\beta} - \boldsymbol{\beta_0}\|$ is of the order $C\alpha_n$. Hence, this upper bound is dominated by the first term in (B.3) as $b_n \to 0$ by the assumption.

Therefore, for any $\epsilon > 0$, there exist sufficiently large $C, D > 0$ so that (B.1) holds, and hence $d(\hat{\eta}_D, \eta_0) = O_p(\alpha_n)$, which gives $d(\hat{\eta}, \eta_0) = O_p(\alpha_n)$, where we recall $\hat{\eta}$ is the local maximizer of $PL(\eta)$ over $\mathbb{R}^p \times \mathcal{G}$. We note that

$$\begin{aligned} d^2(\hat{\eta}, \eta_0) &= \mathbb{E}[(\hat{\boldsymbol{\beta}} - \boldsymbol{\beta}_0)^\top\{\mathbf{x} - \mathbb{E}(\mathbf{x}|\mathbf{z})\} + (\hat{\boldsymbol{\beta}} - \boldsymbol{\beta}_0)^\top\mathbb{E}(\mathbf{x}|\mathbf{z}) + \{\hat{g}(\mathbf{z}) - g_0(\mathbf{z})\}]^2 \\ &= \mathbb{E}[(\hat{\boldsymbol{\beta}} - \boldsymbol{\beta}_0)^\top\{\mathbf{x} - \mathbb{E}(\mathbf{x}|\mathbf{z})\}]^2 + \mathbb{E}[\{\hat{g}(\mathbf{z}) - g_0(\mathbf{z})\} + (\hat{\boldsymbol{\beta}} - \boldsymbol{\beta}_0)^\top\mathbb{E}(\mathbf{x}|\mathbf{z})]^2, \end{aligned}$$

where the second equality holds because, by the definition of $d(\cdot,\cdot)$, $\mathbb{E}$ is taken with respect to the joint density of $\mathbf{v} = (\mathbf{x}^\top, \mathbf{z}^\top)^\top$, which is independent of the observed data, and hence, $\hat{\boldsymbol{\beta}}$ and $\hat{g}$. By Assumptions 2-4, it follows $\|\hat{\boldsymbol{\beta}} - \boldsymbol{\beta}_0\| = O_p(\alpha_n)$ and $\|\hat{g} - g_0\|_{L^2} = O_p(\alpha_n)$.



(a) Selection of λ for 10 simulated datasets

(b) Selection path for the non-zero coefficients

Figure B.1: **Selection of $\boldsymbol{\lambda}$ in Penalized DPLC using BIC.**



Figure B.2: **Image Preprocessing Pipeline**



Figure B.3: **Selection Frequency and Hazard Ratio of Selected Features:** The selection frequency of the most frequently selected five texture features is reported. The hazard ratio is the average of 100 experiments

BIBLIOGRAPHY

[1] Jason Abrevaya, Yu-Chin Hsu, and Robert P Lieli. Estimating conditional average treatment effects. *Journal of Business & Economic Statistics*, 33(4):485–505, 2015.

[2] Amina Adadi and Mohammed Berrada. Peeking inside the black-box: a survey on explainable artificial intelligence (xai). *IEEE access*, 6:52138–52160, 2018.

[3] Sheyan J Armaghani, Dennis S Lee, Jesse E Bible, Kristin R Archer, David N Shau, Harrison Kay, Chi Zhang, Matthew J McGirt, and Clinton J Devin. Preoperative opioid use and its association with perioperative opioid demand and postoperative opioid independence in patients undergoing spine surgery. *Spine*, 39(25):E1524–E1530, 2014.

[4] Susan Athey and Guido W Imbens. Machine learning methods that economists should know about. *Annual Review of Economics*, 11:685–725, 2019.

[5] Peter B Bach, Laura D Cramer, Joan L Warren, and Colin B Begg. Racial differences in the treatment of early-stage lung cancer. *New England Journal of Medicine*, 341(16):1198–1205, 1999.

[6] Brett C Bade and Charles S Dela Cruz. Lung cancer 2020: epidemiology, etiology, and prevention. *Clinics in Chest Medicine*, 41(1):1–24, 2020.

[7] Jyotirmoy Banerjee, Adriaan Moelker, Wiro J Niessen, and Theo van Walsum. 3d lbp-based rotationally invariant region description. In *Asian Conference on Computer Vision*, pages 26–37. Springer, 2012.

[8] Andrew R Barron. Universal approximation bounds for superpositions of a sigmoidal function. *IEEE Transactions on Information Theory*, 39(3):930–945, 1993.

[9] Andrew R Barron. Approximation and estimation bounds for artificial neural networks. *Machine Learning*, 14(1):115–133, 1994.

[10] Benedikt Bauer and Michael Kohler. On deep learning as a remedy for the curse of dimensionality in nonparametric regression. *Annals of Statistics*, 47(4):2261–2285, 2019.

[11] Philippe L Bedard, Aaron R Hansen, Mark J Ratain, and Lillian L Siu. Tumour heterogeneity in the clinic. *Nature*, 501(7467):355–364, 2013.

[12] Mohammad Mahdi Bejani and Mehdi Ghatee. A systematic review on overfitting control in shallow and deep neural networks. *Artificial Intelligence Review*, 54(8):6391–6438, 2021.

[13] Harald Binder, Arthur Allignol, Martin Schumacher, and Jan Beyersmann. Boosting for high-dimensional time-to-event data with competing risks. *Bioinformatics*, 25(7):890–896, 2009.

[14] Christopher M Booth, Frances A Shepherd, Yingwei Peng, Gail E Darling, Gavin Li, Weidong Kong, and William J Mackillop. Adoption of adjuvant chemotherapy for non–small-cell lung cancer: a population-based outcomes study. *Journal of Clinical Oncology*, 28(21):3472, 2010.

[15] Léon Bottou. Large-scale machine learning with stochastic gradient descent. In *Proceedings of COMPSTAT'2010*, pages 177–186. Springer, 2010.

[16] Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, and Ahmedin Jemal. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6):394–424, 2018.

[17] Patrick Breheny and Jian Huang. Coordinate descent algorithms for nonconvex penalized regression, with applications to biological feature selection. *The Annals of Applied Statistics*, 5(1):232, 2011.

[18] Wieland Brendel, Jonas Rauber, and Matthias Bethge. Decision-based adversarial attacks: Reliable attacks against black-box machine learning models. *arXiv preprint arXiv:1712.04248*, 2017.

[19] Lily A Brown, Cecile M Denis, Anthony Leon, Michael B Blank, Steven D Douglas, Knashawn H Morales, Paul F Crits-Christoph, David S Metzger, and Dwight L Evans. Number of opioid overdoses and depression as a predictor of suicidal thoughts. *Drug and Alcohol Dependence*, 224:108728, 2021.

[20] Chad M Brummett, Allison M Janda, Christa M Schueller, Alex Tsodikov, Michelle Morris, David A Williams, and Daniel J Clauw. Survey criteria for fibromyalgia independently predict increased postoperative opioid consumption after lower extremity joint arthroplasty: a prospective, observational cohort study. *Anesthesiology*, 119(6):1434–1443, 2013.

[21] Chad M Brummett, Andrew G Urquhart, Afton L Hassett, Alex Tsodikov, Brian R Hallstrom, Nathan I Wood, David A Williams, and Daniel J Clauw. Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. *Arthritis & Rheumatology*, 67(5):1386–1394, 2015.

[22] Chad M Brummett, Jennifer F Waljee, Jenna Goesling, Stephanie Moser, Paul Lin, Michael J Englesbe, Amy SB Bohnert, Sachin Kheterpal, and Brahmajee K Nallamothu. New persistent opioid use after minor and major surgical procedures in US adults. *JAMA Surgery*, 152(6):e170504(1)–e170504(9), 2017.

[23] Ayesha S Bryant and Robert James Cerfolio. Impact of race on outcomes of patients with non-small cell lung cancer. *Journal of Thoracic Oncology*, 3(7):711–715, 2008.

[24] Zongwu Cai, Jianqing Fan, and Runze Li. Efficient estimation and inferences for varying-coefficient models. *Journal of the American Statistical Association*, 95(451):888–902, 2000.

[25] Zixuan Cang, Lin Mu, and Guo-Wei Wei. Representability of algebraic topology for biomolecules in machine learning based scoring and virtual screening. *PLoS computational biology*, 14(1):e1005929, 2018.

[26] Zhengping Che, David Kale, Wenzhe Li, Mohammad Taha Bahadori, and Yan Liu. Deep computational phenotyping. In *Proceedings of the 21st ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, pages 507–516. ACM, 2015.

[27] Zhengping Che, Jennifer St Sauver, Hongfang Liu, and Yan Liu. Deep learning solutions for classifying patients on opioid use. In *AMIA Annual Symposium Proceedings*, volume 2017, pages 525–534. American Medical Informatics Association, 2017.

[28] Tianqi Chen and Carlos Guestrin. Xgboost: A scalable tree boosting system. In *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, pages 785–794, 2016.

[29] Dmitry Cherezov, Dmitry Goldgof, Lawrence Hall, Robert Gillies, Matthew Schabath, Henning Müller, and Adrien Depeursinge. Revealing tumor habitats from texture heterogeneity analysis for classification of lung cancer malignancy and aggressiveness. *Scientific Reports*, 9(1):1–9, 2019.

[30] Edward Choi, Mohammad Taha Bahadori, Andy Schuetz, Walter F Stewart, and Jimeng Sun. Doctor ai: Predicting clinical events via recurrent neural networks. In *Machine Learning for Healthcare Conference*, pages 301–318, 2016.

[31] A Chu, Chandra M Sehgal, and James F Greenleaf. Use of gray value distribution of run lengths for texture analysis. *Pattern Recognition Letters*, 11(6):415–419, 1990.

[32] Ángel Artal Cortés, Lourdes Calera Urquizu, and Jorge Hernando Cubero. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. *Translational Lung Cancer Research*, 4(2):191, 2015.

[33] National Research Council et al. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. 2011.

[34] David R Cox. Regression models and life-tables. *Journal of the Royal Statistical Society: Series B (Methodological)*, 34(2):187–202, 1972.

[35] David C Cron, Michael J Englesbe, Christian J Bolton, Melvin T Joseph, Kristen L Carrier, Stephanie E Moser, Jennifer F Waljee, Paul E Hilliard, Sachin Kheterpal, and Chad M Brummett. Preoperative opioid use is independently associated with increased costs and worse outcomes after major abdominal surgery. *Annals of Surgery*, 265(4):695–701, 2017.

[36] Peng Cui and Susan Athey. Stable learning establishes some common ground between causal inference and machine learning. *Nature Machine Intelligence*, 4(2):110–115, 2022.

[37] Peng Cui, Zheyan Shen, Sheng Li, Liuyi Yao, Yaliang Li, Zhixuan Chu, and Jing Gao. Causal inference meets machine learning. In *Proceedings of the 26th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining*, pages 3527–3528, 2020.

[38] George Cybenko. Approximation by superpositions of a sigmoidal function. *Mathematics of Control, Signals and Systems*, 2(4):303–314, 1989.

[39] C. Darken, J. Chang, and J. Moody. Learning rate schedules for faster stochastic gradient search. In *Neural Networks for Signal Processing II Proceedings of the 1992 IEEE Workshop*, pages 3–12, 1992.

[40] Jeffrey Dean, Greg Corrado, Rajat Monga, Kai Chen, Matthieu Devin, Mark Mao, Marc'aurelio Ranzato, Andrew Senior, Paul Tucker, Ke Yang, and Andrew Y. Ng. Large scale distributed deep networks. *Advances in Neural Information Processing Systems*, 25:1223–1231, 2012.

[41] Carol E DeSantis, Kimberly D Miller, Ann Goding Sauer, Ahmedin Jemal, and Rebecca L Siegel. Cancer statistics for african americans, 2019. *CA: A Cancer Journal for Clinicians*, 69(3):211–233, 2019.

[42] Xinyu Dong, Sina Rashidian, Yu Wang, Janos Hajagos, Xia Zhao, Richard N Rosenthal, Jun Kong, Mary Saltz, Joel Saltz, and Fusheng Wang. Machine learning based opioid overdose prediction using electronic health records. In *AMIA Annual Symposium Proceedings*, volume 2019, pages 389–398. American Medical Informatics Association, 2019.

[43] David L Donoho and Iain M Johnstone. Ideal spatial adaptation by wavelet shrinkage. *Biometrika*, 81(3):425–455, 1994.

[44] John Duchi, Elad Hazan, and Yoram Singer. Adaptive subgradient methods for online learning and stochastic optimization. *Journal of Machine Learning Research*, 12(7):2121–2159, 2011.

[45] Bradley Efron. Large-scale simultaneous hypothesis testing: the choice of a null hypothesis. *Journal of the American Statistical Association*, 99(465):96–104, 2004.

[46] Bradley Efron. Correlation and large-scale simultaneous significance testing. *Journal of the American Statistical Association*, 102(477):93–103, 2007.

[47] Bradley Efron. Size, power and false discovery rates. *The Annals of Statistics*, 35(4):1351–1377, 2007.

[48] Adel Elkbuli, Margaret M Byrne, Wei Zhao, Mason Sutherland, Mark McKenney, Yeissen Godinez, Devina J Dave, Layla Bouzoubaa, and Tulay Koru-Sengul. Gender disparities in lung cancer survival from an enriched florida population-based cancer registry. *Annals of Medicine and Surgery*, 60:680–685, 2020.

[49] Jianqing Fan and Runze Li. Variable selection via nonconcave penalized likelihood and its oracle properties. *Journal of the American statistical Association*, 96(456):1348–1360, 2001.

[50] Jianqing Fan and Runze Li. Variable selection for Cox's proportional hazards model and frailty model. *The Annals of Statistics*, 30(1):74–99, 2002.

[51] Jianqing Fan, Cong Ma, and Yiqiao Zhong. A selective overview of deep learning. *Statistical science: A Review Journal of the Institute of Mathematical Statistics*, 36(2):264–290, 2021.

[52] Qingliang Fan, Yu-Chin Hsu, Robert P Lieli, and Yichong Zhang. Estimation of conditional average treatment effects with high-dimensional data. *Journal of Business & Economic Statistics*, 40(1):313–327, 2022.

[53] Xenia Fave, Lifei Zhang, Jinzhong Yang, Dennis Mackin, Peter Balter, Daniel Gomez, David Followill, Aaron Kyle Jones, Francesco Stingo, Zhongxing Liao, et al. Delta-radiomics features for the prediction of patient outcomes in non–small cell lung cancer. *Scientific Reports*, 7(1):1–11, 2017.

[54] Enriqueta Felip, Rafael Rosell, José Antonio Maestre, José Manuel Rodríguez-Paniagua, Teresa Morán, Julio Astudillo, Guillermo Alonso, José Manuel Borro, José Luis González-Larriba, Antonio Torres, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non–small-cell lung cancer. *Journal of Clinical Oncology*, 28(19):3138–3145, 2010.

[55] Thomas R Fleming and David P Harrington. *Counting processes and survival analysis*. John Wiley & Sons, 2011.

[56] Xavier Glorot and Yoshua Bengio. Understanding the difficulty of training deep feedforward neural networks. In *Proceedings of the Thirteenth International Conference on Artificial Intelligence and Statistics*, pages 249–256. JMLR Workshop and Conference Proceedings, 2010.

[57] Jenna Goesling, Matthew J Henry, Stephanie E Moser, Mohit Rastogi, Afton L Hassett, Daniel J Clauw, and Chad M Brummett. Symptoms of depression are associated with opioid use regardless of pain severity and physical functioning among treatment-seeking patients with chronic pain. *The Journal of Pain*, 16(9):844–851, 2015.

[58] Jenna Goesling, Stephanie E Moser, Bilal Zaidi, Afton L Hassett, Paul Hilliard, Brian Hallstrom, Daniel J Clauw, and Chad M Brummett. Trends and predictors of opioid use following total knee and total hip arthroplasty. *Pain*, 157(6):1259–1275, 2016.

[59] Mary V Graham, Lynne M Geitz, Roger Byhardt, Sucha Asbell, Mack Roach III, Raul C Urtasun, Walter J Curran Jr, Paul Lattin, Anthony H Russell, and James D Cox. Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer. *JNCI: Journal of the National Cancer Institute*, 84(22):1731–1735, 1992.

[60] Justin Grimmer, Solomon Messing, and Sean J Westwood. Estimating heterogeneous treatment effects and the effects of heterogeneous treatments with ensemble methods. *Political Analysis*, 25(4):413–434, 2017.

[61] Jennifer M Hah, Yasamin Sharifzadeh, Bing M Wang, Matthew J Gillespie, Stuart B Goodman, Sean C Mackey, and Ian R Carroll. Factors associated with opioid use in a cohort of patients presenting for surgery. *Pain Research and Treatment*, 2015, 2015.

[62] Frank E Harrell, Kerry L Lee, and Daniel B Mark. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Statistics in Medicine*, 15(4):361–387, 1996.

[63] Trevor Hastie and Robert Tibshirani. Varying-coefficient models. *Journal of the Royal Statistical Society: Series B (Methodological)*, 55(4):757–779, 1993.

[64] Kaiming He, Xiangyu Zhang, Shaoqing Ren, and Jian Sun. Delving deep into rectifiers: Surpassing human-level performance on imagenet classification. In *Proceedings of the IEEE International Conference on Computer Vision*, pages 1026–1034, 2015.

[65] Rebecca Suk Heist, Rihong Zhai, Geoffrey Liu, Wei Zhou, Xihong Lin, Li Su, Kofi Asomaning, Thomas J Lynch, John C Wain, and David C Christiani. Vegf polymorphisms and survival in early-stage non–small-cell lung cancer. *Journal of clinical oncology*, 26(6):856–862, 2008.

[66] Tomoyuki Hida, Akinori Hata, Junwei Lu, Vladimir I Valtchinov, Takuya Hino, Mizuki Nishino, Hiroshi Honda, Noriyuki Tomiyama, David C Christiani, and Hiroto Hatabu. Interstitial lung abnormalities in patients with stage i non-small cell lung cancer are associated with shorter overall survival: the boston lung cancer study. *Cancer Imaging*, 21(1):1–7, 2021.

[67] Paul E Hilliard, Jennifer Waljee, Stephanie Moser, Lynn Metz, Michael Mathis, Jenna Goesling, David Cron, Daniel J Clauw, Michael Englesbe, Goncalo Abecasis, and Chad M. Brummett. Prevalence of preoperative opioid use and characteristics associated with opioid use among patients presenting for surgery. *JAMA Surgery*, 153(10):929–937, 2018.

[68] Joel L Horowitz. *Semiparametric and nonparametric methods in econometrics*, volume 12. Springer, 2009.

[69] Anning Hu. Heterogeneous treatment effects analysis for social scientists: A review. *Social Science Research*, page 102810, 2022.

[70] Yuao Hu and Heng Lian. Variable selection in a partially linear proportional hazards model with a diverging dimensionality. *Statistics & Probability Letters*, 83(1):61–69, 2013.

[71] Jian Huang. Efficient estimation of the partly linear additive Cox model. *The Annals of Statistics*, 27(5):1536–1563, 1999.

[72] Yanqi Huang, Zaiyi Liu, Lan He, Xin Chen, Dan Pan, Zelan Ma, Cuishan Liang, Jie Tian, and Changhong Liang. Radiomics signature: A potential biomarker for the prediction of disease-free survival in early-stage (i or ii) non—small cell lung cancer. *Radiology*, 281(3):947–957, 2016.

[73] Guido W Imbens. Nonparametric estimation of average treatment effects under exogeneity: A review. *Review of Economics and statistics*, 86(1):4–29, 2004.

[74] Guido W Imbens and Donald B Rubin. *Causal inference for statistics, social, and biomedical sciences: An introduction*. Taylor & Francis, 2016.

[75] H. Ishwaran and U.B. Kogalur. Random survival forests for r. *R News*, 7(2):25–31, October 2007.

[76] Hemant Ishwaran, Udaya B Kogalur, Eugene H Blackstone, and Michael S Lauer. Random survival forests. *The Annals of Applied Statistics*, 2(3):841–860, 2008.

[77] Daniel Jacob. Cate meets ml: Conditional average treatment effect and machine learning. *Digital Finance*, 3(2):99–148, 2021.

[78] Nikhil Jain, John L Brock, Frank M Phillips, Tristan Weaver, and Safdar N Khan. Chronic preoperative opioid use is a risk factor for increased complications, resource use, and costs after cervical fusion. *The Spine Journal*, 18(11):1989–1998, 2018.

[79] Allison M Janda, Sawsan As-Sanie, Baskar Rajala, Alex Tsodikov, Stephanie E Moser, Daniel J Clauw, and Chad M Brummett. Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. *Anesthesiology: The Journal of the American Society of Anesthesiologists*, 122(5):1103–1111, 2015.

[80] Neal Jawadekar, Katrina Kezios, Michelle C Odden, Jeanette A Stingone, Sebastian Calonico, Kara Rudolph, and Adina Zeki Al Hazzouri. Practical guide to honest causal forests for identifying heterogeneous treatment effects. *American Journal of Epidemiology*, page kwad043, 2023.

[81] Hamed Jelodar, Yongli Wang, Rita Orji, and Shucheng Huang. Deep sentiment classification and topic discovery on novel coronavirus or covid-19 online discussions: Nlp using lstm recurrent neural network approach. *IEEE Journal of Biomedical and Health Informatics*, 24(10):2733–2742, 2020.

[82] Bekir Karlik and A Vehbi Olgac. Performance analysis of various activation functions in generalized MLP architectures of neural networks. *International Journal of Artificial Intelligence and Expert Systems*, 1(4):111–122, 2011.

[83] Jared L Katzman, Uri Shaham, Alexander Cloninger, Jonathan Bates, Tingting Jiang, and Yuval Kluger. Deepsurv: personalized treatment recommender system using a cox proportional hazards deep neural network. *BMC medical research methodology*, 18(1):1–12, 2018.

[84] Edward H Kennedy. Towards optimal doubly robust estimation of heterogeneous causal effects. *arXiv preprint arXiv:2004.14497*, 2020.

[85] Diederik P Kingma and Jimmy Ba. Adam: A method for stochastic optimization. *arXiv preprint arXiv:1412.6980*, 2014.

[86] Jens Kleesiek, Gregor Urban, Alexander Hubert, Daniel Schwarz, Klaus Maier-Hein, Martin Bendszus, and Armin Biller. Deep mri brain extraction: a 3D convolutional neural network for skull stripping. *NeuroImage*, 129:460–469, 2016.

[87] Michael Kohler, Kinga Máthé, and Márta Pintér. Prediction from randomly right censored data. *Journal of Multivariate Analysis*, 80(1):73–100, 2002.

[88] Hui Kong, Hatice Cinar Akakin, and Sanjay E Sarma. A generalized laplacian of gaussian filter for blob detection and its applications. *IEEE transactions on cybernetics*, 43(6):1719–1733, 2013.

[89] Sören R Künzel, Jasjeet S Sekhon, Peter J Bickel, and Bin Yu. Metalearners for estimating heterogeneous treatment effects using machine learning. *Proceedings of the National academy of Sciences*, 116(10):4156–4165, 2019.

[90] Mark J Laan and James M Robins. *Unified methods for censored longitudinal data and causality*. Springer, 2003.

[91] Akos Lada, Alexander Peysakhovich, Diego Aparicio, and Michael Bailey. Observational data for heterogeneous treatment effects with application to recommender systems. In *Proceedings of the 2019 ACM Conference on Economics and Computation*, pages 199–213, 2019.

[92] Philippe Lambin, Ralph TH Leijenaar, Timo M Deist, Jurgen Peerlings, Evelyn EC De Jong, Janita Van Timmeren, Sebastian Sanduleanu, Ruben THM Larue, Aniek JG Even, Arthur Jochems, et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nature Reviews Clinical Oncology*, 14(12):749–762, 2017.

[93] Yann LeCun, Yoshua Bengio, and Geoffrey Hinton. Deep learning. *Nature*, 521(7553):436–444, 2015.

[94] Dennis Lee, Sheyan Armaghani, Kristin R Archer, Jesse Bible, David Shau, Harrison Kay, Chi Zhang, Matthew J McGirt, and Clinton Devin. Preoperative opioid use as a predictor of adverse postoperative self-reported outcomes in patients undergoing spine surgery. *JBJS*, 96(11):e89(1)–e89(8), 2014.

[95] Dong Hoon Lee and Edward L Giovannucci. The obesity paradox in cancer: epidemiologic insights and perspectives. *Current Nutrition Reports*, 8:175–181, 2019.

[96] Amanda Leiter, Chung Yin Kong, Michael K Gould, Minal S Kale, Rajwanth R Veluswamy, Cardinale B Smith, Grace Mhango, Brian Z Huang, Juan P Wisnivesky, and Keith Sigel. The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study. *Plos one*, 17(11):e0263911, 2022.

[97] Moshe Leshno, Vladimir Ya Lin, Allan Pinkus, and Shimon Schocken. Multilayer feedforward networks with a nonpolynomial activation function can approximate any function. *Neural Networks*, 6(6):861–867, 1993.

[98] Mingchen Li, Mahdi Soltanolkotabi, and Samet Oymak. Gradient descent with early stopping is provably robust to label noise for overparameterized neural networks. In *International conference on artificial intelligence and statistics*, pages 4313–4324. PMLR, 2020.

[99] Yuanzhi Li and Yang Yuan. Convergence analysis of two-layer neural networks with relu activation. In *Advances in Neural Information Processing Systems*, pages 597–607, 2017.

[100] DY Lin. On the breslow estimator. *Lifetime data analysis*, 13:471–480, 2007.

[101] Zachary C Lipton, David C Kale, Charles Elkan, and Randall Wetzel. Learning to diagnose with LSTM recurrent neural networks. *arXiv preprint arXiv:1511.03677*, 2015.

[102] Liyuan Liu, Haoming Jiang, Pengcheng He, Weizhu Chen, Xiaodong Liu, Jianfeng Gao, and Jiawei Han. On the variance of the adaptive learning rate and beyond. In *International Conference on Learning Representations*, 2020.

[103] Wei-Hsuan Lo-Ciganic, James L Huang, Hao H Zhang, Jeremy C Weiss, Yonghui Wu, C Kent Kwoh, Julie M Donohue, Gerald Cochran, Adam J Gordon, Daniel C Malone, Courtney C. Kuza, and Walid F. Gellad. Evaluation of machine-learning algorithms for predicting opioid overdose risk among medicare beneficiaries with opioid prescriptions. *JAMA Network Open*, 2(3):e190968(1)–e190968(15), 2019.

[104] Meghan G Lubner, Andrew D Smith, Kumar Sandrasegaran, Dushyant V Sahani, and Perry J Pickhardt. Ct texture analysis: definitions, applications, biologic correlates, and challenges. *Radiographics*, 37(5):1483–1503, 2017.

[105] Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. *New England Journal of Medicine*, 350(21):2129–2139, 2004.

[106] Ryo Maeda, Junji Yoshida, Genichiro Ishii, Tomoyuki Hishida, Mitsuyo Nishimura, and Kanji Nagai. Risk factors for tumor recurrence in patients with early-stage (stage i and ii) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition tnm classification. *Chest*, 140(6):1494–1502, 2011.

[107] Sean J Meredith, Vidushan Nadarajah, Julio J Jauregui, Michael P Smuda, Shaun H Medina, Craig H Bennett, Jonathan D Packer, and R Frank Henn III. Preoperative opioid use in knee surgery patients. *The Journal of Knee Surgery*, 32(07):630–636, 2019.

[108] Hrushikesh Mhaskar, Qianli Liao, and Tomaso Poggio. When and why are deep networks better than shallow ones? In *Proceedings of the AAAI conference on artificial intelligence*, volume 31, 2017.

[109] Hrushikesh N Mhaskar. Neural networks for optimal approximation of smooth and analytic functions. *Neural Computation*, 8(1):164–177, 1996.

[110] Julian R Molina, Ping Yang, Stephen D Cassivi, Steven E Schild, and Alex A Adjei. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. In *Mayo Clinic Proceedings*, volume 83, pages 584–594. Elsevier, 2008.

[111] Nathan M Mollberg and Mark K Ferguson. Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. *The Annals of Thoracic Surgery*, 95(3):1112–1121, 2013.

[112] Angel Moran, Megan E Daly, Stephen SF Yip, and Tokihiro Yamamoto. Radiomics-based assessment of radiation-induced lung injury after stereotactic body radiotherapy. *Clinical Lung Cancer*, 18(6):e425–e431, 2017.

[113] Daniel Morgensztern, Pamela S Samson, Saiama N Waqar, Siddhartha Devarakonda, Clifford G Robinson, Ramaswamy Govindan, and Varun Puri. Early mortality in patients undergoing adjuvant chemotherapy for non–small cell lung cancer. *Journal of Thoracic Oncology*, 13(4):543–549, 2018.

[114] Brent J Morris, Aaron D Sciascia, Cale A Jacobs, and T Bradley Edwards. Preoperative opioid use associated with worse outcomes after anatomic shoulder arthroplasty. *Journal of Shoulder and Elbow Surgery*, 25(4):619–623, 2016.

[115] S Navada, P Lai, AG Schwartz, and GP Kalemkerian. Temporal trends in small cell lung cancer: analysis of the national surveillance, epidemiology, and end-results (seer) database. *Journal of Clinical Oncology*, 24(18_suppl):7082–7082, 2006.

[116] Prashant Nayak, Shwetabh Sinha, Jayant S Goda, Arpita Sahu, Kishore Joshi, Oindrilla Roy Choudhary, Ritesh Mhatre, Naveen Mummudi, and Jai Prakash Agarwal. Computerized tomography-based first order tumor texture features in non-small cell lung carcinoma treated with concurrent chemoradiation: A simplistic and potential surrogate imaging marker for survival. 2022.

[117] Xinkun Nie and Stefan Wager. Quasi-oracle estimation of heterogeneous treatment effects. *Biometrika*, 108(2):299–319, 2021.

[118] Marlies Noordzij, Karen Leffondré, Karlijn J van Stralen, Carmine Zoccali, Friedo W Dekker, and Kitty J Jager. When do we need competing risks methods for survival analysis in nephrology? *Nephrology Dialysis Transplantation*, 28(11):2670–2677, 2013.

[119] Byeong U Park, Enno Mammen, Young K Lee, and Eun Ryung Lee. Varying coefficient regression models: a review and new developments. *International Statistical Review*, 83(1):36–64, 2015.

[120] Allan Pinkus. Approximation theory of the mlp model in neural networks. *Acta numerica*, 8:143–195, 1999.

[121] Katherine MW Pisters and Thierry Le Chevalier. Adjuvant chemotherapy in completely resected non–small-cell lung cancer. *Journal of Clinical Oncology*, 23(14):3270–3278, 2005.

[122] Stephen M Pizer, E Philip Amburn, John D Austin, Robert Cromartie, Ari Geselowitz, Trey Greer, Bart ter Haar Romeny, John B Zimmerman, and Karel Zuiderveld. Adaptive histogram equalization and its variations. *Computer vision, graphics, and image processing*, 39(3):355–368, 1987.

[123] Marco Pota, Elisa Scalco, Giuseppe Sanguineti, Alessia Farneti, Giovanni Mauro Cattaneo, Giovanna Rizzo, and Massimo Esposito. Early prediction of radiotherapy-induced parotid shrinkage and toxicity based on ct radiomics and fuzzy classification. *Artificial Intelligence in Medicine*, 81:41–53, 2017.

[124] Samira Pouyanfar, Saad Sadiq, Yilin Yan, Haiman Tian, Yudong Tao, Maria Presa Reyes, Mei-Ling Shyu, Shu-Ching Chen, and Sundaraja S Iyengar. A survey on deep learning: Algorithms, techniques, and applications. *ACM Computing Surveys (CSUR)*, 51(5):1–36, 2018.

[125] Scott Powers, Junyang Qian, Kenneth Jung, Alejandro Schuler, Nigam H Shah, Trevor Hastie, and Robert Tibshirani. Some methods for heterogeneous treatment effect estimation in high dimensions. *Statistics in Medicine*, 37(11):1767–1787, 2018.

[126] Heather A Prentice, Maria CS Inacio, Anshuman Singh, Robert S Namba, and Elizabeth W Paxton. Preoperative risk factors for opioid utilization after total hip arthroplasty. *JBJS*, 101(18):1670–1678, 2019.

[127] Zhen Qin, Qingliang Zeng, Yixin Zong, and Fan Xu. Image inpainting based on deep learning: A review. *Displays*, 69:102028, 2021.

[128] Ramon Rami-Porta, John J Crowley, and Peter Goldstraw. Review the revised tnm staging system for lung cancer. *Ann Thorac Cardiovasc Surg*, 15(1):5, 2009.

[129] Laurie-Anne Roeckel, Glenn-Marie Le Coz, Claire Gavériaux-Ruff, and Frédéric Simonin. Opioid-induced hyperalgesia: cellular and molecular mechanisms. *Neuroscience*, 338:160–182, 2016.

[130] Rafael Rosell, Jose Gomez-Codina, Carlos Camps, Jose Maestre, Jose Padille, Antonio Canto, Jose Luis Mate, Shanrong Li, Jorge Roig, Angel Olazabal, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. *New England Journal of Medicine*, 330(3):153–158, 1994.

[131] Jack A Roth, Frank Fossella, Ritsuko Komaki, M Bernadette Ryan, JB Putnam Jr, Jin Soo Lee, Hari Dhingra, Louis De Caro, Marvin Chasen, Malcoln McGavran, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage iiia non-small-cell lung cancer. *JNCI: Journal of the National Cancer Institute*, 86(9):673–680, 1994.

[132] Tulshi D Saha, Bradley T Kerridge, Risë B Goldstein, S Patricia Chou, Haitao Zhang, Jeesun Jung, Roger P Pickering, W June Ruan, Sharon M Smith, Boji Huang, Deborah S. Hasin, and Grant Bridget F. Nonmedical prescription opioid use and dsm-5 nonmedical prescription opioid use disorder in the United States. *The Journal of Clinical Psychiatry*, 77(6):772–780, 2016.

[133] Aysegul Sakin, Suleyman Sahin, Muhammed Mustafa Atci, Nurgul Yasar, Cumhur Demir, Caglayan Geredeli, Abdullah Sakin, and Sener Cihan. The effect of body mass index on treatment outcomes in patients with metastatic non-small cell lung cancer treated with platinum-based therapy. *Nutrition and Cancer*, 73(8):1411–1418, 2021.

[134] Britt J Sandler, Zuoheng Wang, Jacquelyn G Hancock, Daniel J Boffa, Frank C Detterbeck, and Anthony W Kim. Gender, age, and comorbidity status predict improved survival with adjuvant chemotherapy following lobectomy for non-small cell lung cancers larger than 4 cm. *Annals of surgical oncology*, 23:638–645, 2016.

[135] Peter Sasieni. Information bounds for the conditional hazard ratio in a nested family of regression models. *Journal of the Royal Statistical Society: Series B (Methodological)*, 54(2):617–635, 1992.

[136] Steven E Schild, Philip J Stella, Susan M Geyer, James A Bonner, William L McGinnis, James A Mailliard, Jeffery Brindle, Aminah Jatoi, and James R Jett. The outcome of combined-modality therapy for stage iii non–small-cell lung cancer in the elderly. *Journal of Clinical Oncology*, 21(17):3201–3206, 2003.

[137] Philomena Schlexer Lamoureux, Kirsten T Winther, Jose Antonio Garrido Torres, Verena Streibel, Meng Zhao, Michal Bajdich, Frank Abild-Pedersen, and Thomas Bligaard. Machine learning for computational heterogeneous catalysis. *ChemCatChem*, 11(16):3581–3601, 2019.

[138] Johannes Schmidt-Hieber. Nonparametric regression using deep neural networks with relu activation function. *Annals of Statistics*, 48(4):1875–1897, 2020.

[139] Andrew J Schoenfeld, Philip J Belmont Jr, Justin A Blucher, Wei Jiang, Muhammad Ali Chaudhary, Tracey Koehlmoos, James D Kang, and Adil H Haider. Sustained preoperative opioid use is a predictor of continued use following spine surgery. *JBJS*, 100(11):914–921, 2018.

[140] Shaina Sekhri, Nonie S Arora, Hannah Cottrell, Timothy Baerg, Anthony Duncan, Hsou Mei Hu, Michael J Englesbe, Chad Brummett, and Jennifer F Waljee. Probability of opioid prescription refilling after surgery: does initial prescription dose matter? *Annals of Surgery*, 268(2):271–276, 2018.

[141] Rudy Setiono. A penalty-function approach for pruning feedforward neural networks. *Neural Computation*, 9(1):185–204, 1997.

[142] Ajay Shrestha and Ausif Mahmood. Review of deep learning algorithms and architectures. *IEEE Access*, 7:53040–53065, 2019.

[143] Noah Simon, Jerome Friedman, Trevor Hastie, and Rob Tibshirani. Regularization paths for Cox's proportional hazards model via coordinate descent. *Journal of Statistical Software*, 39(5):1, 2011.

[144] Savannah R Smith, Jennifer Bido, Jamie E Collins, Heidi Yang, Jeffrey N Katz, and Elena Losina. Impact of preoperative opioid use on total knee arthroplasty outcomes. *The Journal of Bone and Joint Surgery*, 99(10):803–808, 2017.

[145] Nitish Srivastava, Geoffrey Hinton, Alex Krizhevsky, Ilya Sutskever, and Ruslan Salakhutdinov. Dropout: a simple way to prevent neural networks from overfitting. *The Journal of Machine Learning Research*, 15(1):1929–1958, 2014.

[146] Mark D Sullivan, Mark J Edlund, Diane Steffick, and Jürgen Unützer. Regular use of prescribed opioids: association with common psychiatric disorders. *Pain*, 119(1-3):95–103, 2005.

[147] Mark D Sullivan, Mark J Edlund, Lily Zhang, Jürgen Unützer, and Kenneth B Wells. Association between mental health disorders, problem drug use, and regular prescription opioid use. *Archives of Internal Medicine*, 166(19):2087–2093, 2006.

[148] Liyang Sun and Sarah Abraham. Estimating dynamic treatment effects in event studies with heterogeneous treatment effects. *Journal of Econometrics*, 225(2):175–199, 2021.

[149] Gabriel Tan, Mark P Jensen, John I Thornby, and Bilal F Shanti. Validation of the Brief Pain Inventory for chronic nonmalignant pain. *The Journal of Pain*, 5(2):133–137, 2004.

[150] J. Kenneth Tay, Balasubramanian Narasimhan, and Trevor Hastie. Elastic net regularization paths for all generalized linear models. *Journal of Statistical Software*, 106(1):1–31, 2023.

[151] National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. *New England Journal of Medicine*, 365(5):395–409, 2011.

[152] Krishna Chaitanya Thandra, Adam Barsouk, Kalyan Saginala, John Sukumar Aluru, and Alexander Barsouk. Epidemiology of lung cancer. *Contemporary Oncology/Współczesna Onkologia*, 25(1):45–52, 2021.

[153] Robert Tibshirani. Regression shrinkage and selection via the lasso: a retrospective. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 73(3):273–282, 2011.

[154] Robert Tibshirani, Michael Saunders, Saharon Rosset, Ji Zhu, and Keith Knight. Sparsity and smoothness via the fused lasso. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)*, 67(1):91–108, 2005.

[155] Hilary A Tindle, Meredith Stevenson Duncan, Robert A Greevy, Ramachandran S Vasan, Suman Kundu, Pierre P Massion, and Matthew S Freiberg. Lifetime smoking history and risk of lung cancer: results from the framingham heart study. *JNCI: Journal of the National Cancer Institute*, 110(11):1201–1207, 2018.

[156] M-N Tran, Nghia Nguyen, David Nott, and Robert Kohn. Bayesian deep net glm and glmm. *Journal of Computational and Graphical Statistics*, 29(1):97–113, 2020.

[157] Phi Vu Tran. A fully convolutional neural network for cardiac segmentation in short-axis MRI. *arXiv preprint arXiv:1604.00494*, 2016.

[158] Masahiro Tsuboi, Tatsuo Ohira, Hisashi Saji, Kuniharu Miyajima, Naohiro Kajiwara, Osamu Uchida, Jitsuo Usuda, and Harubumi Kato. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. *Annals of Thoracic and Cardiovascular Surgery*, 13(2):73, 2007.

[159] Joost JM Van Griethuysen, Andriy Fedorov, Chintan Parmar, Ahmed Hosny, Nicole Aucoin, Vivek Narayan, Regina GH Beets-Tan, Jean-Christophe Fillion-Robin, Steve Pieper, and Hugo JWL Aerts. Computational radiomics system to decode the radiographic phenotype. *Cancer Research*, 77(21):e104–e107, 2017.

[160] Jennifer Waljee, David Cron, Rena Steiger, Lin Zhong, Michael Englesbe, and Chad Brummett. The Effect of Preoperative Opioid Exposure on Healthcare Utilization and Expenditures Following Elective Abdominal Surgery. *Annals of Surgery*, 265(4):715–721, 2017.

[161] Meina Wang, Roy S Herbst, and Chris Boshoff. Toward personalized treatment approaches for non-small-cell lung cancer. *Nature Medicine*, 27(8):1345–1356, 2021.

[162] Zhaoxi Wang, Yongyue Wei, Ruyang Zhang, Li Su, Stephanie M Gogarten, Geoffrey Liu, Paul Brennan, John K Field, James D McKay, Jolanta Lissowska, et al. Multi-omics analysis reveals a hif network and hub gene epas1 associated with lung adenocarcinoma. *EBioMedicine*, 32:93–101, 2018.

[163] Shun-ichi Watanabe, Kazuo Nakagawa, Kenji Suzuki, Kazuya Takamochi, Hiroyuki Ito, Jiro Okami, Keiju Aokage, Hisashi Saji, Hiroshige Yoshioka, Yoshitaka Zenke, et al. Neoadjuvant and adjuvant therapy for stage iii non-small cell lung cancer. *Japanese Journal of Clinical Oncology*, 47(12):1112–1118, 2017.

[164] Robert W Westermann, Jennifer Hu, Mia S Hagen, Michael Willey, Thomas Sean Lynch, and James Rosneck. Epidemiology and detrimental impact of opioid use in patients undergoing arthroscopic treatment of femoroacetabular impingement syndrome. *Arthroscopy: The Journal of Arthroscopic & Related Surgery*, 34(10):2832–2836, 2018.

[165] Yu Xie, Jennie E Brand, and Ben Jann. Estimating heterogeneous treatment effects with observational data. *Sociological Methodology*, 42(1):314–347, 2012.

[166] Yizhe Xu, Nikolaos Ignatiadis, Erik Sverdrup, Scott Fleming, Stefan Wager, and Nigam Shah. Treatment heterogeneity with survival outcomes. *arXiv preprint arXiv:2207.07758*, 2022.

[167] Liuyi Yao, Zhixuan Chu, Sheng Li, Yaliang Li, Jing Gao, and Aidong Zhang. A survey on causal inference. *ACM Transactions on Knowledge Discovery from Data (TKDD)*, 15(5):1–46, 2021.

[168] Matthew D Zeiler. Adadelta: an adaptive learning rate method. *arXiv preprint arXiv:1212.5701*, 2012.

[169] Zhenfa Zhang, Feng Xu, Shengguang Wang, Ni Li, and Changli Wang. Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer. *Lung Cancer*, 60(3):434–440, 2008.

[170] Qixian Zhong, Jonas Mueller, and Jane-Ling Wang. Deep learning for the partially linear Cox model. *The Annals of Statistics*, 50(3):1348–1375, 2022.